Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
01/2011 | Recent  |  14:  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions January recently filed with US Patent Office 01/11

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
01/27/2011 > patent applications in patent subcategories. recently filed with US Patent Office

20110021412 - Human receptor proteins; related reagents and methods: Nucleic acids encoding mammalian, e.g., primate or rodent receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.... Agent: Merck C/o Dnax

20110021411 - Reverse protein: A protein which is composed N-terminally of one or several C-terminal parts of the amino acid sequence of the mature tumour necrosis factor and C-terminally of one or several N-terminal parts of the amino acid sequence of the mature tumour necrosis factor, which activates epithelial ion channels and improves the... Agent: Workman Nydegger 1000 Eagle Gate Tower

20110021413 - Methods of suppressing microglial activation: Methods of suppressing the activation of microglial cells in the Central Nervous System (CNS), methods of ameliorating or treating the neurological effects of cerebral ischemia or cerebral inflammation, and methods of combating specific diseases that affect the CNS by administering a compound that binds to microglial receptors and prevents or... Agent: Cooley LLP Attn: Patent Group

20110021414 - Chimeric phage tail proteins and uses thereof: A multi-protein pyocin-like structure derived from a bacteriophage or a bacteriocin that includes a chimeric tail fiber having a protein receptor binding domain capable of recognizing Lipid A. A multiprotein pyocin-like structure, derived from a bacteriophage or a bacteriocin that includes a chimeric tail fiber capable of recognizing and binding... Agent: Winstead PC

20110021415 - Antimicrobial peptides: wherein l, m and n are integers from 0 to 10; X and Y, which may be the same or different, are an amino acid selected from the group consisting of hydrophobic amino acids and/or cationic amino acids, together with methods for the use of the peptides in the treatment... Agent: Speckman Law Group PLLC

20110021416 - Compositions, methods and uses for treating bacterial infections: A novel method of treating and preventing bacterial diseases is provided. In particular, the present invention relates to compositions and methods for inhibition of Gram negative, Gram positive and acid fast bacilli in general and tuberculosis (TB), mycobacterium avium complex (MAC), and anthrax in particular. Thus, the invention relates to... Agent: Faegre & Benson LLP Patent Docketing - Intellectual Property

20110021417 - Compositions comprising oligosaccharides: The present invention concerns compositions comprising a saccharide for the inhibition of pathogen adhesion to mammalian cells.... Agent: Nestle Healthcare Nutrition

20110021418 - Enriched haptoglobin polymers for the treatment of disease: Haptoglobin (Hp) removes cell-free Hemoglobin (Hb), with different physiological effects depending on the particular Hp polymer. We propose that material enriched for alpha 1 chain Hp polymeric forms, such as those made from Cohn fraction V precipitate, will be more suitable for the treatment of certain diseases benefiting from both... Agent: Knobbe Martens Olson & Bear LLP

20110021419 - Methods and compositions for the treatment of heart failure and other disorders: Peptides that act as GC-C receptor agonists and contain at least one D-cys and are useful for the treatment of diuresis and heart disease as well as other disorders are described.... Agent: Honigman Miller Schwartz & Cohn LLP/iron

20110021420 - Modification of feeding behaviour: The present invention relates to compositions and methods for use in the prevention or treatment of excess weight in a mammal. The compositions comprise oxyntomodulin which is shown to reduce food intake and/or increase energy expenditure.... Agent: Lando & Anastasi, LLP

20110021421 - Liquid enteral nutritional composition with a low specific protein volume: The present invention concerns liquid enteral nutritional compositions that comprise intact protein with a low specific volume allowing the preparation of nutrition with high protein and energy contents which are particularly advantageous for persons that are in, or recovering from, a disease state, persons that are malnourished or sportsmen and... Agent: Foley And Lardner LLP Suite 500

20110021422 - Method and compositions for prevention and treatment of diabetic and aged skin: Method and compositions are provided for treating or preventing a skin pathology or disorder associated with diabetes and/or aging, by topical administration of at least one agent capable of restoring an impaired physiological condition of the skin associated with said skin pathology or disorder. Examples of such agents include PKC... Agent: Fulbright & Jaworski, LLP

20110021423 - Rapid acting insulin analogues: The invention is related to fast acting insulin analogues which can form soluble mix-tures (pre-mixed or self-mixed) with long acting insulin analogues. The fast action is achieved through monomerizing substitutions/deletions in the C-terminus of the B-chain of human insulin and the mixability with long acting insulin analogues is achieved through... Agent: Novo Nordisk, Inc. Intellectual Property Department

20110021424 - Polypeptide derived from protein a and able to bind pdgf: The invention provides a platelet derived growth factor receptor beta (PDGF-Rβ) binding polypeptide, comprising a platelet derived growth factor receptor beta binding motif, PBM, which motif consists of an amino acid sequence as defined herein, wherein the PDGF-Rβ-binding polypeptide binds to PDGF-Rβ such that the KD value of the interaction... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20110021426 - Methods for treatment of pain: The invention provides for methods and compositions for treatment of pain via craniofacial mucosal administration of an analgesic compound (e.g. a non-opioid analgesic peptide, an NOP agonist or N/OFQ). Intranasal administration of certain analgesic peptides such as N/OFQ results in global analgesic effects.... Agent: Morrison & Foerster LLP

20110021425 - Tricyclic inhibitors of jak: e

20110021427 - Biphasic calcium phosphate cement for drug delivery: This invention relates to biomineral-based cements incorporating biopolymer carriers for the site specific introduction of natural or synthetic compounds that influence bone repair and/or patient recovery. The invention further relates to methods for producing such biphasic calcium phosphate cements for drug delivery.... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20110021428 - Prevention of allergy at weaning: A nutritional composition comprising a partially hydrolysed milk protein having a degree of hydrolysis between 15 and 25% and 50 to 1000 nanograms of TGF-β per 100 ml of ready to consume composition and methods for the primary prevention of allergic reactions to newly introduced dietary protein at weaning and... Agent: K&l Gates LLP

20110021429 - Renoprotection by growth hormone-releasing hormone and agonists: The present invention relates to renoprotection by growth hormone-releasing hormone and agonists. More specifically, the present invention relates to methods for protecting a mammal against oxidative renal damage, of promoting regeneration of kidney cells in a mammal in need thereof and/or of preventing the death of kidney cells due to... Agent: Bcf LLP

20110021430 - Modified vitamin k-dependent polypeptides: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.... Agent: Fish & Richardson P.C. (tc)

20110021431 - Methods and compositions for medical articles produced from proteinaceous compounds: The invention disclosed herein provides compositions and methods for biocompatible biomaterials with improved control of microorganisms, improved biocompatibility, lower toxicity, and reduce vCJD transmission potential. These combined benefits cascade to provide improved efficacy, improved patient compliance and improved performance, while limiting clinical complications in treatment.... Agent: P. Jeff Martin The Mcgougan Law Firm, LLC

20110021432 - Manufacture of factor h (fh) and fh-derivatives from plasma: The present invention provides compositions and pharmaceutical formulations of Factor H derived from plasma. Also provided are methods for the manufacture of the Factor H compositions and formulations, as well as methods for the treatment of diseases associated with Factor H dysfunction.... Agent: Townsend And Townsend And Crew LLP

20110021433 - Methods for treating or preventing heart failure: The invention provides methods for inhibiting cell death or inflammation in a mammal brought about by diseases or conditions such as heart failure, wherein the method comprises administering to a mammal in need thereof a Bcl protein in an amount sufficient to inhibit cell death and inflammation in the mammal.... Agent: Fenwick & West LLP

20110021434 - Macrocyclic cysteine protease inhibitors and compositions thereof: The present invention provides a novel class of macrocyclic compounds, which are useful as cysteine protease inhibitors. Also provided are novel intermediates and methods of preparing the compounds. The invention also provides pharmaceutical compositions comprising the compounds. The compounds and compositions are useful in methods of treating or preventing one... Agent: Dann, Dorfman, Herrell & Skillman

20110021435 - Composition for preventing or treating brain diseases: The present invention relates to a composition for preventing or treating neurological diseases, particularly brain diseases and improving cognitive functions by inhibiting apoptosis of neuronal cells and/or promoting generation of neuronal cells. The present invention provide a composition for preventing or treating a neurological disease, particularly brain disease, and a... Agent: Edwards Angell Palmer & Dodge LLP

20110021437 - Method for reducing pain with ziconotide and baclofen: The present invention is direct to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyil, buprenorphine, and sufentanil, or its pharmaceutically... Agent: Howrey LLP-ca

20110021436 - Method for reducing pain with ziconotide and morphine: The present invention is direct to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyil, buprenorphine, and sufentanil, or its pharmaceutically... Agent: Howrey LLP-ca

20110021438 - Novel compounds of the n-acylamino-amide family, compositions comprising them and uses thereof: The invention concerns novel compounds of the N-acylamino-amide family, compositions, in particular cosmetic or pharmaceutical, containing them, and their use for treating body or face skin ageing, whether chronobiologic or light-induced, and in particular skin ageing caused by decrease of skin elasticity and/or by collagen degradation in the structure of... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20110021439 - Use of transesterified olive oil in the cosmetic field: The use of transesterified olive oil for increasing the penetration rate of cosmetically-active and/or dermatologically-active ingredients or as cosmetic moisturiser is disclosed.... Agent: Kenyon & Kenyon LLP

20110021440 - Apoptotic pathway targeting for the diagnosis and treatment of cancer: The invention relates to methods of treating cancer. The invention further relates to a method of treating cancer by exploiting apoptotic pathways. The invention particularly relates to regulation of apoptotic pathways in cancerous cells, to metastasis of cancer cells, and to methods of preventing cancer metastasis.... Agent: Sughrue Mion, PLLC

20110021441 - Conjugate comprising p21 protein for the treatment of cancer: The P21 protein is used as a medicament in the treatment of cancer. A conjugate comprises a first region comprising the P21 protein, or a homologue or functional fragment thereof; and a second region comprising a translocation factor.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20110021442 - Cell preamble runx3 recombinant proteins, polynucleotides encoding the same, and anticancer compositions including the same: The present invention discloses cell permeable RUNX3 recombinant proteins where a Macromolecule Transduction Domain (MTD) is fused to a tumor and metastasis suppressor RUNX3. Also disclosed are polynucleotides encoding the cell permeable RUNX3 recombinant proteins, an expression vector containing the cell permeable RUNX3 recombinant protein, and a pharmaceutical composition for... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20110021443 - Oil in water emulsion comprising nsaids and quaternary ammonium halides: Oil-in-water emulsion including a non-steroidal anti-inflammatory drug and a quaternary ammonium halide useful for the prevention and treatment of inflammation in the eye, and process for manufacturing thereof.... Agent: Young & Thompson

20110021444 - Compositions for controlling hair growth: FP-1 is a protein that is specifically expressed in the follicular papilla of the hair follicle. The nucleic acid and amino acid sequences of FP-1, as well as antibodies that specifically bind FP-1 are provided. In addition, methods of isolating follicular papilla cells and methods of modulating hair growth are... Agent: Wilmerhale/boston

20110021445 - Compositions and methods for treating erectile dysfunction: The present invention features compositions and methods for the treatment of erectile dysfunction. The compositions include substantially pure polypeptides derived from α-latrotoxin and can include other substances, such as pharmaceutically acceptable carriers or diluents, liposomes, hydrogels, and additional active ingredients for the treatment of erectile dysfunction. Also provided are methods,... Agent: Fish & Richardson P.C. (bo)

20110021446 - Compositions and methods for feeding poultry: Feed supplements for poultry raised using a rapid growth regimen are disclosed herein. The supplements include D-ribose in an amount effective to improve the resistance to cardiomyopathy in the poultry. Methods for feeding poultry are also disclosed herein.... Agent: Mueting, Raasch & Gebhardt, P.A.

20110021447 - Acne treatment composition and methods for using: An acne treatment composition is provided according to the present invention. The acne treatment composition includes an effective amount of an anti-acne component to provide anti-acne properties to skin tissue, an effective amount of a skin bounding polymer component to provide sustained release of the anti-acne component over a prolonged... Agent: Merchant & Gould PC

20110021448 - Inhibitors for the soluble epoxide hydrolase: Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.... Agent: Townsend And Townsend And Crew, LLP

20110021449 - Macrolides and uses of macrolides: Macrolides of Formula (I) or (I-A): and wherein the residues R1, R2, R3, R4, R12, R13 and R14 have certain meanings defined in this application are useful for treating or preventing inflammatory or allergic diseases or. cancer in animals and humans.... Agent: Gibbons P.C.

20110021450 - Medicinal composition containing benzo[a]phenoxazine compound as the active ingredient for prevention or treatment of protozoal disease: Provided is a medicinal composition, in particular, a medicinal composition for treatment and/or prevention which has a high therapeutic effect on infection with a parasitic protozoa and a selective toxicity thereto and exhibits a life-prolonging effect and so on. A medicinal composition which contains as the active ingredient a benzo[a]phenoxazine... Agent: Solaris Intellectual Property Group, PLLC

20110021451 - Lipid tumour profile: We describe a method of generating a classification model capable of distinguishing between two biological states, the method comprising the steps of: (a) providing a training dataset, X, comprising concentrations of a plurality of lipids in a biological sample in a first state and a biological sample in a second... Agent: David S. Resnick

20110021452 - Lyophilized preparation of stabilized anthracycline compounds: The present invention provides a lyophilized preparation of amrubicin, which contains L-cysteine or a salt thereof and has a water content of 0 to about 4% by weight within the preparation, and is stable even in a long-term storage, and further provides a method for production of said preparation. Said... Agent: Birch Stewart Kolasch & Birch

20110021610 - Aromatic prenyltransferase from hop: Nucleic acid molecules from hop (Humulus lupulus) have been isolated and characterized wherein said nucleic acid molecules encode polypeptides having aromatic prenyltransferase activity Expression or over-expression of said nucleic acid molecules alters the level of terpenophenolic compounds The polypeptides may be used in vivo or in vitro to produce terpenophenolic... Agent: Robins & Pasternak

20110021601 - Composition containing microrna-21 inhibitor for enhancing radiation sensitivity: Disclosed is a radiation sensitivity-enhancing composition in which a microRNA-21 inhibitor acts as an active ingredient. The microRNA-21 inhibitor is an antisense nucleic acid molecule binding complementarily to microRNA-21. The composition can be administered to a patient in conjunction with irradiation. The inhibitor can act as a radiosensitizer, enhancing the... Agent: Seed Intellectual Property Law Group PLLC

20110021602 - Graft polymers for enhanced intracellular delivery of antisense molecules: Innovative graft polymers designed for the efficient delivery of antisense molecules into biological cells and for maintaining the biological activity of these molecules while in serum and other aqueous environments are provided. Such polymers may comprise an anionic graft polymer comprising an anionic polymer backbone with pendant carboxylic acid groups... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20110021605 - Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye: Described is a method for the specific modulation of the expression of target genes in cells and/or tissues of the CNS and/or eye, wherein a composition comprising one or more doubled stranded oligoribonucleotides (dsRNA) is introduced into the cell, tissue or organism outside the blood-brain or blood-retina barriers. Furthermore, a... Agent: Pepper Hamilton LLP

20110021599 - Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and bph: This invention provides methods of treating androgenetic alopecia (AGA), acne, rosacea, prostate cancer, and benign prostatic hypertrophy (BPH), comprising the step of contacting a subject with a compound or composition capable of decreasing prostaglandin D2 (PGD2) level or activity, a downstream signaling or receptor pathway thereof, or prostaglandin D2 synthase... Agent: Pearl Cohen Zedek Latzer, LLP

20110021604 - Methods and compositions for the specific inhibition of kras by asymmetric double-stranded rna: This invention relates to compounds, compositions, and methods useful for reducing KRAS target RNA and protein levels via use of Dicer substrate siRNA (DsiRNA) agents possessing asymmetric end structures.... Agent: Edwards Angell Palmer & Dodge LLP

20110021607 - Methods and compositions relating to carcinoma stem cells: MicroRNA markers of breast cancer stem cells (BCSC) are provided herein. The markers are polynucleotides that are differentially expressed in BCSC as compared to normal counterpart cells. Uses of the markers include use as targets for therapeutic intervention; as targets for drug development, and for diagnostic or prognostic methods relating... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20110021608 - Methods for nucleic acid transfer into cells: The present invention provides methods for increasing the transfer of nucleic acids into cells. In particular, the present invention provides for the use of inhibitors of HDAC6, a cytoplasmic histone deacetylase present in mammalian cells by, for example, small molecules or siRNA treatment, in increasing gene transfer and/or expression in... Agent: Casimir Jones, S.c.

20110021609 - Microrna signatures associated with cytogenetics and prognosis in acute myeloid leukemia (aml) and uses thereof: Methods and compositions utilizing an miRNA signature for the diagnosis, prognosis and/or treatment of leukemia associated diseases, particularly acute myeloid leukemia, are disclosed.... Agent: Macmillan Sobanski & Todd, LLC

20110021600 - Novel nucleic acid: According to the present invention, it possible to provide a novel nucleic acid, a vector that expresses the nucleic acid, a screening method for a substance that controls the nucleic acid, a method of detecting the expression and a mutation of the nucleic acid, and a diagnostic method or therapeutic... Agent: Leydig Voit & Mayer, Ltd

20110021606 - Rnai modulation of rsv, piv and other respiratory viruses and uses thereof: The present invention is based on the in vivo demonstration that RSV and PIV can be inhibited through intranasal administration of RNAi agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated... Agent: Alnylam/fenwick

20110021603 - Trpm-2 antisense therapy: It has now been determined that antisense therapy which reduces the expression of TRPM-2 provides therapeutic benefits in the treatment of cancer. In particular, such antisense therapy can be applied in treatment of prostate cancer and renal cell cancer. Addition of antisense TRPM-2 ODN to prostatic tumor cells in vivo... Agent: Cooper & Dunham, LLP

20110021611 - Efficient cell culture system for hepatitis c virus genotype 5a: The present inventors developed 5a/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and all of or part of NS2 were replaced by the corresponding genes of the genotype 5a reference strain SA13. Compared to the J6/JFH control virus, after transfection of in vitro transcripts... Agent: Thompson Coburn LLP

20110021612 - Nk1 fragment of hepatocyte growth factor/scatter factor (hgf/sf) and variants thereof, and their use: The present invention relates to variants of the NK1 fragment of the polypeptide growth factor HGF/SF which act as agonists of the MET receptor and their use. The agonists comprise at least one substitution at positions equivalent to 132, 134, 170 and 181 of full length HGF/SF and these substitutions... Agent: K&l Gates LLP

20110021453 - Methods and compositions for providing cardiac protection: The invention provides a method of treating a cardiac disease by administering a pharmaceutically effective amount of at least one compound capable of inhibiting AC5 to a patient. The compound capable of inhibiting AC5 may be administered singly or in combination with another agent, such as, for instance a β-blocker.... Agent: Klauber & Jackson

20110021454 - Modified 4`-nucleosides as antiviral agents: Compounds, methods and compositions for treating a host infected with human immunodeficiency virus and hepatitis B virus comprising administering an effective amount of a described 4′-C-substituted β-D- and β-L-nucleoside or a pharmaceutically acceptable salt or prodrug thereof, are provided.... Agent: Merchant & Gould PC

20110021455 - Sterilised sucralfate gel: The present invention relates to an autoclave-sterilized gel comprising sucralfate and at least 15% by weight of a humectant, relative to the total weight of gel, and having a pH of greater than or equal to 6, more particularly for use in a skin healing treatment by topical application.... Agent: Birch Stewart Kolasch & Birch

20110021457 - Pharmaceutical compositions comprising modified fucans and methods relating thereto: Compositions and methods relating to fucan agents useful for the treatment, prevention, inhibition, etc., of fibrous adhesions or other diseases.... Agent: Graybeal Jackson LLP

20110021456 - Sweetening compositions and processes for preparing them: The invention relates to sweetening compositions containing from about 16% to about 75% mogroside V and from about 30% to about 95% total terpene glycosides on a dry weight basis, and wherein a filtered (0.2 μm) solution of the composition in water having a solids content of 1% w/v has... Agent: Nixon & Vanderhye, PC

20110021458 - Pharmaceutical compositions containing an inclusion complex formed by disulfiram and a cyclodextrine, which can be used in the treatment of alcohol and cocaine dependence: The invention relates to a novel pharmaceutical composition containing a complex of disulfiram (DSF) with a cyclodextrin (CD), to the method for obtaining same and to the use thereof in the treatment of alcohol and cocaine dependence.... Agent: Merchant & Gould PC

20110021459 - Dutpase inhibitors: e

20110021460 - Selective hydrosilylation method and product: An asymmetric siloxane is made by reacting a silicone having the formula MHDxM′H where MH is R1R2HSiO1/2, M′H is R4R5HSiO1/2 and x is an integer 0≦x≦10 under selective hydrosilylation conditions in the presence of a precious metal hydrosilylation catalyst, with a first olefinic compound and in a second step, a... Agent: Philip D. Freedman PC

20110021461 - Combinations to improve animal health and performance: The present invention provides combinations of dietary supplements and methods of using of these combinations to improve the health and production performance of animals. In particular, the combinations of the invention comprise antioxidants, trace minerals, organic acids, essential amino acids, and mixtures thereof.... Agent: Polsinelli Shughart PC

20110021462 - Substituted tetrahydro-2h-isoquinolin-1-one derivatives, and methods for the production and use thereof: e

20110021463 - Method of treating citrus plants to reduce bacterial infections: A method of treating a citrus plant is provided to reduce the incidence of one or more insect-vectored bacterial infections such as citrus greening. The method comprises the step of applying a treatment composition one or more times to the plant, wherein the treatment composition comprises an effective amount of... Agent: Bayer Cropscience Lp

20110021464 - Methods of treating viral infections: The present invention provides methods of treating human immunodeficiency virus (HIV) and/or hepatitis B virus (HBV) infection, including administering a compound described in the invention in an amount effective treat the HIV and/or HBV infection and at least substantially inhibit the development of resistance to said antiviral compounds in the... Agent: Myers Bigel Sibley & Sajovec

20110021465 - Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome: A composition and method of retarding and ameliorating eye diseases and injuries is disclosed. The method comprises administering a synergistic mixture of certain carotenoids, including the carotenoid astaxanthin, with phospholipid and triglyceride bound EPA and DHA derived from Krill oil, in which said krill oil contains at least 30% total... Agent: Allen, Dyer, Doppelt, Milbrath & Gilchrist P.A.

20110021466 - Use of epicatechin and derivatives and salts thereof for cardiac protection of ischemic myocardium and to ameliorate adverse cardiac remodeling: The disclosure provides a method of reducing infarct size in the heart following permanent ischemia or ischemia/reperfusion (IR) event or method for delaying, attenuating or preventing adverse cardiac remodeling comprising administering a drug selected from the group consisting of epicatechin, derivatives thereof and pharmaceutically acceptable salts thereof, wherein the subject... Agent: Joseph R. Baker, Apc Gavrilovich, Dodd & Lindsey LLP

20110021467 - Indazolecarboxamide derivatives for the treatment and prevention of malaria: The invention relates to methods of treating or preventing malaria which comprises administering to a patient in need thereof, an effective amount of a 1H-indazole-3-carboxamide derivative of general formula (I), in the form of a base or of an addition salt with an acid, or in the form of a... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20110021468 - Treatment of cardiovascular disease with salicylates: This invention relates to methods for the treatment of atherosclerotic cardiovascular disease using a non-acetylated forms of salicylate, e.g., salsalate and/or trilisate.... Agent: Fish & Richardson P.C. (bo)

20110021469 - baclofen solution for low-volume therapeutic delivery: A high concentration baclofen solution is provided suitable for therapeutic use in a medical setting. A high concentration solution of baclofen in multivalent physiological ion solution such as artificial cerebrospinal fluid is provided with concentrations of baclofen of 10 mg/ml. Artificial cerebrospinal fluid is particularly advantageous as a baclofen solvent.... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20110021470 - Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same: Methods and compositions for treating cancer are described herein. More particularly, the methods for treating cancer comprise administering a vitamin D compound in combination with at least one additional therapeutic agent, such as an anti-cancer agent or a steroid. Furthermore, disclosed are compositions comprising vitamin D compounds and at least... Agent: Jones Day

20110021471 - Reducing abeta42 levels and abeta aggregation: This document relates to methods and materials for reducing Aβ42 levels, reducing Aβ aggregation, or reducing both Aβ42 levels and Aβ aggregation. For example, this document provides methods and materials related to the use of agents (e.g., 5β-cholanic acid) to reduce Aβ42 levels and to reduce Aβ aggregation in mammals.... Agent: Fish & Richardson P.C. (tc)

20110021472 - 17-hydroxy-19-nor-21-carboxylic acid-steroid y-lactone derivative, use thereof, and medicament containing the derivative: The invention relates to 17-hydroxy-19-nor-21-carboxylic acid-steroid γ-lactone derivatives with the chemical formula I, where R4, R6a, R6b, R7, R15, R16a, R16b, R18 and Z have the meanings stated in claim 1, and their solvates, hydrates, stereoisomers and salts. The invention further relates to the use of these derivatives for the... Agent: Millen, White, Zelano & Branigan, P.C.

20110021477 - Combinations comprising antimuscarinic agents and corticosteriods: Combinations comprising (a) a corticosteroid and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for treatment of respiratory disease, e.g., asthma or chronic... Agent: Hoxie & Associates LLC

20110021476 - Combinations comprising antimuscarinic agents and pde4 inhibitors: A combination which comprises (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is (3R)-1-phenethyl-3-(9H-xanthene-9carbonyloxy)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid.... Agent: Hoxie & Associates LLC

20110021478 - Combinations comprising antimuscarinic agents and pde4 inhibitors: Combinations comprising (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma... Agent: Hoxie & Associates LLC

20110021475 - Compositions and methods for treatment of fibrosis: Methods for the treatment of fibrosis, including liver fibrosis, via administration of FXR agonists are provided.... Agent: Glaxosmithkline Global Patents

20110021474 - Ecdysterone compounds: An ecdysterone compound is described. An ecdysterone compound may include ecdysterone and decanoic acid. An ecdysterone compound may further include ecdysterone and isobutyric acid. An ecdysterone compound may comprise a physiologically active salt or ester of ecdysterone. An ecdysterone compound may further comprise a physiologically active salt or ester of... Agent: Booth Udall, PLC

20110021473 - Inhibitors of phosphodiesterase type-iv: The present invention relates to catechol derivatives of formula (I), which can be used as inhibitors of phosphodiesterase (PDPI) type 4 or type 7, Compounds disclosed herein can be useful in the treatment of CNS disorders, inflammatory diseases such as, AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis,... Agent: Ranbaxy Inc.

20110021479 - Pyrrolopyrimidinecarboxamides: in which R1, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the N-oxides of the compounds and the salts thereof and the stereoisomers of the compounds, the salts, the N-oxides of the compounds and the N-oxides of the salts thereof... Agent: Nath & Associates PLLC

20110021480 - 17-beta hsd1 and sts inhibitors: Substituted steroid compounds which represent selective inhibitors of 17β-hydroxysteroid dehydrogenase type I (17β-HSD1) and, in addition, which may represent inhibitors of the steroid sulfatase, salts thereof, pharmaceutical preparations containing these compounds, and a process for the preparation of these compounds. Also disclosed is a therapeutic method of using such substituted... Agent: Crowell & Moring LLP Intellectual Property Group

20110021481 - Novel compounds and methods for their production: The present invention relates to ansamycin analogues that are useful, e.g. in the treatment of cancer, B-cell malignancies, malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases dependent on angiogenesis, autoimmune diseases or a prophylactic pretreatment for cancer. The present invention also provides methods for the... Agent: Louis J. Wille Bristol-myers Squibb Company

20110021482 - Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents: e

20110021484 - Gallium compounds and methods of use to treat inflammatory bowel disease: Provided are formulations and methods for treating inflammatory bowel disease, including Crohn's disease, ulcerative colitis, and Johne's disease. The formulations provided comprise pharmaceutically acceptable gallium compounds; the methods provided comprise means of using such formulations in the treatment of inflammatory bowel disease and closely related disorders.... Agent: Lawrence R. Bernstein

20110021483 - Platinum (iv) complexes: Provided are nitroplatinum(IV) complexes containing a bidentate dicarboxylate ligand (e.g., oxalate) which maybe useful treating various forms of proliferative diseases, such as cancer. In some instances the platinum(IV) complexes are relatively stable and may be suitable for oral administration. Also provided are methods of treatment, as well as kits and... Agent: Morrison & Foerster LLP

20110021485 - Indole derivatives and their metal conjugates and uses thereof: Provided are compounds which are indole derivatives, as well as pharmaceutical compositions containing the compounds. Also provided are methods of using the indole compounds for preventing or treating a disease, or a condition that predisposes to a disease, wherein the disease or condition is associated with activation of the serine/threonine... Agent: Crowell & Moring LLP Intellectual Property Group

20110021490 - Chromene compounds, a process for their preparationand pharmaceutical compositions containing them: o

20110021491 - Compounds, pharmaceutical composition and methods relating thereto: wherein X1, X2, X3, X4, Y1, Y2, A, R1, R2, R3, R4, m, n, p, and q are as defined herein, including stereoisomers, esters, and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20110021492 - Pyridazine derivatives as factor xia inhibitors: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein the variables A, L1, L2, R2, R11, and M are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of... Agent: Louis J. Wille Bristol-myers Squibb Company

20110021489 - Substituted piperidines: The invention relates to novel substituted piperidines, to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders and tumour disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20110021487 - Cycloalkoxy-substituted 4-phenyl-3,5-dicyanopyridines and their use: The present application relates to novel cycloalkoxy-substituted 4-phenyl-3,5-dicyanopyridine derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, preferably for the treatment and/or prevention of cardiovascular and metabolic disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20110021488 - New compounds: wherein A, B, D, Y, R1, R2, R3, R4 and R5 are defined as in the specification, the enantiomers, the diastereomers, the mixtures and the salts thereof, particularly the physiologically acceptable salts thereof with organic or inorganic acids or bases, which have valuable properties, the preparation thereof, the pharmaceutical compositions... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20110021486 - Viral polymerase inhibitors: e

20110021497 - Amino triazoles as pi3k inhibitors: wherein X, T1 and R1 to R3 have the meaning as cited in the description and the claims. Said compounds are useful as protein kinase inhibitors, especially inhibitors of PI3K, for the treatment or prophylaxis of immunological, inflammatory, autoimmune, or allergic disorders. The invention also relates to pharmaceutical compositions including... Agent: Klauber & Jackson

20110021498 - Indolyl- pyridone derivatives having checkpoint kinase 1 inhibitory activity: Compounds of formula (I) have checkpoint kinase 1 (CHK1) inhibitory activity: wherein R1, R2, R5 and R6 are independently selected from hydrogen, hydroxy, methyl, trifluoromethyl, hydroxymethyl, methoxy, trifluoromethoxy, methylamino and dimethylamino; R3, and R4 are independently selected from hydrogen, hydroxy, C1-C3 alkyl, fluoro-(C1-C3)-alkyl, hydroxy-(C1C3)-alkyl, C1-C3 alkoxy, fluoro-(C1-C3)-alkoxy, hydroxy-(C1-C3)-alkoxy, -AIk-N(R11)—R12, -0-AIk-N(R11)—R12,... Agent: Banner & Witcoff, Ltd.

20110021494 - Novel tetrahydro-fused pyridines as histone deacetylase inhibitors: The compounds of formula (I), wherein ring D and ring E together form a fused ring system selected from formula (II), (III), (IV), (V), (VI), (VII), and the salts of these compounds are novel, effective inhibitors of histone deacetylases.... Agent: Millen, White, Zelano & Branigan, P.C.

20110021495 - Quinazoles useful as modulators of ion channels: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels and calcium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Inc.

20110021493 - Substituted tricyclic compounds and methods of use thereof: This invention relates to novel compounds and processes for their preparation, methods of treating diseases, particularly cancer, comprising administering said compounds, and methods of making pharmaceutical compositions for the treatment or prevention of disorders, particularly cancer.... Agent: Barbara A. Shimei Director, Patents & Licensing

20110021496 - Thienopyrimidine derivatives as p13k inhibitors: Thienopyrimidines of formula (I) wherein W and R1 to R4 are as defined in the claims, and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110δ isoform, which is a class Ia PI3 kinase, over both other class Ia and class Ib kinases. The... Agent: Genentech, Inc.

20110021499 - Urethral suppositories for overactive bladder: Urethral suppositories containing a mixed-activity anti-cholinergic drug and methods of use for treatment of over-active bladder are provided. Buffering drugs to pH near their pKas can result in a desired proportion of uncharged drug and can enhance absorption of the agents into urethral tissues.... Agent: Borson Law Group, PC

20110021500 - Novel compounds: wherein U, V, X, Y, R1, R2, R3 and R4 are defined as in the description, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20110021501 - Substituted piperazino-dihydrothienopyrimidines: e

20110021502 - Use of cholinesterase inhibitors for treating vascular depression: The invention discloses the use of cholinesterase inhibitors in treating vascular depression.... Agent: Novartis Corporate Intellectual Property

20110021503 - Use and composition for treating dementia: There is described a method for increasing the maximal tolerated dose and thus the efficacy of an acetyl choline esterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia by decreasing concomitant adverse effects by administration of said AChEI in combination with a non-selective, peripheral anticholinergic agent, whereby... Agent: Nixon & Vanderhye, PC

20110021504 - Polymorphic form d of bazedoxifene acetate and methods of preparing same: The present disclosure relates to polymorphic Form D of bazedoxifene acetate, pharmaceutical compositions and methods of treatment using the same, and methods of preparing the same.... Agent: Wilmerhale/wyeth LLC

20110021505 - Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid n-phenylamides in the treatment of pain: e

20110021506 - Anthelmintic agents and their use: This invention is directed to compounds and salts that are generally useful as anthelmintic agents or as intermediates in processes for making anthelmintic agents. This invention also is directed to processes for making the compounds and salts, pharmaceutical compositions and kits comprising the compounds and salts, uses of the compounds... Agent: Intervet/schering-plough Animal Health

20110021507 - Inhibiting antipsychotic-induced weight gain: The present invention provides methods, compositions and kits for preventing, inhibiting, reducing and reversing weight gain induced by antipsychotic medications, for example olanzapine and clozapine, by co-administration of an M1R-selective antagonist, for example, telenzepine.... Agent: Townsend And Townsend And Crew, LLP

20110021508 - Methods for alzheimer's disease treatment and cognitive enhancement: The present invention relates to compositions comprising a combination of PKC activators and PKC inhibitors and methods to modulate α-secretase activity; improve or enhance cognitive ability; and or reduce neurodegeneration in individuals suffering from diseases that impair cognitive ability, particularly Alzheimer's Disease. The invention also relates to methods for improving... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20110021509 - Pde10 inhibitors and related compositions and methods: wherein m, n, p, x, R, R1, R2, R3, R4, R5, A and B, are defined herein, including pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the... Agent: Seed Intellectual Property Law Group PLLC

20110021510 - Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc): This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiaziniumcompounds”) including Methylhioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in order:... Agent: Foley And Lardner LLP Suite 500

20110021511 - Substituted 5h-pyrimido[5,4-b]indoles, method for the production thereof and use thereof for treating non-solid malignant tumors of the blood-producing system: to processes for the production thereof, to pharmaceutical preparations containing said compounds and/or physiologically compatible salts and/or solvates which can be produced therefrom as well as to the pharmaceutical use of said compounds, the salts or solvates thereof as inductors of apoptosis in the case of non-solid malignant tumors of... Agent: Intellectual Property / Technology Law

20110021512 - Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1: This invention relates to novel compounds of the Formula Ik, Im1, Im2, Im5, In1, In2, In5, lo1, lo2, lo5, Ip1, Ip3, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals. The... Agent: Foley & Lardner LLP

20110021514 - Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same: Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.... Agent: Klauber & Jackson

20110021515 - Dihyrofuropyrmindine compounds: m

20110021513 - Modulators of interleukin-1 receptor-associated kinase: The present invention relates to modulators of IRAK kinase and provides compositions comprising such modulators, as well as methods therewith for treating conditions or diseases mediated by or associated with IRAK kinase.... Agent: Steptoe & Johnson LLP

20110021516 - Monocyclic cgrp receptor antagonists: The present invention is directed to compounds of the formula (I): (wherein variables A1, A2, A3, A4, A5, A6, A7, A8, G1, G2, G3, G4, J, Q, Ea, Eb, Ec, R6, R7, RPG and Y are as described herein) which are antagonists of CGRP receptors and which are useful in... Agent: Merck

20110021517 - Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents: The present invention provides a combination of a morpholinyl anthracycline derivative, in particular a methoxy morpholino doxorubicin derivative, or a pharmaceutically acceptable salt thereof, and a demethylating agent, having an antineo-plastic effect. Also provided is the use of the said combinations in the treatment or prevention of metastasis, in the... Agent: Scully Scott Murphy & Presser, PC

20110021521 - Fused heterocyclic compounds as ion channel modulators: e

20110021520 - Oxazine derivatives and their use in the treatment of neurological disorders:

20110021518 - Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase: This invention relates to novel compounds and processes for their preparation, methods of treating diseases, particularly Cancer, comprising administering said compounds, and methods of making pharmaceutical compositions for the treatment or prevention of disorders, particularly Cancer.... Agent: Barbara A. Shimei Director, Patents & Licensing

20110021519 - Tetrahydropteridines useful as inhibitors of protein kinases: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Inc.

20110021522 - Activators of executioner procaspases 3, 6 and 7: The present invention provides compounds as activators of procaspases 3, 6 and/or 7 and related derivatives, pharmaceutical compositions thereof, methods for their use, and methods for preparing these compounds. In one aspect, the compounds are useful for treating cancers and neoplastic diseases.... Agent: Townsend And Townsend And Crew, LLP

20110021523 - Aryl sulfonamides: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20110021524 - Compositions and methods for treating cancers: This invention provides a combination of ATP-competitive BCR-ABL inhibitor and a non-ATP competitive BCR-ABL inhibitor. The combination of the present invention may be used for treating cancers known to be associated with BCR-ABL.... Agent: Genomics Institute Of The Novartis Research Foundation

20110021525 - P70s6 kinase modulators and method of use: The invention provides compounds and methods for inhibition of kinases, more specifically p70S6 kinases. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration, chemoinvasion and metabolism. Compounds of the invention inhibit, regulate and/or modulate kinase receptor signal... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20110021526 - Pharmaceutical composition for treatment of diabetic complications: A method for treating diabetic complications by administration of a beta-blocker is disclosed. Diabetic complications arise from diabetes and have few or no existing treatment options. The present invention describes the use of a beta-blocker in the treatment of a diabetic. The present invention also describes the inhibition of aldose... Agent: Crowell & Moring LLP Intellectual Property Group

20110021527 - Dual-acting oxazole antihypertensive agents: wherein: Ar, Z, R3, R4 and R5 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and... Agent: Theravance, Inc.

20110021528 - Novel hydroxamates as therapeutic agents: The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also... Agent: Wilson, Sonsini, Goodrich & Rosati

20110021529 - P53 activating compounds: The present invention relates to compounds which activate the p53 response, and find use in, for example, hyperproliferative diseases such as cancer treatment and potentially other diseases/conditions (involving sirtuin function).... Agent: Hoffmann & Baron, LLP

20110021530 - Pyridazine derivatives and their use as therapeutic agents in the treatment of skin disorders: Methods of treating an SCD-mediated skin disorder or condition in a mammal, preferably a human, including administering to a mammal in need thereof a compound of formula (I): where x, y, W, V, R2, R3, R4, R5, R6, R6a, R7, R7a, R8, R8a, R9 and R9a are defined herein, and... Agent: Osha Liang L.L.P.

20110021531 - Oxazole derivatives useful as inhibitors of faah: The present invention is directed to certain oxazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including... Agent: Merck

20110021532 - Novel substituted heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase: Substituted heteroaromatic compounds of structural formula I are inhibitors of stearoyl-coenzyme A delta-9 desaturase. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; Type 2 diabetes; insulin resistance; hyperglycemia; Metabolic... Agent: Merck

20110021533 - Cysteine prodrugs to treat schizophrenia and drug addiction: The present invention provides cysteine prodrugs for the treatment of schizophrenia and drug addiction. The invention further encompasses pharmaceutical compositions containing prodrugs and methods of using the prodrugs and compositions for treatment of schizophrenia and drug addiction.... Agent: Marquette University - Promentis C/o Quarles & Brady LLP

20110021534 - 2 -substituted- 3 -phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease: The present invention relates to 2-(substituted sulphur, sulphone or sulphoxide)-3-(substituted phenyl) propionic acid derivatives, 2-(substituted oxygen)-3-(substituted phenyl) propionic acid derivatives, benzoic acid derivatives, and derivatives of 2-methyl-2-(phenoxy or phenylthio)propanoic acid and 2-(methylor ethyl)-2-(phenoxy or phenylthio)butanoic acid, to processes for preparing such compounds, to their use in the treatment of inflammatory... Agent: Fish & Richardson P.C. (sv)

20110021535 - Trazodone composition for once a day administration: The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1... Agent: Goodwin Procter LLP Patent Administrator

20110021536 - Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts: Crystalline forms or polymorphs of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one lactic acid salts, as well as to methods of making the same, pharmaceutical compositions comprising the same and methods of treatment using the same.... Agent: Novartis Corporate Intellectual Property

20110021537 - Heterocyclic pyrazole-carboxamidesas p2y12 antagonists: R1; R2; Z; A; B; D; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable, e.g., for the therapy... Agent: Scully, Scott, Murphy & Presser, P.C.

20110021538 - Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor: The present invention relates to processes for preparing pyrazole derivatives of Formula (I) and salts and pharmaceutical compositions of the salts thereof, useful as modulators of 5-HT2A serotonin receptor activity. The present invention also relates to intermediates used in the processes, and their preparation. The present invention also relates to... Agent: Fish & Richardson P.C.

20110021539 - Pyrazinylpyrazoles: e

20110021540 - Bis-(sulfonylamino) derivatives in therapy 066: The invention provides compounds of formula wherein R1, R3, L1, L2, G1, G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20110021541 - Inhibitors of human phosphatidyl-inositol 3-kinase delta: Compounds that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3Kδ plays a role in leukocyte function, using the compounds also are disclosed.... Agent: Morrison & Foerster LLP

20110021542 - Use of a combination of udenafil and alfuzosin or oxybutynin for the treatment of overactive bladder: The invention relates to a specific combination of two active agents: udenafil and one of alfuzosin and oxybutynin and its use for the treatment of overactive bladder.... Agent: Fulbright & Jaworski L.L.P.

20110021543 - Heterocyclic compounds and their use as pesticides: Novel N-aryl substituted heteroindole compounds, processes for their manufacture, veterinary compositions containing such compounds, and methods of controlling ectoparasites are provided. The compounds are believed effective in the control of ectoparasites on warm-blooded productive livestock and domestic animals.... Agent: Novartis Animal Health US Inc.

20110021544 - Hydrochloride salt of ((1s,2s,4r)-4--2-hydroxycyclopentyl)methyl sulfamate: crystalline forms thereof, and solvates thereof; pharmaceutical compositions comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent; and the use of a compound of formula (I), or a crystalline form thereof, or... Agent: Millennium Pharmaceuticals, Inc.

20110021546 - Gene defects and mutant alk kinase in human solid tumors: In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated... Agent: Nancy Chiu Wilker, Ph.d. Chief Intellectual Property Counsel

20110021545 - Novel preparation for external use:

20110021547 - Substantially pure and a stable crystalline form of bosentan: Described is a highly stable crystalline form of bosentan having a water content in the range of about 3-4% by weight, based on the total weight of the bosentan, (bosentan crystalline form A5), a process for preparation thereof, and pharmaceutical compositions comprising the bosentan crystalline form A5. Provided also herein... Agent: Cantor Colburn LLP

20110021548 - Inhibitors of malt1 proteolytic activity and uses thereof: The present invention relates to inhibitors of MALT1 proteolytic and/or autoproteolytic activity. More specifically, it relates to compounds such as, but not limited to peptide derivates such as Z-LSSR-CHO (see SEQ ID NO:1), Z-LSSR-CMK (see SEQ ID NO:1), Z-GASR-CHO (see SEQ ID NO:2), and Z-GASR-CMK (see SEQ ID NO:2), and... Agent: Traskbritt, P.C.

20110021549 - Substituted benzofused derivatives and their use as vanilloid receptor ligands: The present invention relates to substituted benzofused derivatives, which can he used as vanilloid receptor ligands, method of treating diseases, conditions and/or disorders modulated by vanilloid receptors with them, and processes for preparing them.... Agent: Glenmark Pharmaceuticals S.a. C/o Blank Rome

20110021550 - Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation: Compounds of formula (I) wherein the groups R1 to R8 have the meanings indicated in the description, the tautomers, the stereoisomers, the mixtures thereof and the salts thereof have valuable pharmacological properties, which make them useful for the treatment of cardiovascular and related disorders.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20110021551 - Treatment with opioid antagonists and mtor inhibitors: Embodiments of the invention provide methods of treating a disorder or disease characterized by cellular proliferation and migration by co-administering a synergistically effective amount of an mTOR inhibitor and a μ-opioid receptor antagonist.... Agent: Michael Best & Friedrich LLP

20110021552 - Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of depression, anxiety, and neurodegenerative disorders: Pharmaceutical compositions and methods for treating depression, anxiety, and neurodegenerative diseases and cognitive disorders, such as dementia and Alzheimer's disease, by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine.... Agent: Townsend And Townsend And Crew, LLP

20110021553 - Immunosuppressive macrolide powder for oral suspension: The present invention describes pharmaceutical compositions that comprise a tacrolimus powder for oral suspension that exhibits great stability as a powder for suspension and also, once prepared, as the extemporaneous suspension, without the formation of cake-like clusters, same having a satisfactory flavour and a pleasant aroma. The invention also describes... Agent: Hughes Hubbard & Reed LLP

20110021554 - Immune response modifier formulations and methods: An aqueous parenteral pharmaceutical formulation of the IRM drug compound N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide dissolved in water, buffer selected from citric acid, acetic acid, lactic acid, succinic acid, and tartaric acid, and optionally a tonicity adjuster, preferably selected from sorbitol and mannitol, wherein the pH is no greater than 6 and the formulation... Agent: Wolf Greenfield & Sacks, P.C.

20110021555 - Lower dosage strength imiquimod formulations and shorter dosing regimens for treating actinic keratoses: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and... Agent: Edwards Angell Palmer & Dodge LLP

20110021556 - Pyrrolidinyl derivatives and uses thereof: The invention relates to 3,3 disubstituted pyrrole derivatives useful for treatment of diseases associated with monoamine reuptake inhibitors. Also provided pharmaceutical compositions, methods of using, and methods of preparing the compounds.... Agent: Genentech, Inc. Patent Law Dept. M/s 49

20110021557 - Deuterium-enriched pyridinonecarboxamides and derivatives: are partial or full agonists of serotonin (5-Hydroxytryptamine or 5-HT4) receptor subtype 4, and are useful compounds for the prevention and treatment of Alzheimer's disease, cognitive and memory dysfunction, mild cognition impairment, memory decline, cognitive impairment associated with schizophrenia, cognitive impairment associated with age-related dementia or Alzheimer's disease, cognitive impairment... Agent: Dr. D. S. Dhanoa

20110021558 - Thieno-pyridine derivatives as mek inhibitors: A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.... Agent: Feldman Gale, P.A.

20110021559 - Aminopyridines useful as inhibitors of protein kinases: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.... Agent: Vertex Pharmaceuticals Inc.

20110021560 - Compositions and methods for regulating chondrocyte proliferation in bone disorders: The present invention is related to the field of cartilage physiology, repair, and regeneration. In particular, the invention contemplates a treatment for bone healing disorders, especially those related to the articular joints and bone, by upregulating chondrocyte proliferation. For example, inhibition of cysteinyl leukotriene activity on chondrocytes by using cysteinyl... Agent: Medlen & Carroll, LLP

20110021561 - Quinoline compound and pharmaceutical composition, preparation method and uses thereof: The present invention also discloses its pharmaceutical composition and the preparation method thereof and application in manufacturing a medicament for inhibiting HMG-CoA reductase or for the treatment and prophylaxis of the diseases which can be treated effectively by inhibiting HMG-CoA reductase. The quinloline compound and pharmaceutical composition thereof of the... Agent: Birch Stewart Kolasch & Birch

20110021562 - Treatment of friedreich's ataxia using histone deacetylase inhibitors: The invention provides methods of treating Friedreich's ataxia using histone deacetylase inhibitors.... Agent: Schwegman, Lundberg & Woessner, P.A.

20110021563 - Insulin-regulated aminopeptidase (irap) inhibitors and uses thereof: The present invention relates to inhibitors of insulin-regulated aminopeptidase (IRAP) and methods for inhibiting same, as well as compositions comprising said inhibitors. In particular, the inhibitors of the present invention may be useful in therapeutic applications including enhancing memory and learning functions.... Agent: Seed Intellectual Property Law Group PLLC

20110021564 - Method of treating binge eating disorder and obesity resulting from binge eating behavior: The invention provides methods of treating binge eating disorders, obesity resulting from binge eating behavior, and depression. The invention includes methods of treating certain co-morbidities in ADHD and ADD patients; for example the invention includes methods of treating generalized anxiety disorder, obsessional and ruminative thought disorders, and obsessive/compulsive behavior in... Agent: Cantor Colburn LLP

20110021565 - Piperidine derivatives as nk3 antagonists: e

20110021566 - Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms: Methods for predicting whether iloperidone will be efficacious in treating a psychotic symptom in an individual, based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci are described, as are methods for treating an individual based on such prediction.... Agent: Hoffman Warnick LLC

20110021567 - Preparation of lenalidomide: Processes for the preparation of substantially pure lenalidomide. The application also relates to an enriched, substantially pure, and pure amorphous form of lenalidomide and solid dispersions containing amorphous lenalidomide.... Agent: Dr. Reddy''s Laboratories, Inc.

20110021568 - Tubulysin d analogues: The present invention provides novel tubulysin analogues, methods of making and methods of using such analogues and conjugates thereof. The compounds of the invention are highly potent cell-growth inhibitors have been developed that are smaller and considerably more stable than tubulysin D.... Agent: Morgan, Lewis & Bockius LLP (sf)

20110021569 - Piperidine compounds, a process for their preparation and pharmaceutical compositions containing them: e

20110021570 - Pyridone glucokinase activators:

20110021571 - Acyloxyalkyl carbamate prodrugs, methods of synthesis and use: The disclosures herein relate generally to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, pharmaceutical compositions thereof, methods of making prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, methods of using prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, and pharmaceutical compositions thereof for treating or preventing common diseases and/or disorders... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20110021572 - Fungicide hydroximoyl-tetrazole derivatives: The present invention relates to hydroximoyl-tetrazole derivatives, their process of preparation, preparation intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.... Agent: Ostrolenk Faber Gerb & Soffen

20110021573 - Antagonists of prostaglandin d2 receptors: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the antagonists of PGD2 receptors described herein, as well as methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other... Agent: Wilson, Sonsini, Goodrich & Rosati

20110021574 - Anti-cancer compounds, synthesis thereof, and methods of using same: Embodiments relate to the field of chemistry and biochemistry, and, more specifically, to anti-cancer compounds, synthesis thereof, and methods of using same. Disclosed herein are various heterocyclic compounds and methods of using the novel anti-cancer compounds to inhibit the growth of a cancer cell, for instance a leukemia, non-small cell... Agent: Schwabe Williamson & Wyatt Pacwest Center, Suite 1900

20110021575 - Penetration enhancers for insecticidal agents: b

20110021576 - Novel process to prepare pioglitazone via several novel intermediates: A novel process for preparing thiazolidinediones, preferably Pioglitazone, as described. Also described are novel intermediates involved in its synthesis and process for their preparation and use in medicine.... Agent: Nixon & Vanderhye, PC

20110021577 - Aryloxy amine compounds and their use as sodium channel modulators: The present invention relates generally to the field of therapeutic treatment and compounds having utility therefor, in particular the therapy or management of conditions associated with excessive, unwanted or undesirable sodium ion passage through cellular membranes via voltage-gated sodium channels. In one embodiment the invention is concerned with the treatment... Agent: Banner & Witcoff, Ltd.

20110021578 - Compounds which potentiate the ampa receptor and uses thereof in medicine: Compounds of formula (I) and salts thereof are provided: wherein n is 0, 1, 2 or 3; R1 is selected from phenyl and pyridyl, each of which is optionally substituted by one or two groups independently selected from C1-4alkyl and halogen; and R2 is selected from H and CH3 when... Agent: Glaxosmithkline Global Patents -us, Uw2220

20110021579 - Peritoneum protecting agent: It is an objective of the present invention to provide a novel peritoneal membrane protecting agent which can effectively suppress deterioration of peritoneal functions in long-term peritoneal dialysis (PD) patients and the like. The present invention provides a peritoneal membrane protecting agent comprising a pyridoxine or a salt thereof, as... Agent: Greenblum & Bernstein, P.L.C

20110021580 - Plant disease control composition: A plant disease control composition comprising, as an active ingredient, a compound of formula (I) or a salt thereof, and one or more anilinopyrimidine compounds selected from the group consisting of 4,6-dimethyl-N-phenyl-2-pyrimidinamine, 4-methyl-N-phenyl-6-(1-propynyl)-2-pyrimidinamine and 4-cyclopropyl-6-methyl-N-phenyl-2-pyrimidinamine has an excellent plant disease control effect.... Agent: Dickstein Shapiro LLP

20110021581 - Dosing regimen for a selective s1p1 receptor agonist: The present invention relates to a dosing regimen for a selective S1P1 receptor agonist, whereby the selective S1P1 receptor agonist is administered to a subject in such a way that during the initial treatment phase the selective S1P1 receptor agonist is administered at a dose which induces desensitization of the... Agent: Hoxie & Associates LLC

20110021582 - Benzophenone thiazole derivatives useful for inhibiting formation of microtubule and method for producing the same: Disclosed are a novel thiazole-containing benzophenone derivative represented by formula 1, and an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof and a solvate thereof, a pharmaceutical composition comprising the derivative, a use of the derivative as therapeutic agent and a method for preparing the derivative. The benzophenone... Agent: Lucas & Mercanti, LLP

20110021583 - Enhanced transmucosal composition and dosage form: The invention provides a transmucosal pharmaceutical composition comprising an active compound, a bile salt and an osmolality adjusting ingredient, wherein the osmolality adjusting ingredient generates a localized hyperosmotic environment and maintains an osmolality level for a period of time sufficient to produce hypertonicity-facilitated transmucosal transport of said active compound across... Agent: Ross J. Oehler Cephalon, Inc.

20110021584 - Methods and assays for detecting and treating hypoglycemia: Methods for regulating glucagon release and of treating hypoglycemia, and for screening drug candidates for treating hypoglycemia. The methods are useful for treating diabetes mellitus and screening drug candidates for potential efficacy.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20110021585 - Dual-acting antihypertensive agents: wherein: Ar, r, R3, Z, X, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates... Agent: Theravance, Inc.

20110021586 - Phenyl-sulfamates as aromatase inhibitors: wherein X, Y and Z are each independently of each other an optional linker group; R1 is a ring system; R2 is selected from hydrocarbyl groups, oxyhydrocarbyl groups, cyano (—CN), nitro (—NO2) and halogens; R3 and R4 are independently selected from H and hydrocarbyl, ring A and B are independently... Agent: Frommer Lawrence & Haug

20110021587 - Methods of reducing or eliminating bacteria in consumable eggs: Methods are provided for reducing or eliminating bacteria such as Salmonella in eggs for human consumption through the use of at least one N,N-dihalo-5,5-dialkylhydantoin in which each of the alkyl groups independently comprises from 1 to about 6 carbon atoms.... Agent: Albemarle Corporation Patent Department

20110021589 - Imidazolic compounds and use thereof as alpha-2 adrenergic receptors: wherein: R1 is hydrogen, fluorine or a methoxyl group, R1 being in position 2, 3, 4 or 5 of the aromatic carbocycle; R2 is hydrogen or a methyl group; R3 is hydrogen, a methyl group or an ethyl group; and their pharmaceutically acceptable acid addition salt as well as the... Agent: Buchanan, Ingersoll & Rooney PC

20110021588 - Sublingual dexmeditomidine compositions and methods of use thereof: Analgesic sublingual formulations of dexmedetomidine and methods of use thereof are provided for use in the prevention, treatment and management of pain and other conditions.... Agent: Saul Ewing LLP (harrisburg) Attn: Patent Docket Clerk

20110021590 - Aminopyrrolidinone derivatives and uses thereof: a

20110021591 - Phenylbutazone carrier formulation showing increased bioactivity in animals: An improved phenylbutazone carrier composition provides increased palatability to horses. Additionally, the composition improves the bioavailability of the phenylbutazone and thus increases the horse's blood plasma levels of the medicine for the same effective dosage of the medicine.... Agent: BatemanIPLaw Group

20110021593 - Novel crystal of substituted phenylalkanoic acid ester and process for producing the same:

20110021592 - Organic nanoparticles obtained from microemulsions by solvent evaporation: The present invention provides a process for preparing a redispersible powder of nanoparticles of a water-insoluble organic compound, the process including the steps of: (i) preparing an oil-in-water microemulsion comprising a water-insoluble organic compound, a volatile water-immiscible organic solvent, water, and at least one surfactant; and (ii) removing the volatile... Agent: Winston & Strawn LLP Patent Department

20110021594 - Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof: The present invention provides compounds and methods of administering compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce βAPP production... Agent: Riverside Law LLP

20110021595 - Ketorolac tromethamine compositions for treating or preventing ocular pain: The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises mixtures of carboxymethyl cellulose in an aqueous solution wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye and improve visual acuity of the users.... Agent: Allergan, Inc.

20110021596 - Topical therapy for migraine: The invention is directed to formulations and methods of treating a migraine and/or cluster headache with a serotonin agonist, pharmaceutically acceptable salt thereof, or derivative thereof.... Agent: Davidson, Davidson & Kappel, LLC

20110021597 - 3-phenoxymethylpyrrolidine compounds: e

20110021598 - Controlled release formulations: The invention relates to a controlled release formulation for an oral cytokine inhibitor of interleukin-1 beta converting enzyme.... Agent: Jonathan P. O'brien, Ph.d. Honigman Miller Schwartz And Cohn LLP

20110021613 - Plants extracts for use in brain modulation: e

20110021614 - Use of silymarin and silybin in the treatment of neural injury: The present invention provides a method of treating neural injury, e.g., spinal cord injury (SCI), or enhancing recovery from the neural injury with silymarin or silybin.... Agent: Occhiuti Rohlicek & Tsao, LLP

20110021615 - method of protecting plant(s) and a process thereof: The present invention relates to a method of treating plant(s) against larval pests by the use of terreulactone. It also relates to a process for producing meroterpenoid from fungus Aspergillus terreus strain MTCC5390.... Agent: Oliff & Berridge, PLC

20110021616 - Halogenated rhodamine derivatives and applications thereof: Methods for treating a bacterial infection in a tissue sample are described. Tissue samples that are harvested from a patient may be infected with bacteria. A rhodmaine compound is mixed with the infected tissue sample to form a mixture. The mixture is then exposed to radiant energy to inhibit or... Agent: O''melveny & Myers LLP Ip&t Calendar Department La-13-a7

20110021617 - Medicinal acidic cannabinoids: The invention relates to an acidic cannabinoid for medical use and to a cannabis extract comprising an acidic cannabinoid. The extract may comprise one or more compounds selected from the group consisting of cannabidiolic acid (CBD-A), cannabidiol (CBD), cannabigerolic acid (CBGA), cannabigerol (CBG), cannabinolic acid (CBN-A) and cannabinol. The invention... Agent: Banner & Witcoff, Ltd.

20110021618 - Methods of treating fibrotic disorders: Described herein are compositions and methods for preventing and/or treating fibrotic disorders employing one or more benzo[c]chromen-6-one derivatives.... Agent: Burns & Levinson, LLP

20110021619 - External preparation for skin containing flavanone derivative: To increase a tissue regeneration ability of a living body such as a collagens production ability of fibroblast in the dermis in a skin defect area typified by a large wrinkle or wound, a flavanone derivative such as farrerol is used as an active ingredient of an external preparation for... Agent: Knobbe Martens Olson & Bear LLP

20110021620 - Use of tea polyphenols in preparing medicaments for prevention or treatment of tumors: Use of tea polyphenols in preparing medicaments for prevention or treatment of tumors is provided. The tea polyphenols are tea extracts comprising EGCG, EGC, and ECG, or Tegreen 97®, a green tea capsule of PHARMANEX, INC.... Agent: Patterson Thuente Christensen Pedersen, P.A.

20110021621 - Drug for treating circulatory insufficiency: and/or a physiologically acceptable salt thereof as an active ingredient, wherein R1 is an alkyl group having 1 to 10 carbon atoms, or an alkenyl group having 2 to 10 carbon atoms; and any one of R2, R3, R4 and R5 is a hydroxyl group, an alkoxy group, an alkenyloxy... Agent: Kratz, Quintos & Hanson, LLP

20110021622 - Stabilized synthetic brood pheromone and race-specific ratios of components for manipulating the behavior and physiology of honey bees: This invention relates to a 10-component stabilized synthetic honey bee brood pheromone and methods of stabilizing said pheromone by adding one or more antioxidants, thereby enabling the production and sustained use of commercial products based on that pheromone. The 11-component stabilized pheromone composition formed by adding the antioxidant tertiary-butyl hydroquinone... Agent: Oyen, Wiggs, Green & Mutala LLP 480 - The Station

20110021623 - System and methods of melanoma prevention: Inhibiting the enzymic action of tyrosinase in the melanocyte prior to, during, or after ultraviolet (UV) radiation exposure, including over-exposure causing erythema, or sunburn, prevents the production of melanin and thereby melanoma. Melanoma can be prevented by using a tyrosinase inhibitor agent that inhibits the enzymic action of tyrosinase to... Agent: Valauskas Corder LLC

20110021624 - Alpha-amino-n-substituted amides, pharmaceutical composition containing them and uses thereof: Disclosed are a series of α-amino-N-substituted amide compounds having a structure of the following formula, the pharmaceutically acceptable salts thereof, and the pharmaceutical composition comprising the same. The α-amino-N-substituted amide compounds or the pharmaceutically acceptable salts thereof according to the present invention have anti-tumor and/or anti-cancer activities in vivo and... Agent: Baker & Hostetler LLP

20110021625 - Neuronal cell death inhibitor: (where R1 is a hydrogen atom or an optionally substituted hydroxy group; R2 is a hydrogen atom; R3 is a hydrogen atom or an optionally substituted hydroxy group; R4 is a hydrogen atom or an optionally substituted hydroxy group, R3 together with R4 is optionally an oxo group or a... Agent: Oliff & Berridge, PLC

20110021626 - Encapsulation of vitamin c into water soluble dendrimers: The invention relates to a conjugated dendrimer that comprises at least one water-soluble dendrimer and at least one vitamin C molecule. The conjugated dendrimer can be used e.g. for preparing cosmetic or pharmaceutical compositions. The dendrimers have a good vitamin C load capacity and are biocompatible.... Agent: Arent Fox LLP

20110021627 - Nitrile compound and its use for control of arthropod pest: There is provided a nitrile compound having an excellent controlling effect on arthropod pests represented by the formula (I): wherein m represents in integer of 0 to 4; n represents an integer of 1 to 4; q represents an integer of 0 to 4; Q represents a C1-C4 fluoroalkyl group;... Agent: Birch Stewart Kolasch & Birch

20110021628 - Crystalline form of y-aminobutyric acid analog: A crystalline form of a γ-aminobutyric acid analog, and methods of preparing same, are provided.... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20110021629 - Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof: New iron preparations comprising stable, unpolymerized iron(III) citrate complex compositions and methods for their preparation are provided. Further, the invention involves the use stable, unpolymerized iron(III) citrate complex compositions of the invention as a food additive, nutritional supplement, dietary supplement, medical food, nutrient, iron fortificant, and source of iron in... Agent: Casimir Jones, S.c.

20110021630 - Method for treating wounds by administering fullerenes: Disclosed herein are methods for treating wounds. In one embodiment, the method comprises: administering to a subject in need thereof a therapeutically effective amount of a synthetically modified fullerene of the formula Zm—F—Yn wherein F is a fullerene of formula Cp or X@Cp, the fullerene having two opposing poles and... Agent: Buchanan, Ingersoll & Rooney PC

20110021631 - Method of preparing stabilized pharmaceutical compositions comprising active ingredients susceptible to conversion to alternate polymorph forms: A process is described for the preparation of a pharmaceutical comprising an active pharmaceutical ingredient capable of existing in multiple polymorphic forms, wherein the process comprises a step of preparation of a wet phase comprising the active pharmaceutical ingredient and microcrystalline cellulose and a liquid, wherein in the wet phase... Agent: Arent Fox LLP

20110021632 - Use of creatine or creatine compounds for skin preservation: The present invention relates to the use of creatine compounds such as, for example, creatine, creatine phosphate or analogs of creatine, such as creatine-pyruvate, creatine-ascorbate, cyclocreatine, 3 guanidinopropionic acid, guanidinoacetate, homocyclocreatine, guanidino benzoates as energy generating systems and antioxidants for preservation of skin against adverse aging effects and damage secondary... Agent: Mccarter & English, LLP Boston

20110021633 - Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states: This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of... Agent: Stinson Morrison Hecker LLP Attn: Patent Group

20110021634 - Processes for preparing metformin hydrochloride: i

20110021635 - Rbm3 as a marker for breast cancer prognosis: The present invention provides means, such as a method, for determining whether a prognosis for a mammalian subject having a breast cancer is better than a reference prognosis. The method comprises the steps of: providing a sample earlier obtained from the subject; evaluating the amount of RBM3 protein present in... Agent: Ladas & Parry LLP

20110021636 - Method for crystallization of 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-ethyl]-1,3-propanediol hydrochloride: A method for highly efficiently preparing high purity crystals of 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chloro-phenyl]-ethyl]-1,3-propanediol hydrochloride. The method involves dissolving 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol in a mixed solvent comprising a solvent in which its hydrochloride is highly soluble and a solvent in which its hydrochloride is less soluble, to prepare a solution of 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol; and then adding... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20110021637 - Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment: Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on xanthohumol or isoxantohumol, or tetrahydro-isoalpha acids commonly found in hops.... Agent: Mcdermott Will & Emery

20110021638 - Modulation of inflammation by hops fractions and derivatives: A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandin selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops.... Agent: Mcdermott Will & Emery

20110021639 - Microbially stable dispersion medium for emulsions: The present invention relates to novel microbial stable emulsions advantageously utilizing dispersion media characterized by lower water activity and advantageously utilizing dispersants which exhibit high water binding capacity and which exhibit characteristics which provide for steric stabilization and charge distribution (zeta potential) in relation to the dispersed phase, and methods... Agent: The Firm Of Hueschen And Sage

20110021640 - Mechanism-based biochemical standardization of resveratrol products and their uses thereof: The present invention pertains to methods (a) Inhibition of adenosine deaminase by resveratrol products including botanical extracts containing resveratrol and/or oxyresveratrol; (b) Biochemical Standardization of these products as Enzyme Inhibitory Units (EIU) per mg or gram; and (c) Their uses thereof.... Agent: Kailash Chandra Agarwal

20110021641 - Suspension formulation for carbon adsorbents: The invention relates to an aqueous suspension formulation comprising a coarsely particulate carbon adsorbent which is suitable for binding and eliminating harmful substances from the gastrointestinal tract, and a water-soluble or water-dispersible structure-forming agent and a humectant.... Agent: Bayer Healthcare LLC

20110021642 - Water-soluble acrylic acid salt polymer and gelling base: An object of the present invention is to provide a water-soluble acrylate polymer that can form a gelling base. When used in forming a poultice or cooling sheet, the gelling base not only imparts desirable stretchability, but also has an appropriate reaction rate with a polyvalent metal. The gelling base... Agent: Kratz, Quintos & Hanson, LLP

20110021643 - Processed starch powder with excellent disintegration properties and manufacturing method thereof: Disclosed are a processed starch powder in which the amount of water soluble component is greater than 2 wt % but less than 10 wt %, the water retention amount is greater than 600% and 1500% or less, and which comprises nonbirefringent particles, and a manufacturing method thereof.... Agent: Greenblum & Bernstein, P.L.C

  
01/20/2011 > patent applications in patent subcategories. recently filed with US Patent Office

20110015116 - Method for treating muscular dystrophy: The object of the present invention is to provide a method for treating muscular dystrophy. The method for treating muscular dystrophy according to the present invention is characterized in comprising a step of administering a caldecrin.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20110015117 - Methods for increasing absorption of peptides, peptidomimetics and other gastrointestinal transport protein substrates: Methods and compositions useful for enhancing the absorption and/or transport of peptides, peptidomimetics, and other gastrointestinal transport protein substrates through gastrointestinal transport proteins are provided. The methods comprise using hormones such as 5-methoxy-N-acetyltryptamine to increase the transport of the peptides, peptidomimetics, and substrates. The compositions comprise one or more hormones... Agent: Wendell Ray Guffey Nestle Purina Petcare Global Resources, Inc.

20110015118 - C-terminal ifapsoriasin fragments as antimicrobial peptides, the production thereof and use thereof: The present invention relates to novel C-terminal ifapsoriasin fragments as antimicrobially acting peptides and their production and use as pharmaceuticals.... Agent: Diederiks & Whitelaw, PLC

20110015119 - Novel semi-synthetic glycopeptides as antibacterial agents: Semi-synthetic glycopeptides having antibacterial activity are described, in particular, the semi-synthetic glycopeptides described herein are made by chemical modification of a glycopeptide (Compound A, Compound B, Compound H or Compound C) or monosaccharide made by hydrolyzing the disaccharide moiety of the amino acid-4 of the parent glycopeptide in acidic medium... Agent: Jones Day

20110015120 - Pharmaceutical and cosmetic compositions including lactoferrin, ciclopirox, etidronic acid: Pharmaceutical and cosmetic compositions for topical use comprising Lactoferrin, Ciclopirox and/or salts thereof, Etidronic Acid and/or salts thereof and use of said compositions in the treatment of dermatological disorders and conditions such as seborrheic dermatitis and dandruff.... Agent: Bucknam And Archer

20110015121 - Cyclic compound and salt thereof: A compound useful as an antifungal agent, particularly a therapeutic agent for deep-seated mycoses, is provided. A fungus Acremonium persicinum was collected, and cyclic compounds were isolated from culture liquids thereof. The present inventors confirmed that the cyclic compounds or salts thereof have a potent antifungal activity and are useful... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20110015122 - Hepatitis b virus-binding polypeptides and methods of use thereof: The present invention provides non-naturally occurring polypeptides that specifically bind hepatitis B virus (HBV) DNA; and polynucleotides encoding the polypeptides. The present invention further provides methods of detecting HBV DNA; methods of detecting a covalently closed circular DNA (cccDNA) form of HBV; and methods for treating HBV infection.... Agent: Bozicevic, Field & Francis LLP

20110015124 - Leptin agonist and methods of use: Peptides are provided having leptin receptor agonist activity. The peptides are useful for treating obesity, insulin resistance, lipodystrophy and hypothalamic amenorrhea, anorexia-related infertility, among other diseases and conditions related to leptin deficiency and/or leptin resistance.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20110015123 - Modulation of glut4 gene promoter activity by ahnak: Agents capable of alleviating AHNAK phosphoprotein-mediated repression of GLUT4 gene expression are useful for prevention, treatment, and/or alleviation of insulin resistance associated with obesity, lipotoxicity, hypertension, metabolic syndrome and type 2 diabetes. Preferred agents are double-stranded siRNAs.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20110015125 - Adhesives and methods of applying the same: A composition including pre-gel including at least one phenol-based compound, excluding phloroglucinol and derivatives, at least one water miscible polymer, at least one cross linking agent capable of interacting with the polymer. The polymer is selected from one or more natural and/or synthetic carbohydrate, and salt of an anionic polysaccharide.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20110015126 - Compositions and methods for inducing apoptosis in tumor cells: A method is described for using an E-domain peptide for the induction of apoptosis in a cancer cells. In particular, the invention relates to methods for using a-type E-domain peptide from trout IGF and/or a b-type E-domain peptide from human IGF for the induction of apoptosis in a broad spectrum... Agent: Mccarter & English, LLP Stamford

20110015127 - Targeting complement factor h for treatment of diseases: The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which... Agent: Morrison & Foerster LLP

20110015128 - Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same: The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.... Agent: Portola Pharmaceuticals, Inc. C/o Foley & Lardner LLP

20110015129 - New paediatric indications for direct thrombin inhibitors: The invention relates to new paediatric indications for direct thrombin inhibitors such as dabigatran etexilate.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20110015130 - Polypeptides selective for alphavbeta3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof: The invention generally relates to fusion proteins comprising a rhodostomin variant having an RGD motif variant 48ARLDDL53, wherein the rhodostomin variant is conjugated with a variant of Human Serum Albumin (HSA). The invention also relates to the use of these fusion proteins for treatment and prevention of αvβ3 integrin-associated diseases.... Agent: Wood, Phillips, Katz, Clark & Mortimer Citigroup Center, Suite 3800

20110015131 - Methods for preventing and treating alzheimer's disease (ad): The present invention relates to methods for preventing Alzheimer's disease (AD) with an Aβ42 mimotope and binds to an antibody specific for DAEFRH (SEQ ID NO: 1) which is a part of the naturally-occurring Aβ42 sequence.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20110015132 - Synergistic 5'-methylthioadenosine combinations: The present invention relates to combinations of 5′-methylthioadenosine and glatiramer acetate, and to their use in the treatment of multiple sclerosis. In a particular embodiment, the present invention relates to a product comprising 5′-methylthioadenosine and glatiramer acetate as a combined preparation for the simultaneous, separate, or sequential use thereof for... Agent: Moore & Van Allen PLLC

20110015134 - Method of treatment for early stage cancer: This patent describes a method and materials to treat cancer diagnosed at an early stage, particularly breast cancer. It considers that metastatic breast cancer growth includes periods of dormancy, that surgery to remove a primary tumor can induce metastatic growth, and that women with Down Syndrome rarely get breast cancer.... Agent: Michael W. Retsky

20110015133 - Pax2 and pax8 as tumour targets for immunologic and molecular treatment strategies: Briefly, the present invention refers to the transcription factors PAX2 and PAX8 expressed in solid tumours and haematologic malignancies, and their utility as a target in immunotherapy and molecular therapy. In more detail, the invention refers to a method for identifying an immunogenic T-cell epitope from PAX2 and/or PAX8. Furthermore,... Agent: Baker & Daniels LLP

20110015135 - Antitumoral treatments: The present invention relates to combinations of PM02734 with another anticancer drug selected from Cisplatin, Gemcitabine, Paclitaxel, Oxaliplatin, 5-Fluorouracil, Trabectedin, Rapamycin, and Sunitinib, and the use of these combinations in the treatment of cancer.... Agent: King & Spalding

20110015136 - Humanized model of membrane attack complex (mac) formation on murine retina and compositions, kits and methods for treatment of macular degeneration: Methods and compositions for treating a subject having age-related macular degeneration (AMD), methods of assaying human macular degeneration (MD), and methods and kits for assaying potential therapeutic agents for treatment of human MD are provided herein.... Agent: Lawson & Weitzen, LLP

20110015137 - Reca inhibitors and their uses as microbial inhibitors or potentiators of antibiotic activity: The present invention provides RecA inhibitors, compositions containing them, systems for identifying or characterizing them, and methods of using them.... Agent: Choate, Hall & Stewart LLP

20110015138 - Inhibition of inflammation using antagonists of muc1: The invention provides for peptides from the MUC1 cytoplasmic domain and methods of use therefor. These peptides can inhibit MUC1 oligomerization, inhibit the interaction of MUC1 with NF-κB or a STAT, and block inflammatory response mediated by NF-κB or STAT signaling.... Agent: Fulbright & Jaworski L.L.P.

20110015139 - Histidine related compounds for identifying and blocking amyloid beta ion channels: The present disclosure relates to amyloid beta (Aβ) channels and the diseases and disorders caused by abnormal activity in these channels, such as Alzheimer's disease, Lewy body dementia, inclusion body myositis, or cerebral amyloid angiopathy. The disclosure provides compositions and methods that block AO channel activity and/or reduce Aβ-induced toxicity... Agent: Mh2 Technology Law Group, LLP

20110015140 - Anti-diabetes composition containing chicoric acid and/or one of the metabolites thereof: The present invention relates to the use of chicoric acid and/or at least one of these metabolites selected among mono-caffeoyl-tartaric acid and/or m-hydroxyphenylpropionic acid, and/or 4-vinylcatechol and/or 4-ethylcatechol for manufacturing a composition intended for prevention or treatment in an insulin-resistant patient or hypoinsulinemia and/or associated pathologies.... Agent: Foley And Lardner LLP Suite 500

20110015141 - Method for treating cancers having high glucose requirements employing an sglt2 inhibitor and compositions thereof: Methods are provided for treating cancers that have high glucose requirements and that express SGLT2 at levels higher than normal cells, such as metastatic cancers, for example, metastatic lung cancers, employing an SGLT2 inhibitor alone or in combination with a cytotoxic agent and to a composition containing a combination of... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP Bristol-myers Squibb

20110015142 - Method for preparing gynostemma pentaphyllum extract with increasing damulin a and damulin b contents, and pharmaceutical compositions of the same for treating metabolic disease: Disclosed is an AMPK activating material used for improving and treating metabolic syndrome, in which AMPK (AMP-activated protein kinase) is a main enzyme for regulating an energy sensor and lipid/glucose metabolism in the body. The activation of AMPK inhibits the synthesis of fat and cholesterol, and accelerates the reduction of... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20110015143 - Use of one or more of glycyrrhizic acid for reducing the irritating action of surfactants in cosmetic compositions: The present invention relates to the use of an agent to combat and reduce the irritating action of primary surfactants in compositions to be applied to the skin for care or cleansing of the face and body, characterized in that said agent is chosen from Cone or more salts of... Agent: Squire, Sanders & Dempsey L.L.P.

20110015144 - Administration method proposing device: An administration method proposing device (100) includes an input unit (101) that receives an input of the cancer type of a cancer patient, an administration procedure determination unit (102) that determines the administration order of an FEC (F: 5-fluorouracil, E: epirubicin, and C: cyclophosphamide) administration cycle and a docetaxel administration... Agent: Wenderoth, Lind & Ponack, L.L.P.

20110015253 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.... Agent: Seed Intellectual Property Law Group PLLC

20110015250 - Compositions and methods for inhibiting expression of eg5 gene: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Eg5 gene (Eg5 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part... Agent: Alnylam/fenwick

20110015252 - Lipid formulated dsrna targeting the pcsk9 gene: This invention relates to composition and methods using lipid formulated siRNA targeted to a PCSK9 gene.... Agent: Alnylam/fenwick

20110015249 - Methods and compositions for treatment of cancer and other angiogenesis-related diseases: The present invention provides nucleic acid molecules that modulate the expression of molecules in the angiopoietin/Tie2 signaling pathway. Methods of using the nucleic acid molecules are also provided.... Agent: Ropes & Gray LLP

20110015254 - Ptph1 inhibitors for the treatment of alzheimer's disease: The present invention relates to the use of PTPH1 inhibitors in the prevention or treatment of Alzheimer's Disease, or a symptom thereof. The present invention also relates to a method of identifying compounds useful in the prevention or treatment of Alzheimer's Disease, or a symptom thereof.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20110015251 - Rna interference mediated inhibition of human immunodeficiency virus (hiv) gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of human immunodeficiency virus... Agent: Merck C/o Sirna Therapeutics, Inc.

20110015258 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.... Agent: Seed Intellectual Property Law Group PLLC

20110015256 - Delivery of restriction endonucleases to treat hiv, cancer, and other medical conditions: A method of treating a medical condition caused by the presence of an undesired DNA sequence in a predetermined cell type of a subject by administering to the subject one or more restriction endonucleases to specifically cleave the undesired DNA sequence.... Agent: Sheldon Mak & Anderson PC

20110015257 - Hypoxia inducible vegf plasmid for ischemic disease: Plasmids useful for treating ischemic disease, such as ischemic heart disease, are described. The plasmids express vascular endothelial growth factor (VEGF) under the control of a promoter (RTP801) that is up-regulated under hypoxic conditions. Pharmaceutical compositions for treating ischemic disease include mixtures of the hypoxia-regulated VEGF plasmids and pharmaceutically acceptable... Agent: Alan J. Howarth

20110015255 - Treatment of an infection by an rna virus due to an rna dependent rna polymerase: The present invention concerns a simple RNA strand, which includes, from extremity 3′ to extremity 5′, (i) a sequence of complementary nucleic acid to the non-coding region 5′ (5′UTR) of the genomic RNA (strand (+)) of the hepatitis C virus (VHC) or another RNA virus replicating thanks to an RNA... Agent: Harness, Dickey & Pierce, P.L.C

20110015145 - Cladribine formulations for improved oral and transmucosal delivery: Provided are compositions of cladribine and cyclodextrin which are especially suited for the oral and buccal administration of cladribine.... Agent: Buchanan, Ingersoll & Rooney PC

20110015146 - Nucleoside phosphoramidates: A nucleoside compound having activity against hepatitis C virus is disclosed.... Agent: Merchant & Gould PC

20110015147 - Anti-viral pyrimidine nucleoside analogues: A compound of formula (I) wherein Ar can be one six-membered or two fused six-membered aromatic rings; R8 and R9 can be hydrogen, alkyl, cycloalkyl, halogens, amino, alkylamino, dialkylamino, nitro, cyano, alkyoxy, aryloxy, thiol, alkylthiol, arythiol, or aryl; Q can be O, S or CY2, where Y may be H,... Agent: Stites & Harbison PLLC

20110015148 - Antiviral nucleosides: 4-Amino-1-((2R,3S,4S,5R)-5-azido-4-hydroxy-5-hydroxymethyl-3-methyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one (22) and prodrugs thereof are hepatitis C (HCV) polymerase inhibitors. Also disclosed are compositions and methods for inhibiting HCV and treating HCV-mediated diseases, processes for making the compounds and synthetic intermediates employed in the process.... Agent: Birch Stewart Kolasch & Birch

20110015149 - Compounds, compositions and methods for the treatment of viral infections and other medical disorders: The present application provides methods and compositions for improving the bioavailability of a lipid-containing antiviral compound, and in particular, an antiviral lipid-containing compound. In one embodiment, pharmaceutically acceptable compositions are provided that include an antiviral lipid-containing compound, or salt, ester, or prodrug thereof and one or more bioavailability enhancing compounds,... Agent: Myers Bigel Sibley & Sajovec

20110015150 - Methods of administering compositions including iron: Nutritional or dietary supplement compositions that promote and/or maintain dietary iron absorption through administration of iron with an organic acid and optionally similar iron absorption promoters are provided. Also provided are methods of nutritional or dietary supplementation using one or more compositions that promote and/or maintain health through the prevention,... Agent: Kv Pharmaceutical Company

20110015151 - Combination of viscoelastics for use during surgery: An improved viscoelastic composition useful in the performance of ophthalmic surgical procedures and especially cataract procedures is disclosed. The embodiments of the composition comprise combinations of sodium hyaluronate and chondroitin sulfate and exhibit an improved rheological profile.... Agent: Alcon

20110015152 - Diarylmethyl and related compounds: wherein R1, R2, R3, R4, R5, R6, R7, Ar1, Ar2, E, a, b, c and z are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity and therefore,... Agent: Theravance, Inc.

20110015153 - Fly control method: e

20110015154 - Supporting acetylcholine function: This document provides methods and materials related to regulating inflammatory pathways. For example, compositions and kits containing two or more of an anticholinesterase compound, a choline compound, and a carnitine compound and methods for using the compositions and kits described herein to support acetylcholine function to regulate one or more... Agent: Fish & Richardson P.C. (tc)

20110015155 - Deuterated 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses: The present disclosure provides biologically active deuterated 2,4-pyrimidinediamine compounds and prodrugs thereof, compositions comprising the deuterated compounds, intermediates and methods for synthesizing the deuterated compounds and methods of using the deuterated compounds in a variety of applications.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20110015156 - Heterocyclic compounds for the treatment of neurological and psychological disorders: Lactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.... Agent: Elmore Patent Law Group, PC

20110015157 - Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1: This invention relates to novel compounds of the Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih); (Ii); (Ij), (Ik), (II) pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals.... Agent: Foley & Lardner LLP

20110015158 - Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties: The presently disclosed subject matter is described to metalloenzyme inhibitors having metal binding moieties linked to a targeting moiety through a linking group or a direct bond, method of screening for metalloenzyme inhibitors, and methods for treating a metalloenzyme related disorder by administering a metalloenzyme inhibitor to a subject in... Agent: Alston & Bird LLP

20110015159 - Methods of inhibiting vascular permeability and apoptosis: Agonists of vascular endothelial sphingosine-1-phosphate receptors are described. Compounds such as FTY720 can be phosphorylated by sphingosine kinase-2 into the phosphorylated forms which serve as sphingosine-1-phosphate receptor agonists. The vascular endothelial sphingosine-1-phosphate receptor agonists are employed in methods of treating a mammal for vascular permeability disorders and unwanted vascular endothelial... Agent: Cantor Colburn LLP

20110015160 - Methods of treating neurological diseases using docosahexaenoic acid and arachidonic acid compositions: A method of treating a neurological disorder comprises administering to a person affected from such a disorder a microbial oil comprising DHA, a microbial oil comprising ARA or a combination of DHA and ARA oils in an amount sufficient to elevate the levels of circulating DHA and/or ARA in the... Agent: Dechert LLP

20110015162 - 15,16-methylene-17-hydroxy-19-nor-21-carboxylic acid-steroid y-lactone derivative, use thereof and medicinal products containing the derivative: The invention relates to 15,16-methylene-17-hydroxy-19-nor-21-carboxylic acid-steroid γ-lactone derivatives with the general chemical formula I, and R4, R6a, R6b, R7 and Z have the meanings stated in claim 1, and their solvates, hydrates, stereoisomers and salts. The invention further relates to the use of these derivatives for the production of a... Agent: Millen, White, Zelano & Branigan, P.C.

20110015161 - Pharmaceutical containing a horomone combination having a contraceptive effecr and an insulin sensitizer: The present invention relates to a medicament in the form of daily units, which contain an active ingredient combination consisting of a hormone combination with contraceptive action consisting of at least one oestrogen selected from the group consisting of estradiol and ethinyl estradiol and at least one gestagen selected from... Agent: Briscoe, Kurt G. Norris Mclaughlin & Marcus, Pa

20110015163 - Crystalline freebase forms of a biphenyl compound: The invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases; processes and intermediates for preparing the crystalline freebases; and methods of using the crystalline freebases to treat a pulmonary disorder.... Agent: Theravance, Inc.

20110015164 - Method of treating men with metabolic and anthropometric disorders: A method of safely and specifically treating the combined metabolic disturbances of insulin resistance and visceral adiposity in male subject with visceral adiposity, metabolic syndrome (also known as the ‘insulin resistance syndrome’, and ‘syndrome X’), type II diabetes, or insulin resistance by administering a 5-alpha reductase inhibiting compound of structural... Agent: Merck

20110015165 - Modified, hydroxy-substituted aromatic structures having cytoprotective activity: The present invention is directed to a process for conferring cytoprotection on a population of cells which comprises administering to that population of cells a compound comprising a hydroxy-substituted aromatic ring structure and a non-fused polycyclic, hydrophobic substituent attached thereto. In particular, the present invention is directed to such a... Agent: Patrick W. Rasche (15060) Armstrong Teasdale, LLP

20110015166 - Topically active steroids for use in interstitial pulmonary fibrosis: The present invention features methods of delivering corticosteroids or metabolites thereof for treating inflammatory conditions otherwise difficult to cure with topical administration.... Agent: Lewis Kohn & Fitzwilliam LLP

20110015167 - Use of norgestimate as a selective inhibitor of trpc3, trpc6 and trpc7 ion channels: TRPC ion channels are non-selective channels widely expressed in human tissues. These channels are involved in numerous physiological functions and are putative targets for the development of novel medicines. There is a need to gain a better understanding of TRPC ion channels in cells and beyond. The present invention provides... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20110015168 - Methods for increasing levels of human fetal hemoglobin: The invention provides methods for increasing the level of human fetal hemoglobin in a subject or cell in need thereof. The methods can be used with subjects suffering from a β-chain hemoglobinopathy including thalassemia (e.g., β-thalassemia) or sickle cell anemia.... Agent: Choate, Hall & Stewart LLP

20110015169 - Methods for in vitro maturation of ovarian follicles: The invention relates to methods to be used in the maturation of ovarian follicles and oocytes. More specifically, the invention concerns the use of inhibitors of the phosphatase PTEN, such as oxovanadate and peroxovanadate complexes, in methods for in vitro and in vivo maturation of follicles and oocytes.... Agent: Schwegman, Lundberg & Woessner, P.A.

20110015170 - Azetidinyl diamides as monoacylglycerol lipase inhibitors: e

20110015171 - Azetidinyl diamides as monoacylglycerol lipase inhibitors:

20110015172 - Pyrrolopyrazine inhibitors of kinases:

20110015173 - Pyrrolopyridine inhibitors of kinases:

20110015174 - Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer: A CPT1 inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to... Agent: Foley & Lardner LLP

20110015175 - Bicyclic compounds for the reduction of beta-amyloid production: C

20110015177 - Substituted arylamide oxazepinopyrimidone derivatives:

20110015176 - Substituted heteroarylamide oxazepinopyrimidone derivatives:

20110015178 - Amido-thiophene compounds and their use: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both... Agent: Swanson & Bratschun, L.L.C.

20110015179 - Compositions for treating cognitive disorders: e

20110015181 - Alkylaminopyridine derivative:

20110015180 - Chemokine receptor antagonists:

20110015182 - Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof: Carbamate linked prodrugs of meptazinol and other opioid analgesics are provided. The prodrug moiety may comprise a single amino acid or short peptide. Additionally, the present invention relates to methods for reducing gastrointestinal side effects in a subject, the gastrointestinal side effects being associated with the administration of an opioid... Agent: Mcdermott Will & Emery LLP

20110015183 - Substituted pyrazole sigma receptor antagonists: r

20110015184 - Vinyl-phenyl derivatives for inflammation and immune-related uses:

20110015185 - Benzofuran compounds:

20110015186 - Methods and compositions for protecting and treating neuroinjury: A method and composition for protecting and/or treating neuroinjury are disclosed. In one aspect, the present application discloses a method for protecting and/or treating a subject from organophosphate-induced neuronal injury. The method comprises administering to a subject an effective amount of 4R cembranoid, 4S cembranoid or a cembranoid analogue. In... Agent: Andrews Kurth LLP

20110015187 - Substituted heteroarylamide diazepinopyrimidone derivatives: m

20110015188 - Treatment of seasonal conditions: Multi-dose active agent packages and methods for using the same for treating a subject for a condition are provided. Aspects of the invention include a multi-dose active agent package containing a plurality of unit dosage forms of an active agent configured to modulate at least a portion of a subject's... Agent: Bozicevic, Field & Francis LLP

20110015190 - Gamma secretase modulators: This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula (I) wherein R2 is a fused bicyclic ring of the formula (II). Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's disease using the compounds of formula (I).... Agent: Merck Patent Department (k-6-1, 1990)

20110015189 - Methods of making efavirenz and intermediates thereof: The present invention provides a process for the preparation of Efavirenz. A compound of Formula 1 may be prepared by a process comprising cyclizing, in the presence of a first base, a compound of Formula 5 with a haloformate of Formula 6. Other processes are also provided as well as... Agent: Mckinnons Patents Inc

20110015191 - Organic compounds: Novel polymorph form III of Aprepitant and a method for preparation of novel form III is disclosed. New processes for the preparation of Aprepitant form II are disclosed. The processes involve transformation of form III to form II by heating in decalin and the precipitation of form II from a... Agent: Manelii Denison & Selter PLLC

20110015192 - Sirtuin modulating compounds: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases,... Agent: Ropes & Gray LLP Iprm - Floor 43

20110015193 - 1, 5-dihydro-pyrazolo (3, 4-d) pyrimidin-4-one derivatives and their use as pde9a mudulators for the treatment of cns disorders: The invention relates to novel substituted pyrazolopyrimidines. Chemically, the compounds are characterised by general Formula (I): with R1 being phenyl or pyridyl, any of which is substituted with 1 to 4, preferably 1 to 3 substituents X; X independently of each other being selected from C2-C6-alky1 or Ci-C6-alkoxy, where C2-C6-alkyl... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20110015194 - Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes: e

20110015195 - Aryl ureas with angiogenisis inhibiting activity: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.... Agent: Millen, White, Zelano & Branigan, P.C.

20110015196 - Lupeol-type triterpene derivatives as antivirals: The invention relates to novel lupeol-type triterpene derivatives and related compounds, and pharmaceutical compositions useful for therapeutic treatment of viral diseases and particularly HIV mediated diseases.... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20110015197 - Mtor inhibitor salt forms: e

20110015198 - Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism: Wherein R1a, R1b, R2a, R2b, R3a, and R3b independently represent a hydrogen atom or the like, R4 represents a hydrogen atom, C1-6 alkyl, or the like, R5 represents a hydrogen atom or the like, Z represents C1-6 alkyl or the like, or R4 and Z together form a 4- to... Agent: Merck

20110015199 - Gpr119 agonists: e

20110015200 - Nitrogen-containing bycyclic compounds active on chronic pain conditions: The invention refers to compounds of general formula (I) wherein the R groups are, independently, H, C1-6alkyl, aryl, CF3; Y is CH2, C═O; X is bond, C═O, SO2, or C═N—CN; m is 0, 1; n is 0, 1; A is a heterocycle, or a phenyl group optionally substituted as defined... Agent: Abelman, Frayne & Schwab

20110015201 - Hedgehog pathway antagonists and methods of use: The present disclosure provides for compounds, pharmaceutical preparations, kits and methods for the inhibition of the Hh pathway and the alleviation of cancer and developmental disorders associated with the Hh pathway.... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20110015202 - Imidazoles: e

20110015203 - Viral polymerase inhibitors:

20110015204 - Pyrimidyl cyclopentanes as akt protein kinase inhibitors: The present invention provides compounds of Formula (I), including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.... Agent: Viksnins Harris & Padys Pllp

20110015205 - Trazodone composition for once a day administration: The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1... Agent: Goodwin Procter LLP Patent Administrator

20110015206 - Method of stabilizing lipid-rich plaque and method of preventing rupture thereof: A method of stabilizing lipid-rich plaques and method of preventing the rupture thereof, characterized in that an effective amount of 2-[4-[2-(benzimidazol-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide, its acid adduct salt or a hydrate thereof is administered to patients with lipid-rich plaques. Prevention of plaque rupture and stabilization of plaques can be attained by reducing the... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20110015207 - Sulfated benzimidazolone derivatives having mixed serotonine receptor affinity: m

20110015208 - Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands: The present invention relates to pharmaceutical compositions containing dopamine receptor ligands and selective serotonin reuptake inhibitors and to methods of treating disorders such as schizophrenia, major depressive disorder and bipolar depression using combinations of dopamine receptor ligands and selective serotonin reuptake inhibitors. The present invention also relates to methods of... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20110015209 - Sigma ligands for neuronal regeneration and functional recovery: The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptor, wherein the ligand is preferably AGY-94806, or salts, or solvates thereof. These molecules can be delivered alone or in combination with agents which... Agent: Paul N. King King PLLC

20110015210 - Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes: The present invention relates to pyrazinone derivatives of formula (I), wherein n, R1, R2, R3 and R4 are as defined in claim 1, as insulin secretion stimulators. The invention also relates to the preparation and use of these pyrazinone derivatives for the prophylaxis and/or treatment of diabetes and pathologies associated.... Agent: Millen, White, Zelano & Branigan, P.C.

20110015211 - Fibrosis inhibitor: e

20110015212 - Pyrimidinones as pi3k inhibitors: The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.... Agent: Fish & Richardson PC

20110015213 - Quinazoline derivatives: e

20110015214 - Tricyclic benzo[4,5]thieno-[2,3-d]pyrimidine-4-yl-amin derivatives, their salts, process for producing the compounds and their pharmaceutical use: The invention relates to novel tricyclic benzo[4,5]thieno-[2,3-d]pyrimidine-4-yl-amin derivatives, as well as their pharmaceutically acceptable salts. The subject of the invention too the process for producing the compounds and their use as a pharmaceutically active agent and as pharmaceutical compositions for prophylaxis and/or treatment of proliferative diseases such as cancer.... Agent: Hahn & Voight PLLC

20110015215 - Crystalline forms of 4-[6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester: The present invention is directed to a novel crystalline forms of 4-[6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester, pharmaceutical compositions containing said crystalline form and the use of said crystalline forms in the treatment of metabolic related disorders. The present invention is further directed to processes for the preparation of the crystalline forms... Agent: Philip S. Johnson Johnson & Johnson

20110015216 - Solid pharmaceutical dosage form: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable... Agent: Paul D. Yasger Abbott Laboratories

20110015218 - Aza-bicyclohexyl substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase: s

20110015217 - Pro-neurogenic compounds: This invention relates generally to stimulating neurogenesis (e.g., post-natal neurogenesis, e.g., post-natal hippocampal neurogenesis) and protecting from neuron cell death.... Agent: Fish & Richardson P.C. (bo)

20110015219 - (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof: The present invention provides (+)-morphinans comprising Toll-like receptor 9 (TLR9) antagonist activity, as well as a method for identifying (+)-morphinans that may be therapeutically effective by determining whether the (+)-morphinan inhibits the activation of TLR9. Also provided are methods of using the (+)-morphinans comprising TLR9 antagonist activity to treat conditions... Agent: Mallinckrodt Inc.

20110015220 - Mixed orl1/mu-agonists for the treatment of pain: The invention relates to the use of compounds which exhibit an affinity for the μ-opioid receptor of at least 100 nM (Ki value, human) and an affinity for the ORL-1 receptor, wherein the ratio between the affinities ORL1/μdefined as 1/[Ki(ORL1)/Ki(μ)] is from 0.1 to 30, for the treatment of pain.... Agent: Briscoe, Kurt G. Norris Mclaughlin & Marcus, Pa

20110015221 - Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same: The invention relates to a pharmaceutical composition of vinflunine in the form of a stable sterile aqueous solution of a water-soluble salt of vinflunine with a pH of between 3 and 4. The invention also relates to the method of preparing said composition and to the use thereof as a... Agent: Birch Stewart Kolasch & Birch

20110015222 - Benzoquinolizinium salt derivatives as anticancer agents: e

20110015223 - Compounds and methods for treatment of cancer-related anemia: The invention relates to methods and compounds for treating anemia of cancer. In particular, methods for treating anemia of cancer in a subject having cancer, and methods for increasing reticulocytes, increasing hemoglobin, increasing hematocrit, and increasing red blood cell count in subjects having anemia of cancer, wherein such subjects are... Agent: Fibrogen, Inc.

20110015224 - Combination of a carbostyril and carnitine: The present invention relates to a medicament for treating occlusive and/or ischemic vascular disorder comprising a carbostyril derivative and carnitine.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20110015225 - Heterocyclic compound: e

20110015226 - Treatment of energy utilization disease: Described are compositions comprising imino sugar acids for the treatment of energy utilization disease (e.g. metabolic syndrome, including any disease or disorder associated therewith, for example central obesity, elevated levels of triglycerides and diabetes, including type 1 diabetes, type 2 diabetes and insulin resistance), processes for producing said compositions from... Agent: Heslin Rothenberg Farley & Mesiti PC

20110015227 - Warming sensate composition: The invention relates to a warming sensate composition of (i) a hot component, (ii) a cooling component, and (iii) optionally a bitter component. The weight ratio of (i):(ii) is from 1:3 to 1:100. If a solvent is provided in the composition, the solvent is present in an amount of less... Agent: Winston & Strawn LLP Patent Department

20110015228 - Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione: Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.... Agent: Jones Day

20110015229 - Method of treating neuropathic pain: A method for treating subjects experiencing neuropathic pain is provided. The method involves the application of a solid-forming local anesthetic formulation to a skin surface of the subject experiencing the neuropathic pain and then maintaining the formulation on the skin surface for a period of time sufficient to allow itself... Agent: Thorpe North & Western, LLP.

20110015230 - Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same: The present disclosure provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease... Agent: Merchant & Gould PC

20110015231 - Isoxazole and isothiazole compounds useful in the treatment of inflammation: e

20110015234 - Indazole derivatives:

20110015232 - Pyrrolydine derivatives as iap inhibitors: The present invention relates to novel IAP inhibitor compounds of: Formula (I).... Agent: Novartis Institutes For Biomedical Research, Inc.

20110015233 - Stable pharmaceutical omeprazole formulation for oral administration: The present invention is directed to a pharmaceutical solution or syrup formulation for oral administration comprising; omeprazole, a solubilizing agent, a sweetening agent, a flavoring agent, and an antioxidant.... Agent: Scully Scott Murphy & Presser, PC

20110015235 - Novel phenylethynyl derivatives of 8-aza-bicyclo[3.2.1]octane and their use as monoamine neurotransmitter re-uptake inhibitors: This invention relates to novel phenylethynyl derivatives of 8-aza-bicyclo[3.2.1]octane useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.... Agent: Birch Stewart Kolasch & Birch

20110015236 - Fungicide hydroximoyl-tetrazole derivatives: The present invention relates to hydroximoyl-tetrazole derivatives of formula (I), their process of preparation, preparation intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.... Agent: Ostrolenk Faber Gerb & Soffen

20110015237 - Solid composition for pest control: e

20110015238 - Blood flow promoters for cauda equina tissues: It is intended to provide highly safe and efficacious blood flow promoters for cauda equina tissues. Among prostaglandin-like compounds having a weak hypotensive effect, compounds having an effect of promoting the blood flow in cauda equina tissues (excluding limaprost) are useful as highly safe blood flow promoters for cauda equina... Agent: Sughrue-265550

20110015239 - Inhibitors of calcium-activated chloride channels: Provided herein are methods for identifying compounds that are inhibitors of a calcium-activated chloride channel. Aminothiophene and aminothiazole compounds, and compositions comprising these compounds, described herein that inhibit efflux of chloride through a calcium-activated chloride channel are useful for treating diseases, disorders, and sequalae of diseases, disorders, and conditions that... Agent: Seed Intellectual Property Law Group PLLC

20110015240 - Thiazole derivative and use thereof as vap-1 inhibitor: The invention provides a thiazole derivative useful as a VAP-1 inhibitor, as well as a pharmaceutical agent for the prophylaxis or treatment of VAP-1 associated diseases and the like, a method of inhibiting VAP-1 in a subject, and a method for the prophylaxis or treatment of VAP-1 associated disease in... Agent: Leydig Voit & Mayer, Ltd

20110015241 - Substituted heterocycles and use thereof: The invention relates to substituted heterocycles, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of thromboembolic disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20110015242 - Pdk-1/akt signaling inhibitors: wherein X is selected from the group consisting of alkyl and haloalkyl; Ar is an aryl radical selected from the group consisting of phenyl, biphenyl, naphthyl, anthryl, phenanthryl, and fluorenyl; and wherein Ar is optionally substituted with one or more radicals selected from the group consisting of halo, C1-C4 alkyl,... Agent: Calfee Halter & Griswold, LLP

20110015243 - Co-solvent compositions and methods for improved delivery of dantrolene theraputic agents: The present invention provides for methods of using tert-butyl alcohol (TBA) co-solvent systems in the formulation and production of a pharmaceutical agent with low solubility. The present invention also provides for pharmaceutical compositions made using the novel co-solvent system. In one embodiment, the invention provides for a method of making... Agent: Frost Brown Todd, LLC

20110015244 - Bendamustine amphiphilic anionic compositions: The present invention is directed to pharmaceutical compositions comprising bendamustine and one or more amphiphilic anionic compounds and self assembled aggregates, which aggregates exhibit enhanced stability in aqueous solutions, including plasma, are disclosed. The unexpectedly enhanced stability afforded by such aggregates permits patients to be treated with bendamustine in lower... Agent: Diane Dunn Mckay Porzio, Bromberg & Newman, P.C.

20110015245 - Bendamustine amphiphilic cationic compositions: The present invention is directed to pharmaceutical compositions comprising bendamustine and one or more amphiphilic cationic compounds, which self assemble to form aggregates. The exhibiting enhanced stability in aqueous solutions, including plasma. The unexpectedly enhanced stability afforded by such aggregates permits patients to be treated with bendamustine in lower and/or... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20110015246 - Lofexidine enantiomers for use as a treatment for cns disease and pathologies and its chiral synthesis: The invention relates to methods for treatment of CNS disease and pathologies using non-racemic mixtures of lofexidine enantiomers. The invention also relates to processes for the manufacture of chirally pure enantiomers of lofexidine.... Agent: Frost Brown Todd, LLC

20110015247 - Novel crystalline form of carvedilol dihydrogen phosphate and related processes: The present patent application relates to a novel crystalline form (Form S) of Carvedilol dihydrogen phosphate and a process for its preparation. It also relates to an improved process for the preparation of Carvedilol dihydrogen phosphate.... Agent: Kaplan Gilman & Pergament LLP

20110015248 - Substituted heterocycles: The present invention relates to substituted heterocycles, processes for their preparation, and their use in medicaments, especially for the treatment of inflammatory disease, i.e. asthma, or cancer.... Agent: Briscoe, Kurt G. Norris Mclaughlin & Marcus, Pa

20110015259 - Tle3 as a marker for chemotherapy: Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.... Agent: Patent Department Choate, Hall & Stewart LLP

20110015260 - Anti-malarial pharmaceutical composition: The invention provides pharmaceutical compositions for the treatment and prophylaxis of malaria, comprising artemether and a medium chain triglyceride formulated for transmucosal sublingual, buccal or nasal delivery, especially by a spray. Also provided are delivery devices containing the compositions.... Agent: Workman Nydegger 1000 Eagle Gate Tower

20110015261 - Use of a composition comprising at least one beta-blocker for the treatment of sleep disorders: A composition comprising specific beta-blockers such as bisoprolol and nebivolol for the treatment of insomnia and/or another sleep disorder. The composition should be given in such an amount that it causes a less than 40% decrease in the amount of aMT6s in complete nocturnal urin. The composition can be a... Agent: Clark & Elbing LLP

20110015262 - Systems and methods for treating human inflammatory and proliferative diseases, with a combination of compounds, or a bifunctional compound, that provides fatty acid metabolism and glycolysis inhibition: Methods and compositions for treating inflammatory and proliferative diseases, enabling treatment of MDR tumor cells by using combination of compounds, or a bifunctional compound, that inhibits both fatty acid metabolism and glycolysis. In particular, the invention combines or links a glycolysis inhibitor that is, or that is derived from, hypoglycin... Agent: Wolf Greenfield & Sacks, P.C.

20110015263 - Therapeutic delivery of carbon monoxide: Compounds, pharmaceutical compositions and methods for the therapeutic delivery of carbon monoxide to humans and other mammals that employ transition metal complexes having at least a substituted cyclopentadienyl, indenyl or fluorenyl ligand and two or more carbonyl ligands.... Agent: Wolf Greenfield & Sacks, P.C.

20110015264 - Intramuscular antiviral treatments: The invention provides unit dosage forms, kits, and methods useful for treating viral infections.... Agent: Viksnins Harris & Padys Pllp

20110015265 - Method for controlling diseases on turfgrass: The present invention provides a method for controlling diseases on turfgrass which comprises applying to turfgrass that has been cut back an effective amount of a compound of formula (1).... Agent: Sughrue Mion, PLLC

20110015266 - Lyophilized nanoemulsion: The present invention relates to a lyophilised nanoemulsion comprising a lipophilic phase and one or more sucrose fatty acid esters, to the nanoemulsion which can be prepared from the lyophilised nanoemulsion by redispersion, and to a process for the preparation of the lyophilised nanoemulsion.... Agent: Millen, White, Zelano & Branigan, P.C.

20110015267 - Methods for the preparation and use of aqueous solutions of magnesium valproate hydrate and l-carnitine: The present invention relates to methods for preparing liquid valproate compositions comprising solutions of a magnesium valproate and L-carnitine in water and administering said compositions to a subject in need of treatment with valproate and L-carnitine. The compositions of the invention are particularly useful treatments for infants, young children, women... Agent: Casimir Jones, S.c.

20110015268 - Pharmaceutical composition: A pharmaceutical composition comprising a docusate; an osmotic laxative; and a benzoate.... Agent: Fish & Richardson P.C. (ny)

20110015269 - Process for the preparation of diacerin: The invention concerns a new process for the preparation of high purity diacerein, by oxidisation of the protected aloe-emodin in the presence of an oxidising system and radical catalyst and subsequent substitution of the protector groups with acetyl groups.... Agent: Nixon & Vanderhye, PC

20110015270 - Novel niddm regimen: The present invention relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering in connection with the meals a short-acting oral hypoglycaemic agent.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20110015271 - Topical nepafenac formulations: Topical suspension compositions of nepafenac are disclosed. The compositions are especially suitable for topical ophthalmic administration.... Agent: Alcon

20110015272 - Sirtuin 1 and the treatment of neurodegenerative diseases: This invention relates to bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable salts and their use in the modulation of Sirtuin 1 (Sirt1) and there use in neuroprotection for subject suffering from neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson's disease,... Agent: Proteotech, Inc.

20110015273 - Stable pharmaceutical aqueous compositions: The present invention refers to an parenterally administerable aqueous formulation containing paracetamol. For enhancing stability the formulation contains a sulphur containing antioxidant, preferably sodium metabisulfite. For making the formulation more soluble it contains hydroxy propyl beta cyclodextrin. The composition is used as analgesic.... Agent: Blank Rome LLP

20110015274 - Form of an aminoindan mesylate derivative: The present disclosure relates generally to rasagiline mesylate with improved flowability and with advantageously reduced stickiness, to processes for the preparation thereof, and to the use thereof for milling and for preparing pharmaceutical formulations. Methods for improving the flowability and/or alleviating the stickiness of rasagiline mesylate having a very poor... Agent: Ip Patent Docketing K&l Gates LLP

20110015275 - Materials and methods for improving alcohol metabolism and alleviating the effects of hangovers: The subject invention provides materials and methods for improving alcohol metabolism in animals. In a preferred embodiment, the invention provides methods for increasing the ability of people to consume alcohol while reducing hangovers or other effects of intoxication. Specifically exemplified herein is the use of a cysteamine compound to reduce... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20110015277 - Method of producing egg yolk based functional food product and products obtainable thereby: The present invention relates to the field of food products, especially food products specifically designed for providing health benefits beyond the basic function of nutrition for a subject consuming the product on a regular basis, e.g. on a daily basis. According to the present invention eggs are produced, in particular... Agent: Nixon & Vanderhye, PC

20110015276 - Therapeutical uses of inecalcitol: The present invention thus concerns a method for treating and/or preventing rickets, osteoporosis, osteomalacia, psoriasis, autoimmune diseases such as multiple sclerosis or type I diabetes, hyperparathyroidism, benign prostate hyperplasia, any type of cancer or any vitamin D relevant disease comprising administering inecalcitol at doses comprised between 1 mg/day and 100... Agent: Stites & Harbison PLLC

20110015278 - Phytol as a cholesterol lowering agent: Phytol (3,7,11,15-Tetramethyl-2-hexadecen-1-ol), or derivates thereof, of natural or synthetic origin are used as active ingredient in formulations to lower serum levels of triglycerides and/or cholesterol. Phytol can be administered to patients with disease conditions related to increased levels of cholesterol or triglycerides such as type II diabetes, obesity or other... Agent: Manelii Denison & Selter PLLC

20110015279 - Skin care composition: The invention relates to skin care compositions containing special polyurethanes for application to the skin. The invention also relates to the use of said polyurethanes for producing skin care products.... Agent: Connolly Bove Lodge & Hutz, LLP

20110015280 - Ampholytic copolymer, production thereof, and use of the same: The present invention relates to an ampholytic copolymer, to a process for its preparation, to cosmetic or pharmaceutical compositions which comprise at least one such ampholytic copolymer, and to further uses of these copolymers.... Agent: Connolly Bove Lodge & Hutz LLP

  
01/13/2011 > patent applications in patent subcategories. recently filed with US Patent Office

20110009312 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20110009310 - Drug for treating states related to the inhibition of angiogenesis and/or endothelial cell proliferation: Soluble recombinant CD44 hyaluronic acid binding domain (CD44HABD) inhibits angiogenesis in vivo in chick and mouse and thereby inhibits human tumor growth of various origins. The anti-angiogenic effect of CD44-HABD is independent of hyaluronic acid (HA) binding, since non-HA-binding mutants of CD44HABD still maintain anti-angiogenic properties. The invention discloses soluble... Agent: Dodds & Associates

20110009311 - Peptides and their utility in modulation of behavior of cells expressing alpha3 beta1 integrins: The present invention relates to a peptide comprising the sequence R1—X1—X2—X3—X4—R2, wherein X1 is selected from the group consisting of N, Q, D and S; X2 is selected from the group consisting of V, I and L; X3 is selected from the group consisting of R and K; and X4... Agent: Townsend And Townsend And Crew, LLP

20110009313 - Polyethylene glycolated lactoferrin complex and method of producing the same: A method of producing a polyethylene glycolated (PEGylated) lactoferrin complex having a linear polyethylene glycol (PEG) or a modified product thereof covalently bonded to lactoferrin via an amide bond includes causing a reaction to occur in a reaction liquid, which contains the lactoferrin and a linear PEG derivative having a... Agent: Osha Liang L.L.P.

20110009314 - Single-chain insulin analogues and pharmaceutical formulations thereof: The present invention is related to fast acting single-chain insulin comprising a modified B-chain and the A-chain of human insulin or an analogue thereof connected by a connecting peptide wherein one or more of the amino acid residues in position B25, B26 or B27 in the human B-chain are Glu... Agent: Novo Nordisk, Inc. Intellectual Property Department

20110009315 - Long-acting transient polymer conjugates of exendin: Long-acting polymer exendin-4 or exendin agonist derivatives of the formula Pol-L-E are provided wherein Pol is a polymer, L is a releasing linker undergoing slow autohydrolysis and E is an exendin or exendin agonist. These exendin or exendin agonists are slowly released from Pol-L upon administration to a living organism.... Agent: Frommer Lawrence & Haug

20110009316 - Proteolysis resistant active vegf: The invention relates to endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino acid. The invention also relates to derivatives of the VEGF according to the invention, nucleic acids, expression... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20110009317 - Conjugates of insulin-like growth factor-1 and poly(ethylene glycol): A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or... Agent: Hoffmann-la Roche Inc. Patent Law Department

20110009318 - Transdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome: Compositions and methods for alleviating the symptoms associated with chronic fatigue syndrome and fibromyalgia syndrome are provided. The compositions are based on use of a transdermal gel formulation delivery system for androgens, either alone or in combination with other hormones.... Agent: Loeb & Loeb, LLP

20110009319 - Cripto antagonism of activin and tgf-b signaling: Cripto, a developmental oncoprotein, antagonizes activin and TGF-b signaling by forming a complex with activin and TGF-b and their type II receptors. This complex precludes the formation of a functional activin/TGF-b•type II•type I complex, thereby blocking the signaling of activin and TGF-b. Cripto may be generally capable of blocking antiproliferative... Agent: Fulbright & Jaworski, L.L.P.

20110009320 - Glucagon-like peptide-2 analogs: Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.... Agent: Stoel Rives LLP - Slc

20110009321 - Nasal calcitonin formulations containing chlorobutanol: An aqueous solution of calcitonin suitable for intranasal administration comprised of calcitonin, chlorobutanol at a concentration of less than 0.4% weight/weight, and water and having a pH of less than 4 with the proviso that benzalkonium chloride is not present in the solution. The aqueous solution of calcitonin can be... Agent: Foley And Lardner LLP Suite 500

20110009322 - Use of bradykinin and related b2r agonists to treat ocular hypertension and glaucoma: The invention provides methods for treating and/or preventing ocular disorders associated with increased intraocular pressure comprising administering a bradykinin B2 receptor agonist to a patient in need thereof.... Agent: Alcon

20110009323 - Non-immunoglobulin antigen binding scaffolds for inhibiting angiogenesis and tumor growth: In certain embodiments, this present invention provides polypeptide or nucleotide non-immunoglobulin antigen binding scaffold compositions, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases.... Agent: Ropes & Gray LLP Iprm - Floor 43

20110009324 - Stable therapeutic proteins: The invention relates to storable medicaments produced from pharmaceutical active ingredient preparations which are virus safe. Said medicaments contain at least one intact therapeutic protein obtained from plasma or by means of genetic engineering, as an active pharmaceutical substance. Said active ingredient preparations contain active enzymes, especially proteases, which are... Agent: Baker Botts L.L.P.

20110009325 - Crystalline forms of rapamycin analogs: Provided is a rapamycin analog composition including a crystalline form of a rapamycin analog. The crystal can be a hydrate. dehydrate, solvate, or desolvate. The rampamycin analog can have a structure of Formula 1, which is optionally a prodrug, salt, derivative, or combination thereof:... Agent: Squire, Sanders & Dempsey LLP

20110009326 - Methods or use of lamin b1 nuclear antigen, fragments and compositions thereof, for inhibiting or reducing a thrombotic event: A method for preventing a thrombotic event in a patient susceptible to such an event, which comprises the step of administering an effective amount of a lamin 131 nuclear (LB1) antigen to said patient is provided along with an anti-thrombotic composition which comprises an effective amount of a lamin 131... Agent: Goudreau Gage Dubuc

20110009327 - Bioactive nanocomposite material: The present invention relates to a porous inorganic/organic hybrid nanoscale composite comprising an enzymatically biodegradable organic polymer and a sol-gel derived silica network, its production and use as a macroporous scaffold in tissue engineering.... Agent: Pepper Hamilton LLP

20110009328 - Polypeptide derivatives of parathyroid hormone (pth): Novel parathyroid hormone (PTH) polypeptide derivatives are disclosed, as are pharmaceutical compositions containing said polypeptides, and synthetic and recombinant methods for producing said polypeptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing said polypeptides. Also disclosed are methods... Agent: Clark & Elbing LLP

20110009330 - Medicament for treating parkinson's disease: The invention relates to the manufacture of a unit dose of a medicament for relieving the symptoms and/or restoring and/or protecting the neurons of patients suffering from Parkinson's disease. According to the invention, apamine is used in an amount of between 1 and 10 micrograms inclusive, for the manufacture of... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20110009329 - Method for treating neurodegenerative diseases: A method for preventing a break out of a neurodegenerative disease in an individual and for treating an individual suffering from a neurodegenerative disease comprising the administration of an effective amount of an antimicrobial and neurotrophic peptide... Agent: Young & Thompson

20110009331 - Protein kinase c peptides for use in withdrawal: A method for managing withdrawal from an addictive substance is described. The method involves administering one or more peptides having specific activity for the ε and/or γ isozyme of protein kinase C (PKC). The peptide(s) can be administered prior to, concurrent with, or subsequent to administration of the addictive substance.... Agent: King & Spalding LLP

20110009332 - Therapeutic treatment of wounds: The present disclosure relates to compositions and methods for treating wounded skin and/or increasing the mechanical strength of wounded skin through the administration of an effective amount of a proteasome inhibitor to such wounded skin.... Agent: Grossman, Tucker, Perreault & Pfleger, PLLC

20110009333 - Pharmaceutical or cosmetic composition and use of a pkc inhibitor with an mmp inhibitor for inhibiting langerhans' cell migration: Disorders of the skin or mucous membranes which are linked to migration of Langerhans cells are treated by the administration of an effective amount of at least one retinoid, optionally in combination with a PKC inhibitor.... Agent: Foley And Lardner LLP Suite 500

20110009334 - System and method for inhibiting cellular proliferation with tachykinins: Systems and methods are described providing therapeutic preparations of tachykinins, and more specifically sialokinins, for treating various types of abnormal cellular proliferation conditions in regions of tissue associated with the body of a patient. The sialokinins may be isolated and purified from natural or bioengineered sources, or may be synthesized,... Agent: John P. O'banion O'banion & Ritchey LLP

20110009335 - anticancer treatments: The present invention relates to combinations of aplidine with another anticancer drug selected from sorafenib, temsirolimus, and sunitinib, and the use of these combinations in the treatment of cancer.... Agent: King & Spalding

20110009336 - Treatment of cancers with immunostimulatory hiv tat derivative polypeptides: Disclosed herein are methods of treating cancer by administering a modified Human Immunodeficiency Virus (HIV) trans-activator of transcription (Tat) polypeptide with increased immunostimulatory properties relative to the non-modified Tat polypeptide.... Agent: K&l Gates LLP

20110009337 - Q3 sparc deletion mutant and uses thereof: The invention provides for SPARC polypeptides with a mutation corresponding to a deletion of the third glutamine in the mature fault of the human SPARC protein, nucleic acids encoding such polypeptides, antibodies against such polypeptides, and methods of the use of such polypeptides, nucleic acids, and antibodies.... Agent: Leydig Voit & Mayer, Ltd

20110009338 - Controlled release formulations of octreotide: A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a... Agent: Foley And Lardner LLP Suite 500

20110009340 - Combination of an iron chelator and an immunosuppressant and use thereof: The invention relates to a combination comprising an iron chelator and an immunosuppressant, to the use of such combination for the improvement of immunosuppression, e.g. in hematopoietic stem cell transplantation.... Agent: Novartis Corporate Intellectual Property

20110009339 - Method of treating blurred vision and other conditions of the eye with cyclosporin compositions: Disclosed herein is a method of treating blurred vision, of increasing keratocyte density, of increasing goblet cell density, and of treating psychological distress following surgery on the eye, the method comprising administering a cyclosporin composition to the affected eye of an individual.... Agent: Joel B. German Allergan, Inc. - T2-7h

20110009341 - N-alkylated cyclic peptide melanocortin agonists: s

20110009342 - Uses of pdcd5 polypeptide for tumor chemotherapy and organ protection: The invention relates to the use of PDCD5 polypeptides or polynucleotides that code the PDCD5 polypeptides in preparation of sensitizers of chemotherapeutic agents for cancers. The invention also relates to the use of PDCD5 polypeptides or polynucleotides that code the PDCD5 polypeptides to protect normal or diseased tissues or organs... Agent: Schwegman, Lundberg & Woessner, P.A.

20110009343 - Modulators of amyloid aggregation: Compounds that modulate the aggregation of amyloidogenic proteins or peptides are disclosed. The modulators of the invention can promote amyloid aggregation or, more preferably, can inhibit natural amyloid aggregation. In a preferred embodiment, the compounds modulate the aggregation of natural β amyloid peptides (β-AP). In a preferred embodiment, the β... Agent: Mccarter & English, LLP Boston

20110009344 - Control of radiation injury: The invention relates to the field of drug development against acute radiation injury caused by exposure to high-energy electromagnetic waves (X-rays, gamma rays) or particles (alpha particles, beta particles, neutrons). To date, there is no effective drug to ameliorate radiation injury after accidental exposure to ionizing irradiation. The invention provides... Agent: Traskbritt, P.C.

20110009345 - Food ingredient comprising functional peptide: With efficient extracting of peptide from coffee bean, and by providing food ingredient in which small quantity of peptide is uniformly dispersed by harmless means or dispersing means, the peptide is easily orally ingested. That is, so much material and long time is required for extracting. And, quantity of novel... Agent: Lipsitz & Mcallister, LLC

20110009346 - Methods and compositions for increasing the anaerobic working capacity in tissues: Provided are compositions comprising beta-alanylhistidine peptides and/or beta-alanines, and methods for administering these peptides and amino acids. In one aspect, the compositions and methods cause an increase in the blood plasma concentrations of beta-alanine and/or creatine.... Agent: K&l Gates LLP

20110009348 - Carbohydrate gel: The present invention generally relates to the field of nutrition, in particular performance nutrition. In particular, the present invention relates to a novel carbohydrate gel comprising glucose and fructose in a ratio in the range of 3:1 to 1:1. The carbohydrate gel of the present invention can be used to... Agent: Gerber Products Company

20110009347 - Combination therapy for the treatment of diabetes: The present invention is directed to co-therapy and methods for the treatment and prevention of glucose-related disorders such as Type 2 diabetes mellitus and Syndrome X. The present invention is further directed to pharmaceutical compositions for the co-therapy and methods described herein.... Agent: Philip S. Johnson Johnson & Johnson

20110009349 - Methods of maintaining or increasing growth or cognitive development: One or more complex lipids including gangliosides to achieve particular health benefits including maintaining or increasing cognitive development or maintaining or increasing growth in a foetal, infant or child subject.... Agent: Knobbe Martens Olson & Bear LLP

20110009350 - Oil-in-water formulation of avermectins: Oil-in-water emulsion formulations (EW) of avermectins based on esters of fatty acids as solvent and the use of such formulations for the control of crop pests.... Agent: Jacobson Holman PLLC

20110009352 - Restorative agent for antibacterial peptide production ability: There is provided a medicament capable of enhancing the antimicrobial peptide production ability. The medicament contains, as an active ingredient, a compound which is glycyrrhizin or a pharmaceutically acceptable salt thereof and capable of inhibiting the production of at least one of interleukin-10 (IL-10) and chemokine CCL2. The antimicrobial peptide... Agent: Connolly Bove Lodge & Hutz, LLP

20110009351 - Screening assay to identify correctors of protein trafficking defects: The present invention relates to a novel assay or screen for identifying compounds with potential therapeutic value for the treatment of protein trafficking diseases such as Cystic Fibrosis (CF) and nephrogenic diabetes insipidus (NDI). The usual approach involves expressing the mutant form of the gene in cells and assaying function... Agent: Foley And Lardner LLP Suite 500

20110009353 - Targeting cdk4 and cdk6 in cancer therapy: The invention involves methods of inhibiting the cancer cell cycle to make cancer cells more susceptible to chemotherapeutic agents. In particular, inhibition of CDK4 and/or CDK6 inhibits cell cycle progression in cancer cells. When combined with chemotherapy such cell cycle inhibition can effectively treat even aggressive cancer types that are... Agent: Schwegman, Lundberg & Woessner, P.A.

20110009469 - Compositions and methods of treating neoplasia: The present invention provides compositions and methods featuring microRNA polynucleotides for the diagnosis, treatment or prevention of neoplasia.... Agent: Edwards Angell Palmer & Dodge LLP

20110009466 - Methods of increasing gene expression through rna protection: This invention relates to the use of one or more RNA target protectors to inhibit the binding of an RNA, e.g., small RNA, to a target RNA (e.g., a target mRNA), thus increasing the stability of the target RNA and its function (e.g., increasing the gene expression of the gene... Agent: Ropes & Gray LLP Iprm - Floor 43

20110009467 - Methods to increase or decrease bone density: The SOST gene gives rise to sclerostin, a protein that leads to apoptosis of bone progenitor cells. The invention provides antagonists to the sclerostin protein, and methods for identifying new sclerostin antagonists. The invention also provides molecules that can depress expression of the SOST gene, as well as methods for... Agent: Marshall, Gerstein & Borun LLP

20110009468 - Mirna, sirna and use thereof in therapy: The present invention relates to a mixture of molecules comprising at least one miRNA and at least one siRNA, or at least two miRNAs, or at least two siRNAs for inducing hematopoietic differentiation or for treating leukemia wherein the miRNA is able to modulate hematopoietic differentiation and/or to act as... Agent: Lucas & Mercanti, LLP

20110009470 - Nucleic acid external skin formulation: The present invention provides a nucleic acid external skin formulation having a high skin permeability and which is prepared from a polymeric nucleic acid having a high molecular weight and sodium alginate. The nucleic acid external skin formulation is highly skin permeable and delivers its active ingredient nucleic acid to... Agent: Flynn Thiel Boutell & Tanis, P.C.

20110009471 - Oligonucleotide analogues and methods utilizing the same: e

20110009473 - Pttg1 as a biomarker for cancer treatment: The present invention relates to the use of pituitary tumor transforming gene 1 (PTTG1) as a biomarker for diagnosing cancer as well as for determining cancer treatment responsiveness. In one embodiment, the present invention provides a method of treating cancer by inhibiting the expression of PTTG1, and administering a therapeutically... Agent: Davis Wright Tremaine LLP/los Angeles

20110009472 - Rnai probes targeting cancer-related proteins: RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2,... Agent: Larson & Anderson, LLC

20110009475 - Methods for treating stress induced emotional disorders: The invention relates to methods and products for treating emotional disorders such as stress induced emotional disorders, as well as related assays and kits. Methods include administering to a subject an effective amount of an agent for targeting the Rac1, Cdk5, p35, PAK-1 pathway to treat the emotional disorder. The... Agent: Wolf Greenfield & Sacks, P.C.

20110009477 - Oligonucleotide-based compounds as inhibitors of toll-like receptors: The invention provides novel oligonucleotide-based TLR antagonists containing a modified immune stimulatory motif and the use of such compounds in the prevention and treatment of TLR-medicated diseases. These oligonucleotide-based TLR antagonists containing a modified immune stimulatory motif have one or more chemical modifications in the immune stimulatory motif, which would... Agent: Preti, Flaherty, Beliveau & Pachios, LLP

20110009474 - Sirtuin based methods and compositions for treating beta-catenin-related conditions: Provided herein are methods and compositions relating to sirtuin modulation of Wnt pathway signaling, including the use of sirtuin and sirtuin-modulating agents in the prevention and treatment of cancer and other diseases.... Agent: Wolf Greenfield & Sacks, P.C.

20110009478 - Theranostic polycation beacons comprising oligoethyleneamine repeating units and lanthanide chelates: the oligoamine backbone comprises from 1 to 8 ethlyeneamines and is chosen from diethyleneamine, triethylenediamine, tetraethylenetriamine, pentaethylenetetraamine, hexaethylenepentamine, heptaethylenehexamine, octaethyleneheptamine or nonethyleneoctaamine. Especially preferred, are structures chelated with either Eu3+ or Gd3+ for microscopy or MRI imaging, respectively. Such chelated lanthanides allow for the visualization of the delivery vehicle both... Agent: New River Valley Intellectual Property Law

20110009476 - Transcription factor decoys, compositions and methods: Compositions and methods for identifying and using cis-regulatory and decoy sequences.... Agent: Sughrue Mion, PLLC

20110009354 - 5',-substituted adenosynes preparation thereof and use as inhibitors of s-adenosylmethionine decarboxylase: The crystal structure of the complex of S-adenosylmethionine methyl ester with hΛdoMetDC F223A, a mutant where the stacking of the aromatic rings of F7, adenine and F223 would be eliminated. The structure of this mutant with the ester shows that the ligand still maintains a syn conformation aided by pi-pi... Agent: Connolly Bove Lodge & Hutz LLP (southern Research Institute)

20110009355 - Azapeptide derivatives: This invention relates to novel compounds that are azapeptides, and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel azapeptide compounds that are derivatives of the HIV protease inhibitor atazanavir sulfate. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier,... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20110009356 - Novel phosphorus-containing prodrugs: i

20110009357 - Lipid composition for improving brain function: The invention pertains to the use of a lipid fraction for the support of brain function. The lipid fraction comprises the medium-chain fatty acids at least 4 g hexanoic acid and/or at least 5 g octanoic acid, at least 1 g eicosapentaenoic acid, and in addition more than 0.4 g... Agent: Foley And Lardner LLP Suite 500

20110009358 - Agent for suppressing glucose level increase, agent for suppressing body fat accumulation and food compound: A method for reducing body fat accumulation is provided that includes: providing a reducer of body fat accumulation, wherein the reducer comprises isomaltulose; having an individual ingest the reducer; and having the individual consume a carbohydrate having an α-1,6-glucosyl bond ratio of from 0% to less than 50% relative to... Agent: Griffin & Szipl, PC

20110009360 - Nutraceutical composition and methods for preventing or treating multiple sclerosis: The present invention embraces nutraceutical compositions containing isolated Bacteroides fragilis capsular polysaccharide A for use in methods of preventing or treating multiple sclerosis.... Agent: Jane Massey Licata Licata & Tyrrell P.C.

20110009359 - Use of non-digestible carbohydrates for improving intestinal microbiota: A composition comprising at least two non-digestible carbohydrates for providing and/or maintaining an optimal intestinal microbiota is provided. The composition is especially suitable for infant nutrition.... Agent: Foley And Lardner LLP Suite 500

20110009361 - Design and selection of medicaments that modulate the function and activity of interleukin 13: The present invention relates generally to the field of medicaments in the form of therapeutic molecules including inflammatory modulators and their design and selection. More specifically, the present invention relates to a target site on Interleukin 13 (IL-13) by which a GAG molecule or polyanionic glycoconjugate or anionic polysaccharide modulates... Agent: Knobbe Martens Olson & Bear LLP

20110009362 - Solubility-enhanced forms of aprepitant and pharmaceutical compositions thereof: Solubility-enhanced forms of aprepitant and processes for preparing such forms. The invention also provides solubility-enhanced forms of aprepitant that also possess stability against solid state conversions. Certain solubility-enhanced forms of aprepitant comprise a cyclodextrin or any of its derivatives. Other solubility-enhanced forms of aprepitant comprise fine particle preparations of aprepitant.... Agent: Dr. Reddy''s Laboratories, Inc.

20110009364 - Azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof: l

20110009365 - Derivatives of indole-2-carboxamides and of azaindole-2-carboxamides substituted with a silanyl group, preparation thereof and therapeutic use thereof:

20110009363 - Synthesis and biological activities of new tricyclic-bis-enones (tbes): This invention describes novel tricyclic-bis-enone derivatives (TBEs), such as TBE-31, TBE-34, TBE-45 and water-soluble TBEs. The methods of preparing these compounds are also disclosed. The inventors demonstrate the ability of these new TBEs to inhibit proliferation of human myeloma cells, inhibit the induction of iNOS in cells stimulated with interferon-γ,... Agent: Fulbright & Jaworski L.L.P.

20110009366 - Bicyclic pyrimidinones and uses thereof: The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of Formula I or a... Agent: Fish & Richardson P.C. (ny)

20110009367 - 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors: The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders... Agent: Edwards Angell Palmer & Dodge LLP

20110009368 - Solid forms of tenofovir disoproxil: The Present Invention Provides Tenofovir Disoproxil Succinate, Tenofovir Disoproxil L-Tartrate, Tenofovir Disoproxil oxalate, Tenofovir disoproxil saccharate, Tenofovir disoproxil citrate, Tenofovir disoproxil salicylate and various solid forms thereof, methods for the preparation thereof and their use in pharmaceutical applications, in particular in anti-HIV medicaments. The forms of Tenofovir disoproxil can be... Agent: Hoffmann & Baron, LLP

20110009369 - Anti-influenza compounds: The present invention provides pyrimidinyl compounds of formula (I) and pharmaceutically acceptable salts thereof. These compounds may be used for the inhibition of influenza. In particular, the compounds of the invention may be used for the treatment or prophylaxis of influenza A, most particularly H1N1 or H5N1 influenza. The compounds... Agent: Borden Ladner Gervais LLP Gail C. Silver

20110009370 - Method to enhance tissue regeneration: The present invention provides for compositions and methods for modulating tissue growth using tissue growth modulators, which are agents that either enhance or inhibit tissue growth as desired by a particular indication by modulating the PG or Wnt signaling pathways, or employing modulators of both PG and Wnt signaling pathways... Agent: David S. Resnick

20110009371 - Synthesis of tetracyclines and analogues thereof: The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines... Agent: Harvard University & Medical School C/o Wolf, Greenfield & Sacks, P.C.

20110009373 - Composition comprising a combination of an aromatase inhibitor, a progestin and an oestrogen and its use for the treatment of endometriosis: The invention relates to a method of treating endometriosis using a combination of an aromatase inhibitor, a progestin and an oestrogen. The invention also relates to pharmaceutical formulations comprising said combination.... Agent: Astrazeneca R&d Boston

20110009372 - Compounds and compositions: The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v/v water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds... Agent: Harbor Biosciences, Inc.

20110009374 - Method of wound healing and scar modulation: The invention relates to methods of promoting wound healing and reducing scar formation by administration of corticosteroids, and pharmaceutical compositions comprising corticosteroids.... Agent: Morrison & Foerster LLP

20110009375 - Fusidic acid regimens for treatment of bacterial infections: Novel dosing regimens for the treatment and prevention of bacterial infections using fusidic acid are described. The use of a high loading dose of fusidic acid, followed by moderate maintenance doses of the drug, have been found to prevent development of drug-resistant strains of bacteria, to increase the effective spectrum... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20110009376 - Prophylactic or therapeutic agent for eye disease accompanied by optic nerve disorder: The present invention provides a novel pharmaceutical use of 2-phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof. 2-Phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof exhibits an excellent suppressive effect on retinal ganglion cell death in a pharmacological test using rats, and is therefore useful as a prophylactic or therapeutic agent for an eye disease accompanied... Agent: Holtz, Holtz, Goodman & Chick PC

20110009378 - Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy: e

20110009379 - Indolinone compound: [Means for Solution] The present inventors have extensively studied compounds having TRPA1 channel activation activity, and confirmed that an indolinone compound has a TRPA1 channel activation activity, and thus completed the present invention. The indolinone compound of the present invention has a TRPA1 channel activation activity and can be used... Agent: Fitzpatrick Cella Harper & Scinto

20110009377 - Azetidine derivatives, their preparation and their application in therapy: e

20110009380 - Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor:

20110009381 - Solubilized thiazolopyridines: Provided herein are novel sirtuin-modulating compounds Structural Formula (I): and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes,... Agent: Ropes & Gray LLP Iprm - Floor 43

20110009382 - Substituted benzimidazoles, benzothiazoles and benzoxazoles: Substituted benzimidazoles, benzothiazoles and benzoxazoles, processes for their preparation, pharmaceutical compostions containing these compounds and the use of these compounds for treating or inhibiting disorders or disease states mediated at least in part by bradykinin receptor 1 (BR1).... Agent: Crowell & Moring LLP Intellectual Property Group

20110009383 - Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias: The present invention relates to a method of treating a warm-blooded animal, especially a human, having Mixed Lineage Leukemia (MLL rearranged ALL) comprising administering to said animal a therapeutically effective amount of a staurosporine derivative, especially PKC412 or a pharmaceutically acceptable salt thereof, alone or in combination with further therapeutic... Agent: Novartis Corporate Intellectual Property

20110009384 - Fused ring compounds as partial agonists of ppar-gamma: e

20110009385 - Compounds: Compounds of formula (I) exhibit surprisingly high dual efficacies for human cathepsin S and K and are useful for the treatment of rheumatoid arthritis, osteoarthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, cardiovascular diseases which exhibit significant damage and remodeling of extracellular matrix (ECM) and chronic pain.... Agent: Edwards Angell Palmer & Dodge LLP

20110009386 - Furo[3, 2-b] pyrr0l-3-0nes as cathespin s inhibitors: Compounds of formula (I) exhibit surprisingly high efficacies for human cathepsin S, excellent selectivity verses other mammalian cathepsins and are useful for treatment of diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, transplant rejection, diabetes, Sjogrens syndrome, Grave's disease, systemic lupus erythematosis, osteoarthritis, psoriasis, idiopathic thrombocytopenic purpura, allergic rhinitis,... Agent: Edwards Angell Palmer & Dodge LLP

20110009387 - Histone h2ax (hh2ax) biomarker for fti sensitivity: The present invention relates e.g., to methods for predicting cellular sensitivity to farnesyl protein transferase inhibitors, such as lonafarnib; manumycin A; FTI-276; L-744832; BMS-214662; tipifarnib; BMS-316810K. The methods involve determining if malignant cells exhibit increased expression. of phosphorylated histone H2Ax following contact of one or more of said cells with... Agent: Merck Patent Department (k-6-1, 1990)

20110009388 - Formulations and methods of administration of cephalotaxines, including homoharringtonine: The present invention is directed to compositions and methods for the treatment of patients with cephalotaxines, for example, homoharringtonine. The invention is also directed to improvements in the purity, manufacturing process, formulation and administration of homoharringtonine for the treatment of cancer and other aberrant cellular diseases. The invention also provides... Agent: Morgan, Lewis & Bockius, LLP (sf)

20110009389 - Imidazole derivative, their production and use: wherein R represents an optionally substituted cyclic hydrocarbon group or an optionally substituted heterocyclic group, W represents a bond or an optionally substituted divalent linear hydrocarbon group, X represents an optionally substituted divalent hydrocarbon group, Y represents —CO—, —S(O)—, —S(O)2— or a bond, ring A represents an optionally substituted pyrrolidine... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20110009390 - 2-oxo-2- (2-phenyl-5,6,7,8-tetrahydro-indolizin-3-yl) -acetamide derivatives and related compounds as antifungal agents: The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof: wherein: R1, R2, R3, R4, R5, R6, R7, R8, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in the manufacture of medicaments for use in the prevention... Agent: Fulbright & Jaworski, LLP

20110009391 - Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application: The present invention relates to tetrahydroquinoxaline urea derivatives, to their preparation and to their therapeutic application.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20110009392 - Gamma secretase modulators: In its many embodiments, the present invention provides a novel class of heterocyclic compounds as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or... Agent: Merck Patent Department (k-6-1, 1990)

20110009393 - Novel soluble 1,4 benzodiazepine compounds and stable salts thereof: The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and related compounds and methods of using benzodiazepine derivatives and related compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation... Agent: Casimir Jones, S.c.

20110009395 - Bace inhibitors: e

20110009394 - Tricyclic nitrogen compounds and their use as antibacterial agents: Tricyclic nitrogen containing compounds and their use as antibacterials.... Agent: Glaxosmithkline Global Patents

20110009396 - Tricyclic compounds for the treatment of inflammatory disorders: wherein, R1 R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13 and X are as defined in the specification, in all its stereoisomeric and tautomeric forms and mixtures thereof in all ratios, and its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable polymorphs and prodrugs. These compounds... Agent: Ladas & Parry LLP

20110009401 - 2-aza-bicyclo[2.2.1]heptane derivatives: e

20110009400 - Bicyclic derivatives of azabicyclic carboxamides, preparation thereof and therapeutic use thereof:

20110009399 - Organic compounds: The application relates to trisubstituted piperidines of the general formula (I) and their salts, preferably their pharmaceutically acceptable salts, in which R1, R2′, X, U, W, m and n have the meanings explained in the description, a process for their preparation and the use of these compounds as medicines, especially... Agent: Novartis Institutes For Biomedical Research, Inc.

20110009398 - P27 protein inducer: wherein G1, G2, G3 and G8 are each independently selected from —N═ etc., Ring G6 is selected from divalent aryl etc., A is selected from amino etc., G4 is selected from oxygen etc., G5 is selected from oxygen etc., G7 is selected from —CH2— etc., and R2 is selected from... Agent: Morgan Lewis & Bockius LLP

20110009397 - Triazone compounds that modulate hsp90 activity: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising... Agent: Foley & Lardner LLP

20110009402 - Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1: The invention relates to novel compounds of the Formula Ik, Im1, Im2, Im5, In1, In2, In5, Io1, Io2, Io5, Ip1, Ip3, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention... Agent: Foley & Lardner LLP

20110009403 - 2-morpholinylpurines as inhibitors of pi3k: The present invention relates to purine compounds that are useful as kinase inhibitors. More particularly, the present invention relates to purine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for... Agent: Connolly Bove Lodge & Hutz LLP

20110009404 - 4-aryl-2-anilino-pyrimidines: The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to compounds that are kinase inhibitors useful for the treatment of disease states mediated by kinase, especially PLK4, in particular such compounds that are useful in... Agent: Philip S. Johnson Johnson & Johnson

20110009405 - Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy: Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazoles of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.... Agent: Jones Day

20110009406 - Tetrahydro-1h-pyrrolo fused pyridones: The present invention relates to tetrahydro-1H-pyrrolo fused pyridone compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.... Agent: Merck

20110009407 - Pyridinone antagonists of alpha-4 integrins: or a tautomer, mixture of tautomers, salt or solvate thereof, wherein Cy, ring A, m, n, p, R1, R2, R3, R4, R5 and R6 are defined in the specification. The invention further provides pharmaceutical compositions including the compounds of the invention as well as methods of making and using the... Agent: Foley & Lardner LLP

20110009408 - Methods for identifiying inhibitors against viruses that use a class i fusion protein: The invention concerns the generation of a three dimensional model of the six helix bundle (6HB) complexed with an inhibitor and the use of that model to identify, screen and/or develop inhibitors against viruses that use a class I fusion protein. Such inhibitors of viruses that use a class I... Agent: Philip S. Johnson Johnson & Johnson

20110009410 - Apoptosis signal-regulating kinase inhibitors: where in X1, X2, X3, X4, X5, X6, X7, X8, R1, R2, R3 are as defined above. The compounds have apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases. The invention also relates... Agent: Gilead Sciences Inc

20110009409 - Dual-acting pyrazole antihypertensive agents: wherein: Ar, Z, R3, R4 and R5 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and... Agent: Theravance, Inc.

20110009411 - Therapeutic compositions and the use thereof: The invention includes methods, compositions, and kits useful for treating a viral infection by coadministering 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, with lopinavir or a pharmaceutically acceptable salt thereof.... Agent: Viksnins Harris & Padys Pllp

20110009413 - Cyclic triazo and diazo sodium channel blockers: Compounds of general structure in which X and Y are each N or C with at least one of X and Y being N; Z is a single bond or an optionally substituted linking group R1 is hydrogen or a substituent group; R2 is amino or a substituent group; N*... Agent: Occhiuti Rohlicek & Tsao, LLP

20110009412 - Macrophage migration inhibitory factor antagonists and methods of using same: Methods of inhibiting one or more biological activities of Macrophage migration inhibitory factor (MIF) polypeptides are provided using an MIF inhibitory compound. The methods include therapeutic methods for treating cancers and inflammatory diseases.... Agent: Dinsmore & Shohl LLP

20110009414 - Heterocyclic derivatives and their use as therapeutic agents: t

20110009415 - Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses: The present invention relates to thienopyridazine compounds of formula (I), their pharmaceutically acceptable salts or hydrates, wherein R1 and R2 are independently H or C1-4 alkyl, R3 is a saturated or unsaturated 5- or 6-membered ring containing N, S or O, or its optical isomers, R4 is a halophenyl monosubstituted... Agent: Ashok Tankha

20110009416 - Ph independent formulations of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]pyrazine: Pharmaceutical compositions of zopiclone [(6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine)] that render the aqueous solubility/dissolution of the free base independent of the pH of the gastrointestinal tract are disclosed. The compositions are useful for oral administration.... Agent: Heslin Rothenberg Farley & Mesiti P.C.

20110009417 - Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes: The present invention relates to pyridopyrazinone derivatives of formula (I), wherein X, Y, Z, W, A and R1 are as defined in claim 1, as insulin secretion stimulators. The invention also relates to the preparation and use of these pyridopyrazinone derivatives for the prophylaxis and/or treatment of diabetes and pathologies... Agent: Millen, White, Zelano & Branigan, P.C.

20110009418 - Therapeutic agents useful for treating pain: where Ar1, Ar2, X, R3, and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Phenylene Compound”); compositions comprising an effective amount of a Phenylene Compound; and methods for treating or preventing pain and other conditions in an animal comprising administering to an animal in need thereof... Agent: Dechert LLP

20110009419 - Enantiomers of 2'-fluoralkyl-6-nitroquipazine as serotonin transporter positron emission tomography imaging agents and antidepressant therapeutics: Racemic mixtures and individual enantiomers of fluorine-18 or carbon-11 radiolabelled 2′-alkyl-6-nitroquipazine ligands are serotonin transporter (SERT) tracers for positron emission tomography (PET) imaging. The non-radioactive ligand forms possess therapeutic antidepressant in vitro and in vivo pharmacological binding profiles in rodent brain and cells expressing human serotonin transporter (hSERT). Twelve 2′-alkyl-6-nitroquipazine... Agent: Jean Kyle

20110009421 - Compound having 6-membered aromatic ring: c

20110009420 - Histamine h3 receptor ligands:

20110009422 - 1- [2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of pain or residual symptoms in depression relating to sleep and cognition: The use of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine in the treatment of pain and residual symptoms in depression is provided.... Agent: Fish & Richardson P.C. (ny)

20110009423 - Phenyl-piperazine derivatives as serotonin reuptake inhibitors: e

20110009424 - Co-crystals and pharmaceutical compositions comprising the same: The invention relates to co-crystals and compositions each comprising VX-950 and a co-crystal former selected from the group consisting of 3-methoxy-4-hydroxybenzoic acid, 2,4-dihydroxybenzoic acid, and 2,5-dihydroxybenzoic acid. Also within the scope of this invention are methods of making and using the same.... Agent: Jonathan P. O''brien, Ph.d. Honigman Miller Schwartz & Cohn LLP

20110009425 - Tetrahydrothieno pyridines: The present invention relates to tetrahydrothienopyridine compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.... Agent: Merck

20110009426 - 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation thereof and therapeutic application thereof as urotensin ii receptor antagonists: The present invention relates to 5,6-bisaryl-2-pyridinecarboxamides, to their preparation and to their therapeutic use as urotensin II receptor antagonists.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20110009427 - Aryl pyrimidine derivatives, preparation methods and pharmaceutical uses thereof: The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof. Various substituents in the formula (I) are as defined in the specification. The present invention also relates to a pharmaceutical composition comprising the compound of formula (I), the preparation method of compound... Agent: Brinks Hofer Gilson & Lione/ann Arbor

20110009428 - Novel androgens: e

20110009429 - Heterocyclic compounds as inhibitors of cxcr2:

20110009430 - Methods and compositions for treating pain: The present application relates to compounds and methods for treating pain, incontinence and other conditions.... Agent: Lando & Anastasi, LLP

20110009431 - Compositions and methods for treating fibroproliferative disorders: The present invention relates, in general, to fibroproliferative disorders, and, in particular, to methods and compositions for treating fibroproliferative disorders by administering to a mammal in need of treatment pharmacologically effective doses of a phosphodiesterase inhibitor, such as pentoxifylline, and an anti-oxidant which is a precursor of glutathione, such as... Agent: Chernoff, Vilhauer, Mcclung & Stenzel, LLP

20110009432 - Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof: e

20110009433 - Bicyclic pyrrole compound: Disclosed is a compound composed of an easily-handleable crystal form and having storage stability that is practical enough to be used as an active ingredient of a pharmaceutical product. Specifically disclosed is 6-[(3R)-3-aminopiperidin-1-yl]-5-(2-chloro-5-fluorobenzyl)-1,3-dimethyl-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione monohydro chloride hemihydrate.... Agent: Sughrue Mion, PLLC

20110009435 - Hetero bicyclic carboxamide derivatives and their pharmaceutical use and compositions: s

20110009436 - Novel therapeutic uses of adrenergic alpha-1 receptor antagonists: The disclosure relates to methods of using an adrenergic α-1 receptor antagonist or its pharmaceutically acceptable salts for treating and/or preventing interstitial cystitis, overactive bladder or detrusor overactivity.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20110009434 - Crystals of isopropyl ester of n-(2,6-dichlorobenzoyl)-4-[6-(methylamino)methyl -1-methyl-2,4-dioxo-1,4-dihydroquinazoline-3(2h)-yl]-l- phenylalanine hydrochloride, production method thereof and use thereof: Crystals of isopropyl ester of N-(2,6-dichlorobenzoyl)-4-[6-(methylamino)methyl-1-methyl-2,4-dioxo-1,4-dihydroquinazoline-3(2H)-yl]-L-phenylalanine hydrochloride are useful as α4 integrin inhibitors.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20110009437 - Carboxamide-heteroaryl derivatives for the treatment of diabetes: y

20110009438 - Substituted isoxazoline compound and pest control agent: where A1, A2 and A3 independently are CH or N, etc., X1, X2 and X3 are independently are H, a halogen atom, etc., Y1 is H, etc., R1 is —C(O)R1a, —C(S)R1a, R1a is —C(R9)(R9a)—S(O)rR10, —C(R9)(R9a)—S(O)t(R10)═NR11, etc., R2 is H, etc., R3 is CF3, CClF2, etc., R4 is H, etc., R9... Agent: Oliff & Berridge, PLC

20110009439 - Indene derivatives as pharmaceutical agents: e

20110009440 - Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders: wherein R1, R2, R6, R7, R8, R9 and m are as defined in the description. Uses of the compounds as medicaments, and in the manufacture of medicament for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder are also disclosed. The invention further comprises pharmaceutical formulations... Agent: Glaxosmithkline Global Patents -us, Uw2220

20110009441 - Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors: The present invention relates to novel compounds, in particular novel imidazo[1,2-a]piridine derivatives according to Formula (I). The compounds according to the invention are positive allosteric modulators of metabotropic receptors-sub-type 2 (‘mGluR2’) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases... Agent: Mckeon Meunier Carlin & Curfman LLC

20110009442 - Methods for stereoselective reduction: The invention is directed to a method to reduce a C—C double bond of an enone of a steroidal compound to produce a mixture of β ketone product and α ketone product, comprising treating a solution or suspension of the steroidal compound in a solvent with hydrogen gas in the... Agent: Fish & Richardson P.C.

20110009443 - Pyrazolospiroketone acetyl-coa carboxylase inhibitors: The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating mammals suffering from the condition of being overweight.... Agent: Pfizer Inc. Patent Department

20110009444 - N-azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof: e

20110009445 - Neuroprotectants: Methods of protecting cells against cytotoxic insults are provided. The methods involve administering a composition including a CpG oligonucleotide to a subject. The methods are applicable to the protection of neural and non-neural cells. For example, methods of protecting a neural cell against excitotoxic brain injury are provided. Methods for... Agent: Klarquist Sparkman LLP

20110009446 - Oligomer-guanidine class conjugates: The invention relates to (among other things) oligomer-guanidine class conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.... Agent: Nektar Therapeutics

20110009447 - Substituted benzoic acid amides and use thereof for the inhibition of angiogenesis: Substituted benzoic acid amides of formula (I) and their use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis as well as their intermediate products for the production of benzoic acid amides are described.... Agent: Millen, White, Zelano & Branigan, P.C.

20110009448 - Compound: b

20110009449 - N-aryl-n-piperidin-4-yl-propionamide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors:

20110009450 - Crystalline form of benzothiophene compound and process for preparation thereof: Crystalline raloxifene hydrochloride in hydrated form, particularly the monohydrate, processes for its preparation, pharmaceutical compositions comprising it and uses thereof.... Agent: Conley Rose, P.C.

20110009451 - Controlled delivery system: The present invention relates to novel anesthetic compositions containing a non-polymeric carrier material and an anesthetic, where the compositions are suitable for providing a sustained local anesthesia without an initial burst and having a duration for about 24 hours or longer. Certain compositions are also provided that include a first... Agent: Durect Corporation Legal Department

20110009452 - Hydroxyalkanyl amides as modulators of chemokine receptor activity: The application describes modulators of MIP-1α or CCR-1 of the formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein ring A, T, V, R1, R2 and R5, are defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well... Agent: Louis J. Wille Bristol-myers Squibb Company

20110009453 - s1p3 receptor inhibitors for treating inflammation: Disclosed herein are compositions and methods for treating inflammation using S1 P3 receptor inhibitors.... Agent: Allergan, Inc.

20110009454 - Composition for agricultural use for controlling or preventing plant diseases caused by plant pathogens: Disclosed is a composition for agricultural use, which is used for controlling or preventing plant diseases caused by plant pathogens. The composition for agricultural use contains a compound represented by formula (1), a salt thereof or a hydrate of the compound or the salt. (1) [In the formula, Z represents... Agent: Sughrue Mion, PLLC

20110009455 - 5-oxo-2,3,4,5-tetrahydro-benzo[b]oxepine-4-carboxylic acid amides and 2,3-dihydro-benzo[b]oxepine-4-carboxylic acid amides for treatment and prevention of diabetes typ 1 and 2: s

20110009456 - Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases: Methods of using di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus.... Agent: Kramer Levin Naftalis & Frankel LLP Intellectual Property Department

20110009457 - Aminobenzamide derivatives as useful agents for controlling animal parasistes: The invention relates to a composition comprising at least one aminobenzamide compound or a salt thereof for controlling animal parasites, veterinary pharmaceutical compositions comprising at least one aminobenzamide of formula (I) for preventing infection with diseases transmitted through parasites, its use for the preparation of a veterinary pharmaceutical for controlling... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20110009458 - Stable formulations of thiadiazole derivative: The present invention provides formulation parameters and manufacturing conditions for stable pharmaceutical compositions comprising N-{4-(2,2-dimethyl-propionyl)-(5R)-5-[(2-ethylamino-ethanesulfonylamino)-methyl]-5-phenyl-4,5-dihydro-[1,3,4]thiadiazol-2-yl}-2,2-dimethyl-propionamide that minimize undesirable chiral conversion to the less active S enantiomeric form.... Agent: Eli Lilly & Company

20110009459 - Epothilone derivatives: Epothilone derivatives of Formula (I) and their use as a pharmaceutical.... Agent: Novartis Institutes For Biomedical Research, Inc.

20110009460 - Compositions and methods for treating amyotrophic lateral sclerosis: Pharmaceutical compositions of dexpramipexole and methods of using such compositions for the treatment of ALS are disclosed.... Agent: Honigman Miller Schwartz And Cohn LLP/biib

20110009461 - 2-aza-bicyclo[3.3.0]octane derivatives: The invention relates to 2-aza-bicyclo[3.3.0]octane derivatives of Formula (I) wherein A, B, and R1 are as described in the description, and to the use of such compounds, or of pharmaceutically acceptable salts of such compounds, as medicaments, especially as orexin receptor antagonists.... Agent: Hoxie & Associates LLC

20110009462 - Stable, synergistic mixtures: The present invention relates to storage-stable, synergistically acting combinations comprising glutaraldehyde (GDA) and 2-methyl-2H-isothiazol-3-one (methylisothiazolinone, MIT) and, where appropriate, 2-bromo-2-nitropropane-1,3-diol (bronopol) and/or other active substances for protecting industrials materials.... Agent: Lanxess Corporation

20110009463 - Geranylgeranyl transferase inhibitors and methods of making and using the same: The present invention is directed to compounds useful in the treatment of diseases associated with prenylation of proteins and pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising same, and to methods for inhibiting protein prenylation in an organism using the same.... Agent: Sheridan Ross PC

20110009464 - Immune system stimulation by light therapy induced apoptotic cell death in abnormal tissue: The efficacy of light activated therapy treatment is enhanced by stimulating the immune system of the patient substantially above the pre-therapy level. Abnormal tissue that is destroyed by the light activated therapy releases factors that stimulate the immune system, leading to systemic reductions in abnormal tissue (i.e., reduction beyond the... Agent: Law Offices Of Ronald M Anderson

20110009465 - 3-phenoxymethylpyrrolidine compounds: e

20110009479 - Stimulating neuronal growth using brevetoxins: Disclosed are methods of treating neurodegenerative diseases or disorders in a subject in need of such treatment. The methods comprise administering to a subject in need of such treatment a therapeutically effective amount of brevetoxin or brevetoxin derivatives. Included in the diseases and disorders are Alzheimer's Disease, Huntington's Disease, Parkinson's... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20110009480 - Biologically active taxane analogs and methods of treatment: wherein R1 and R2 are each selected from H, alkyl, alkenyl or aryl; R3 is hydroxyl or OP1; R4 is OH or R7COO; R7 is alkyl, alkenyl or aryl, R8 and R9 are each independently selected from H, alkyl or alkenyl. The compounds of the present application may particularly be... Agent: Morgan, Lewis & Bockius LLP

20110009481 - Medicament for the treatment of viral skin and tumour diseases: The invention relates to a medicament containing a compound of general formula (I), where R1=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C11-C21 alkyl, alkylene or alkinyl group, preferably a C11-C15 alkyl, alkylene or alkinyl group, particularly a C11-C13 alkyl, alkylene or alkinyl group, most preferably a... Agent: Clark & Elbing LLP

20110009482 - Methods of treating copd: Disclosed is a method of treating chronic obstructive disease, said method comprising administering an effective amount of a CXCR2 antagonist and administering an effective amount of at least one drug selected from the group consisting of: angiotensin-converting enzyme inhibitors, Angiotensin II receptor antagonists, cardioselective beta blockers, and lipid regulating drugs.... Agent: Merck Patent Department (k-6-1, 1990)

20110009483 - Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use: Acyloxyalkyl carbamate prodrugs of trans-4-(aminomethyl)-cyclohexanecarboxylic acid, pharmaceutical compositions thereof, methods of making prodrugs of trans-4-(aminomethyl)-cyclohexane-carboxylic acid, and methods of using prodrugs of trans-4-(aminomethyl)-cyclohexanecarboxylic acid and pharmaceutical compositions thereof to treat or prevent various diseases or disorders are disclosed. Acyloxyalkyl carbamate prodrugs of trans-4-(aminomethyl)-cyclohexanecarboxylic acid and pharmaceutical compositions thereof suitable for... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20110009484 - Disinfectant and method of making: A non-toxic environmentally friendly aqueous disinfectant is disclosed for specific use as prevention against contamination by potentially pathogenic bacteria and virus. The aqueous disinfectant is formulated by electrolytically generating silver ions in water in combination with a citric acid. The aqueous disinfectant may include a suitable alcohol and/or a detergent.... Agent: Morrison & Foerster LLP

20110009486 - Method for treating pruritus by administering fullerenes: Disclosed herein are methods of treating pruritus in a subject in need thereof. A method of treating pruritus comprises administering a therapeutically effective amount of fullerenes to a subject in need thereof.... Agent: Buchanan, Ingersoll & Rooney PC

20110009485 - Synthesis of scabronines and analogues thereof: A novel synthesis of scabronines, which are related to a broader class of angularly fused tricyclic diterpenoids known as cyathanes, is provided. Scabronine G, its methyl ester derivative, and other analogs have been shown to have neurotrophic activity. Therefore, these compounds are particularly useful in treating neurodegenerative diseases such as... Agent: Choate, Hall & Stewart LLP/mskcc Sloan-kettering Institute For Cancer Research

20110009487 - Method of obtaining a solid component rich in a petroselinic compound: A method of obtaining a solid component rich in a petroselinic compound from the seed of a plant of the Apiaceae or Araliaceae families, the method comprising: (a) treating a portion of the seed of the plant with an extraction solvent; and (b) inducing formation of the solid component.... Agent: Hoffman Warnick LLC

20110009488 - Lipoxin a4 protection for cornea endothelial cells: Lipoxin A4 and its analogs have been discovered to promote the cell proliferation of cornea endothelial cells, and thus promote the proper functioning of the labile tissue layer of cornea endothelial cells. These lipoxin compounds can be administered alone or in combination with other known compounds as a solution that... Agent: Patent Department Taylor, Porter, Brooks & Phillips, L.l.p

20110009489 - Cosmetic composition comprising vitamin u as active ingredient for healing wounds and reducing wrinkles: The present invention relates to a cosmetic composition comprising vitamin U as an active ingredient, more precisely a cosmetic composition for improving the skin wrinkles that contains vitamin U as an active ingredient. The cosmetics containing the composition of the present invention demonstrate excellent wound healing and wrinkle improvement effects.... Agent: Cantor Colburn LLP

20110009490 - Preparation of the formaurindikarboxyl acid base and its derivations and use: A pharmaceutical composition comprising at least 0.1 μmol of formaurindicarboxylic acid or its derivatives in 1 kg of pharmaceutically acceptable carrier. The pharmaceutical composition of claim 1 wherein the composition is in the form of solution prepared using aqueous alcali or water.... Agent: Ostrolenk Faber Gerb & Soffen

20110009491 - Process for producing 1,4-dihydroxy-2-naphthoic acid: A composition containing 1,4-dihydroxy-2-naphthoic acid at a high concentration is obtained by intracellularly and extracellularly producing 1,4-dihydroxy-2-naphthoic acid using a bacterium belonging to the genus Propionibacterium and collecting it. This composition is efficacious in improving intestinal flora, alleviating abdominal ailments in association with the intake of milk, and preventing metabolic... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20110009492 - ß-phenylethylidenehydrazine derivatives: The present invention provides new β-phenylethylidenehydrazine derivatives, processes for preparing them and their use as pharmaceutical compostions. The β-phenylethylidenehydrazine derivatives according to the invention generally correspond to the general formula:... Agent: Choate, Hall & Stewart LLP

20110009493 - Broad spectrum disinfecting and sterilizing composition: The present invention relates to antimicrobial compositions including an aromatic dialdehyde and a quaternary ammonium compound wherein the aromatic dialdehyde is orthophthalaldehyde, isophthalaldehyde, terephthalaldehyde, or combinations thereof; the quaternary ammonium compound is didecyldimethylammonium bicarbonate, didecyldimethylammonium carbonate, or didecyldimethylammonium bicarbonate/carbonate; and the ratio of aromatic dialdehyde to quaternary ammonium compound is... Agent: Hoffmann & Baron, LLP

20110009495 - Inhibition of the survival of bone cancer by cyclohexenone compounds from antrodia camphorata: The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of bone cancer cells and be used as a pharmaceutical composition to inhibit the bone... Agent: Wpat, PC Intellectual Property Attorneys

20110009494 - Inhibition of the survival of pancreatic cancer by cyclohexenone compounds from antrodia camphorata: The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of pancreatic cancer cells and be used as a pharmaceutical composition to inhibit the pancreatic... Agent: Wpat, PC Intellectual Property Attorneys

20110009496 - Resveratrol formulations: Resveratrol can be used to treat or inhibit the onset of many diseases that are related to the aging process, but large doses are required. The present invention provides concentrated liquid formulations of resveratrol, typically having a resveratrol concentration of at least 10% by weight. These formulations improve patient compliance... Agent: Ropes & Gray LLP Iprm - Floor 43

20110009497 - Drug-containing composition: It is an object of the present invention to provide a drug-containing composition which is capable of dissolving a poorly water-soluble drug, has low toxicity to the human body, and has high binding affinity with drugs. The present invention provides a composition which is composed of: (a) at least one... Agent: Sughrue Mion, PLLC

  
01/06/2011 > patent applications in patent subcategories. recently filed with US Patent Office

20110003733 - Reconstituted surfactant composition containing analogs of surfactant protein b (sp-b) and surfactant protein c (sp-c): Reconstituted pulmonary surfactants comprising a lipid carrier, a combination of polypeptide analog of the native surfactant protein SP-C with a particular polypeptide analog of the native surfactant protein SP-B may be used for the treatment or prophylaxis of RDS and other respiratory disorders.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20110003734 - Proteins and polynucleotides of vibrio cholerae: Therapeutic, diagnostic and environmental monitoring methods employing proteins encoded by the rbmBCDEF gene cluster and by bap1.... Agent: Bell & Associates

20110003735 - Peptide derivative fusion inhibitors of hiv infection: This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral... Agent: Hunton & Williams LLP Intellectual Property Department

20110003736 - Pesticidal proteins: The subject invention concerns new classes of pesticidally active proteins and the polynucleotide sequences that encode these proteins. In preferred embodiments, these pesticidal proteins have molecular weights of approximately 40-50 kDa and of approximately 10-15 kDa.... Agent: Baker & Daniels LLP- Dow Agrosciences

20110003737 - Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof: Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.... Agent: Nixon Peabody LLP - Patent Group

20110003739 - Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof: Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.... Agent: Nixon Peabody LLP - Patent Group

20110003738 - Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof: Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.... Agent: Nixon Peabody LLP - Patent Group

20110003740 - Insulin sensitisers and methods of treatment: The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitisers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as... Agent: Seed Intellectual Property Law Group PLLC

20110003741 - Novel neurturin conjugates for pharmaceutical use: The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20110003742 - Naphthalimide dosing by n-acetyl transferase genotyping: The present invention provides methods for dosing patients with naphthalimides, including amonafide, amonafide salts, and analogs thereof based on N-acetyl transferase genotyping. The invention also provides methods for dosing the amount of granulocyte colony stimulating factor (GCSF) used in combination with naphthalimide to prevent or modulate leukocytopenia.... Agent: Morgan, Lewis & Bockius, LLP (sf)

20110003743 - Stem cell derived factors for treating pathologic conditions: A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic condtions.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20110003744 - Glycopegylated erythropoietin formulations: The present invention provides conjugates between erythropoietin and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified... Agent: Leydig Voit & Mayer, Ltd

20110003745 - Granulate-matrix: Composition comprising a granulate selected from the group consisting of autogenous bone material, bone/bone like material from natural sources, synthetic materials and mixtures thereof and a matrix obtainable by a self selective reaction of at least two precursors A and B in the presence of water. A kit for preparing... Agent: Rissman Hendricks & Oliverio, LLP

20110003746 - Protein variants: IGF-I variants having an alanine, glycine, or serine amino acid residue at position 16, 25, 49 or at positions 3 and 49 of native-sequence IGF-I are provided that are useful to treat a disorder characterized by dysregulation of the GH/IGF axis in a mammal, such as a renal disorder.... Agent: Arnold & Porter LLP (24126) Attn: Sv Docketing Dept.

20110003747 - Use of nrf2 inducers to treat epidermolysis bullosa simplex and related diseases: The present invention relates to methods and compositions for the prevention and treatment of keratin-based skin diseases. In particular, the application describes compositions and methods of treating a patient suffering from skin blistering comprising the use of phase II enzyme inducers.... Agent: Edwards Angell Palmer & Dodge LLP

20110003748 - Method of treatment and compositions of d-chiro inositol and phosphates thereof: The present invention relates to the use of D-chiroinositol or a phosphate thereof in combination with folate for the reduction or prevention of congenital deformations such as anorectal malformations, neural tube defects, cleft-lip, cleft palate, and other birth defects. The invention further relates to the use of D-chiroinositol or a... Agent: Mchale & Slavin, P.A.

20110003749 - Use of somatostatin or one of its analogues for preparing a medicament intended to regulate the ovarian follicular reserve in non-menopausal women: The invention primarily relates to the use of somatostatin or one of the agonistic analogs thereof for producing a medicament serving to regulate the ovarian follicular reserve and, in particular, to reduce the depletion of the ovarian follicular reserve over time in non-menopausal women or to the use of an... Agent: Hunton & Williams LLP Intellectual Property Department

20110003750 - Human 3 relaxin: Human H3 preprorelaxin, human H3 prorelaxin, human H3 relaxin, human relaxin analogues having a modified A chain and/or a modified B chain are described. Also described are nucleic acid sequences encoded human H3 preprorelaxin, human H3 prorelaxin, human H3 relaxin, human relaxin analogues. Also described are methods for the treatment... Agent: Merchant & Gould PC

20110003751 - Novel immunoregulatory peptides, compositions and uses thereof: A biologically active peptide, of Formula (1) [X-L-γ-Glu-Trp-Y], a novel pharmaceutical composition containing the peptide, a method for preparing the peptide and uses of the peptide are disclosed.... Agent: Bozicevic, Field & Francis LLP

20110003752 - New blood coagulation factor inhibitors: The invention relates to novel compounds with formula (I) X1-X2-X3-X4-X5-(X6)n-(X7)m-Y useful as blood coagulation factor inhibitors. The compounds (I) may be used for treatment of thrombotic conditions or as stabilizers of liquid formulations of blood coagulation factors, in particular liquid formulations of FVIIa, Factor VII variants, or Factor VII derivatives.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20110003753 - Compositions and methods for disrupting the function of the transcriptional repressor component sin3a-pah2 domain to induce differentiation and growth inhibition in breast cancer: The present invention relates, generally, to compositions for treating breast cancer, use of the compositions to sensitize breast cancer cells to treatment, and methods for treating breast cancer by administering the compositions. The compositions comprise peptides derived from the mSin3A interaction domain (SID) and derivatives thereof, as well as small... Agent: Arent Fox LLP

20110003754 - Peptide-conjugated oligonucleotide therapeutic and method of making and using same: e

20110003755 - Tumor endothelial marker 5-alpha molecules and uses thereof: The present invention provides Tumor Endothelial Marker 5α (TEM5α) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TEM5α polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, or prevention of diseases,... Agent: Amgen Inc.

20110003756 - C5a receptor antagonists: the connecting lines—in formula (I) represent chemical bonds, whereby the chemical bond is individually and independently selected from the group comprising covalent bonds, ionic bonds and coordinative bonds, whereby preferably the bond is a chemical bond and more preferably the chemical bond is a bond selected from the group comprising... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20110003758 - Inhibitors of glycolysis useful in the treatment of brain tumors: Provided herein are methods of treating brain tumors by administering a therapeutically effective amount of a compound of the Formulas I or II to a patient in need thereof.... Agent: NielsenIPLaw LLC

20110003757 - Pharmaceutical compositions for treating fatty liver disease: The present invention provides a pharmaceutical composition useful as a therapeutic agent for fatty liver disease. A pharmaceutical composition, which comprises (1S)-1,5-anhydro-1-[5-(azulen-2-ylmethyl)-2-hydroxyphenyl]-D-glucitol or a pharmaceutically acceptable salt thereof, (1S)-1,5-anhydro-1-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-D-glucitol or a pharmaceutically acceptable salt thereof, or alternatively, (1S)-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D-glucitol or a pharmaceutically acceptable salt thereof, more specifically such a pharmaceutical composition... Agent: Sughrue Mion, PLLC

20110003760 - Abnormal protein removing method: A method for treating symptoms or diseases associated with accumulation of abnormal protein in the body includes administrating to a subject desiring such treatment a composition containing silybin and soybean saponin in an amount effective to reduce or remove abnormal protein produced in the body.... Agent: Knobbe Martens Olson & Bear LLP

20110003759 - Non-basic melanin concentrating hormone receptor-1 antagonists and methods: Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or... Agent: Louis J. Wille Bristol-myers Squibb Company

20110003761 - Biologically active extract from dendrobium plant, use thereof and process for preparing the same: d

20110003762 - Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia: A process of enhancing insulin excretion in a subject includes administering to the subject a polyphenol active ingredient. The polyphenol active ingredient is a purified cyanidin-3-glycoside alone or purified cyanidin alone. The pharmaceutically acceptable carrier is administered with the polyphenol active ingredient.... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20110003763 - Avermectin/benzoyl peroxide compositions for treating afflictions of the skin, e.g., rosacea: Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and benzoyl peroxide, are useful for treating afflictions of the skin, especially rosacea.... Agent: Buchanan, Ingersoll & Rooney PC

20110003879 - Antisense oligonucleotides targeted to the coding region of thymidylate synthase and uses thereof: Antisense oligonucleotides directed to the coding region of a mammalian thymidylate synthase mRNA that are capable of inhibiting the proliferation of cancer cells without decreasing the level of thymidylate synthase mRNA in the cells are provided. The antisense oligonucleotides are also capable of inducing apoptosis in the cancer cells. The... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20110003880 - Compositions and methods for inhibiting optic nerve damage: Provided herein is a method of inhibiting optic nerve damage in an individual in need thereof, comprising administering to the individual an agent that inhibits peptidyl arginine deiminase 2 (PAD2). In a particular embodiment, the present invention is directed to a method of inhibiting glaucomatous optic nerve damage in an... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20110003882 - Rnai modulation of aha and therapeutic uses thereof: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an Aha gene (Aha1 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part... Agent: Alnylam/fenwick

20110003881 - Single stranded extended dicer substrate agents and methods for the specific inhibition of gene expression: The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a single... Agent: Edwards Angell Palmer & Dodge LLP

20110003883 - Allosteric trans-splicing group i ribozyme whose activity of target-specific rna replacement is controlled by theophylline: Provided is an allosteric trans-splicing group I ribozyme whose target-specific RNA replacement activity is controlled by theophylline, wherein the hTERT-targeting trans-splicing ribozyme recognizes mRNA of human telomerase reverse transcriptase (hTERT) as a cancer-specific RNA transcript to bind a theophylline aptamer to an hTERT target trans-splicing ribozyme via a communication module,... Agent: Merchant & Gould PC

20110003885 - Methods and compositions for inhibition of immune responses and autoimmunity: The application relates to the use of immunoregulatory polynucleotides and/or immunoregulatory compounds in combination with other therapeutic agents. The application further relates to immunoregulatory polynucleotides and/or immunoregulatory compounds comprising a modified immunoregulatory sequence. It also relates to the administration of the immunoregulatory polynucleotides and/or immunoregulatory compounds comprising a modified immunoregulatory... Agent: Morrison & Foerster LLP

20110003886 - Selection of rna aptamers as anti-malaria agents: The present invention relates to an aptamer or an active fragment thereof raised against the semi-conserved duffy binding ligand domain 1α, DBL1α, region of the Plasmodium falciparum erythrocyte membrane protein 1, PfEMPI, which aptamer has an effect against malaria, in particular severe cerebral malaria.... Agent: Brooks Kushman P.C.

20110003884 - Viral vectors and methods of use: This invention relates to viral vectors and methods employing these vectors. The vectors of the invention can be base on flaviviruses, such as chimeric flavi viruses, which may be used to deliver heterologous antigens, such as influenza virus antigens.... Agent: Clark & Elbing LLP

20110003764 - Methods for treatment of hiv or malaria using combinations of chloroquine and protease inhibitors: The present invention relates to a drug combination capable of conferring therapeutic benefits in the treatment of both AIDS and malaria. In particular, it relates to a drug combination including at least one quinolinic antimalarial compound such as chloroquine or hydroxychloroquine, and at least one inhibitor of the Human Immunodeficiency... Agent: Mccarter & English, LLP Hartford Cityplace I

20110003766 - Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as a2ar agonists: Provided herein are alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof and pharmaceutical compositions containing the same that are selective agonists of A2A adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.... Agent: Mccarter & English, LLP Boston

20110003765 - Substituted 4--piperidine-1-carboxylic acid esters as a2ar agonists: The present invention provides substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters and pharmaceutical compositions containing the same that are selective agonists of A2A adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.... Agent: Mccarter & English, LLP Boston

20110003767 - Inhibitors of acetyl-coa carboxylase for treatment of neuronal hypometabolism: This invention relates to methods of using inhibitors of the enzyme acetyl-CoA carboxylase (ACC) for the treatment, prevention, inhibition or alleviation of diseases associated with neuronal hypometabolism and/or loss of cognitive function caused by reduced neuronal metabolism such as, for example, Age Associated Memory Impairment (AAMI), Mild Cognitive Impairment (MCI),... Agent: Swanson & Bratschun, L.L.C.

20110003769 - Anti-aging composition for external use comprising low and high molecular weight hyaluronic acids and the polysaccharides extracted from root bark of ulmus davidiana: Disclosed is an anti-aging composition for external use on skin, which includes low-molecular weight hyaluronic acids, high-molecular weight hyaluronic acids and polysaccharides extracted from root bark of Ulmus davidiana, as active ingredients. The composition including the low-molecular weight hyaluronic acids, high-molecular weight hyaluronic acids and polysaccharides extracted from root bark... Agent: Cantor Colburn LLP

20110003768 - Prebiotic compositions: The present invention concerns nutritional compositions comprising oligosaccharides for controlling inflammatory bowel disease and related disorders, such as diarrhoea and constipation.... Agent: Nestle Healthcare Nutrition

20110003770 - Method and pharmaceutical to treat spinal discs: Methods for reducing chronic pain caused by a disrupted spinal disc are described. In one method, a physiologically acceptable amount of an injectable is injected into the disc. The injectable is obtained from a stock solution comprising chondroitin sulphate, glucosamine HCl, aqueous solution of dextrose; sodium carboxymethylcellulose, and a buffer... Agent: O''melveny & Myers LLP Ip&t Calendar Department La-13-a7

20110003771 - Wood preservative composition: A wood preservative composition comprising a mixture of a fungicide which is a combination of a boric acid ester, which is soluble in an organic solvent and has a sterically hindered di-alcohol or tri-alcohol group, such as trihexylene glycol biborate, an organo-iodine compound, a triazole, and a synthetic pyrethroid insecticide,... Agent: Merchant & Gould P.C.

20110003772 - Use of sphingolipids in the treatment of type 2 diabetes mellitus, insulin resistance and metabolic syndrome: w

20110003773 - Using fullerenes to enhance and stimulate hair growth: Described herein are methods for treating lack of hair growth or a reduction or loss of existing hair by stimulating and/or restoring hair growth, or preventing hair loss. The methods comprise administering to a subject in need thereof a therapeutically effective amount of a fullerene.... Agent: Buchanan, Ingersoll & Rooney PC

20110003774 - Compounds having anti-proliferative properties: There is provided a method of inhibiting the occurrence of one of more of the following conditions:—the proliferation of monocytes/macrophages; or—the proliferation of smooth muscle cells; or—the expression of CD36 receptors; or—the uptake of oxidized LDL, the method comprising the step of administering an effective amount of one or more... Agent: Michael Best & Friedrich LLP

20110003775 - Composition and method for promoting survival of aged basal forebrain cholinergic neuron leading to provention and treatment of age-related neurodegenerative disorder: A method of treating a subject and preventing in a subject age-dependent basal forebrain cholinergic dysfunction related neurodegenerative disorders, comprising: administering a lipid composition comprising a therapeutically effective amount of highly enriched 1-acyl chains/2-docosahexaenoic acid containing molecular species of highly pure phospholipids to promote survival of aged basal forebrain cholinergic... Agent: Law Office Of Michael A. Blake, LLC

20110003776 - Tetrahydropyranonaphthyridines derivatives, pharmaceutical compositions and therapeutic treatment thereof: m

20110003777 - Methods of treatment employing prolonged continuous infusion of belinostat: The present invention relates generally to the treatment of diseases and disorders that are mediated by histone deacetylase (HDAC), for example, cancer, with Belinostat™ (also known as (E)-N-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide; PXD101; and PX 105684), and more particularly, to improvement treatments of such diseases (for example, cancers, for example, leukemias), which employ prolonged... Agent: Swanson & Bratschun, L.L.C.

20110003779 - 15, 16-methylene-17-(1'-propenyl)-17,3'-oxidoestra-4-en-3-one derivative , use thereof, and medicament containing said derivative: The invention relates to 15,16-methylene-17-(1′-propenyl)-17-3′-oxidoestra-4-en-3-one derivatives with the general chemical formula I, where the Z, R4, R6a, R6b, R7 and R18 have the meanings stated in claim 1, and solvates, hydrates and salts thereof, including all crystal modifications and all stereoisomers of these compounds. The invention also relates to the... Agent: Millen, White, Zelano & Branigan, P.C.

20110003778 - Mineralcorticoid receptor antagonists for the treatment of endometriosis: e

20110003780 - Hydrogen chloride salt of a substituted 5-oxazol-2-yl-quinoline compound and a process for the production thereof:

20110003781 - Non-sedating antihistamine injection formulations and methods of use thereof: Described herein are injectable compositions containing non-sedating or second and third generation antihistamines such as cetirizine/levocetirizine and methods of use thereof. Specifically, methods of treating acute allergic reactions including anaphylaxis with the compositions are disclosed. In certain embodiments, the injectable compositions are bioequivalent to currently marketed oral dosage forms. In... Agent: Cantor Colburn LLP

20110003782 - 23-substituted bile acids as tgr5 modulators and methods of use thereof: The invention relates to compounds of Formula A: (A) or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including obesity, insulin sensitivity, inflammation, cholestasis, and bile desaturation.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20110003783 - Nicotinic acid compositions for treating hyperlipidemia and related methods therefor: An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyper lipidemic having a substantially periodic... Agent: Lisa V. Mueller Polsinelli Shughart PC

20110003784 - Opsin-binding ligands, compositions and methods of use: Compounds and compositions of said compounds along with methods of use of compounds are disclosed for treating ophthalmic conditions related to mislocalization of opsin proteins, the misfolding of mutant opsin proteins and the production of toxic visual cycle products that accumulate in the eye. Compounds and compositions useful in the... Agent: Alan J. Grant, Esq. C/o Carella, Byrne

20110003786 - 2-carboxamide cycloamino ureas: m

20110003788 - Fused heterocyclic derivative and use thereof: The present invention provides a compound having a superior Smo inhibitory activity and lower toxicity, which is sufficiently satisfactory as a pharmaceutical product. The present invention provides a compound represented by the formula (I) wherein ring A is 5- to 7-membered ring optionally having substituent(s), where substituents are optionally bonded... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20110003785 - Fused thiazole derivatives as kinase inhibitors: A series of 6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one derivatives, which are substituted in the 2-position by a substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20110003787 - Novel phenylpyrrole derivative: A represents, for example, an oxygen atom or sulfur atom, R1 represents, for example, a C1-C6 alkyl group, a C1-C6 alkoxy group or a C1-C6 halogenated alkyl group, A and R1 together with the carbon atom bonded thereto form a heterocyclic group that may be substituted with 1 to 3... Agent: Dorsey & Whitney LLP Intellectual Property Department

20110003789 - 5-aminocyclylmethyl-oxazolidin-2-one derivatives: r

20110003790 - Pyrido [4, 3-d] pyrimidinone derivatives as kinase inhibitors: The invention provides a class of compounds of Formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly Syk, ZAP70, KDR, FMS, FLT3, c-Kit, RET, TrkA, TrkB, TrkC, IGR-IR, AIk, c-FMS, or... Agent: Genomics Institute Of The Novartis Research Foundation

20110003791 - Cyclized derivatives as eg-5 inhibitors: The present invention relates to new substituted imidazole compounds have the following Formula (I) and to the pharmaceutically acceptable salts, esters, or prodrugs thereof, to compositions of the compounds together with pharmaceutically acceptable carriers, and to uses of the compounds:... Agent: Novartis Institutes For Biomedical Research, Inc.

20110003792 - Anti-inflammatory agents: e

20110003793 - Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof: Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.... Agent: Nixon Peabody LLP - Patent Group

20110003794 - Naphthyridine integrase inhibitors: The present invention features compounds that are HIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.... Agent: Glaxosmithkline Global Patents

20110003795 - Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands: The invention relates to substituted aromatic carboxamide and urea derivatives, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions.... Agent: Crowell & Moring LLP Intellectual Property Group

20110003796 - Method for the treatment of psychic disorders: Method for the treatment of psychiatric disorders, comprising administering to a subject in need thereof an amount of fatty acids and a suboptimal dose of at least one antidepressant. Wherein the fatty acid may be omega-3 (ω3), for example the docohexaenoic acid (DHA) and the eicosapentaenoic acid (EPA). The omega-3... Agent: Young & Thompson

20110003797 - Hexahydrocyclopentyl[f]indazole carboxamides and derivatives thereof as selective glucocorticoid receptor modulators: The present invention is directed to hexahydrocyclopentyl[f]imidazole carboxamides and derivatives thereof as selective glucocorticoid receptor ligands useful for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.... Agent: Merck

20110003798 - Compounds and compositions as kinase inhibitors: The invention provides a novel class of 2,7-naphthyridin derivatives; pharmaceutical compositions comprising such compounds and methods of using such compounds to treat o prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly Syk, ZAP70, KDR, FMS, FLT*, c-Kit, RET, TrkA, TrkB, TrkC-GR-1R, Alk, c-FMS or combinations thereof.... Agent: Genomics Institute Of The Novartis Research Foundation

20110003799 - 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators: e

20110003800 - Benzimidazole derivatives useful as trpm8 channel modulators:

20110003801 - Benzimidazole derivatives useful as trpm8 channel modulators:

20110003802 - Bridged n-cyclic sulfonamido inhibitors of gamma secretase: wherein A is as described in the specification and R1 and R2 combine to form a [3.3.1] or a [3.2.1] ring system, where the nitrogen is attached to the two bridgehead carbons, and the [3.3.1] or [3.2.1] ring systems are optionally fused with an heteroaryl or heterocycloalkyl ring. Compounds of... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20110003803 - Compositions and methods for treating ophthalmic, otic, or nasal infections: The present invention relates to methods for treating an ophthalmic, otic, or nasal infection comprising treating the infected tissue with a composition comprising finafloxacin or a finafloxacin derivative. The present invention also relates to antimicrobial compositions comprising finafloxacin or a finafloxacin derivative. The compositions are suitable for the treatment of... Agent: Alcon

20110003804 - Oxazolidinones for the treatment and/or prophylaxis of heart failure: The present invention relates to the use of selective inhibitors of coagulation factor Xa, in particular of oxazolidinones of the formula (I), for the treatment and/or prophylaxis of heart failure and/or disorders related to heart failure as well as their use for the preparation of pharmaceutical drugs for the treatment... Agent: Connolly Bove Lodge & Hutz, LLP

20110003805 - Concomitant drug: Provided is a combination drug. The present invention provides a pharmaceutical agent comprising (1) a HER2 inhibitor having a pyrrolopyrimidine skeleton or pyrazolopyrimidine skeleton, and (2) not less than one pharmaceutical agent selected from an mTOR inhibitor, a PI3 kinase inhibitor and a cMet inhibitor in combination.... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20110003806 - Heteroaryls and uses thereof: o

20110003808 - Octahydroquinolizines for antidiabetic treatment: This invention relates to novel octahydroquinolizines for treatment or prevention of diabetes mellitus and its complications, for treatment or prevention of hyperlipidemia, for treatment of diabetic dyslipidemia, for treatment or prevention of the metabolic syndrome, for treatment of diseases related to metabolic dysfunction, for treatment of obesity or obesity-related diseases.... Agent: Workman Nydegger 1000 Eagle Gate Tower

20110003807 - Thiazole derivatives: i

20110003809 - Imidazo [4,5-b] pyridine derivatives used as raf inhibitors: Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.... Agent: Viksnins Harris & Padys Pllp

20110003810 - Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors: The present invention relates to novel heterocyclic compounds which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.... Agent: Lisa V. Mueller Polsinelli Shughart PC

20110003811 - Subsituted pyridine derivatives: The present invention relates to pyridine derivatives of the general formula (I) and their use as openers of the KCNQ family potassium ion channels for the treatment of CNS disorders.... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20110003812 - Human adam-10 inhibitors: Magnesium salts/complexes of compounds useful for inhibiting the ADAM-IO protein and methods of making and purifying them are provided. Further provided are compositions comprising magnesium salts/complexes of the compounds in combination with a pharmaceutically acceptable carrier. The compounds well as such compositions comprising them are useful for the treatment of... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20110003814 - Pyrimidines useful as modulators of voltage-gated ion channels: The present invention relates to compounds useful as inhibitors of voltage-gated ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Inc.

20110003813 - Substituted biaryl piperazinyl-pyridine analogues: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods... Agent: Edwards Angell Palmer & Dodge LLP

20110003815 - Diphenyl substituted cycloalkanes: The present invention provides compounds of Formula I which are FLAP inhibitors useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.... Agent: Merck

20110003816 - Ophthalmic composition: An ophthalmic composition comprising therapeutically effective amount of a beta-blocker and a polymeric vehicle consisting essentially of a water soluble cellulose derivative and polyvinylpyrrolidone; wherein the composition is a clear aqueous solution with a viscosity id 20 cps to 60 cps.... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20110003817 - Whitening agent and skin external preparation: wherein X1, X2, and X3 are each CR2 or N; R1, R2, and R3 are each H, C1-6 alkyl, C1-6 alkoxy, SH, OH, or NRbRc, wherein Rb and Rc are each H, C1-6 alkyl, or hydroxy-C1-6 alkyl, or NRbRc forms a saturated or unsaturated 5- or 6-membered hetero ring; and... Agent: Rankin, Hill & Clark LLP

20110003818 - Substituted 2-carboxamide cycloamino ureas: e

20110003819 - Methods of treating multiple sclerosis using neurotrophin mimetics: Methods and compounds for treating neurodegenerative and other disorders. Included is the administering to a subject in need thereof an effective amount of a compound having binding specificity for a p75NTR receptor molecule. Enhanced survival of neural and other cells has been observed.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20110003820 - Pyrazolopyrimidines, a process for their preparation and their use as medicine: The invention relates to pyrazolopyrimidine derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.... Agent: The Firm Of Hueschen And Sage

20110003821 - Pyrrolotriazine kinase inhibitors: e

20110003823 - Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage: The invention provides compositions and methods for treating diseases and conditions, including systemic diseases and conditions, through an intravenous administration of a selective α-2 adrenergic receptor agonists having a binding affinity of 300 fold or greater for α-2 over α-1 adrenergic receptors. The amounts of the selective α-2 adrenergic receptor... Agent: Wood, Phillips, Katz, Clark & Mortimer

20110003822 - P2x3 receptor antagonists for treatment of pain: The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.... Agent: Merck

20110003824 - Caspase inhibitors and uses thereof: wherein R1 is hydrogen, CHN2, R, or —CH2Y; R is an aliphatic group, an aryl group, an aralkyl group, a heterocyclyl group, or a heterocyclylalkyl group; Y is an electronegative leaving group; R2 is CO2H, CH2CO2H, or esters, amides or isosteres thereof; X2-X1 is N(R3)—C(R3), C(R3)2—C(R3), C(R3)2—N, N═C, C(R3)═C, C(═O)—N,... Agent: Vertex Pharmaceuticals Inc.

20110003825 - Substituted amide beta secretase inhibitors: Also disclosed are methods of treating a cognitive or neurodegenerative disease comprising administering to a patient I need of such treatment a combination of at least one compound of formula I and at least one compound selected from the group consisting of β-secretase inhibitors other than those of formula I,... Agent: Merck Patent Department (k-6-1, 1990)

20110003826 - Anticoagulant compounds, pharmaceutical compositions on their basis to treat thrombotic conditions, and plasma-substituting solution to correct hypercoagulation defects of hemodilution: This invention relates to new chemical compounds, application of these compounds as anticoagulants, pharmaceutical compositions, and plasma-substituting solutions on their basis, and can be used for treating thromboembolic complications of diseases such as myocardial infarction, stroke, and thrombosis of deep veins or a pulmonary artery; and for preventing hypercoagulation conditions... Agent: Knobbe Martens Olson & Bear LLP

20110003827 - Hiv protease inhibiting compounds: i

20110003828 - Prodrugs of nh-acidic compounds: The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is... Agent: Elmore Patent Law Group, PC

20110003829 - Enrofloxacin hexahydrate: The present invention relates to a novel hexahydrate of enrofloxacin, to processes for its preparation, to pharmaceuticals containing it, and to its use in combating diseases.... Agent: Bayer Healthcare LLC

20110003830 - Process for the preparation of 3-amino-8-(1-piperazinyl)-2h-1-benzopyran-2-one and salts and solvates thereof: e

20110003831 - N-(-3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide as an anticancer agent: The use of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, in the treatment of cancer and/or pain in a warm blooded animal such as man is described.... Agent: Astrazeneca R&d Boston

20110003832 - New capped pyrazinoylguanidine sodium channel blockers: The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20110003833 - Novel aminopyridine derivatives having aurora a selective inhibitory action: The present invention relates to a compound of formula I: wherein: R1 is a hydrogen atom, F, CN, etc.; R2 is CO, SO2, etc.; R3 is a phenyl which may be substituted; X1, X2, and X3 each independently CH, N, etc. provided, however, that among X1, X2 and X3, the... Agent: Merck

20110003834 - Production method and production apparatus for a high theobromine-containing composition: An object is to provide a method for producing a high theobromine-containing composition effectively in a simple way. The method for producing a theobromine-containing composition comprises: (a) performing an extraction of a theobromine-containing plant or a processed product thereof with a solvent, to obtain a crude theobromine extract; (b) applying... Agent: The Nath Law Group

20110003835 - Methods for the treatment of respiratory depression: This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in regulation of breathing, and cognitive abilities related... Agent: Henry D Coleman

20110003837 - Modified release formulations of hmg coa reductase inhibitors: Modified release formulations of HMG Co-A reductase inhibitors, which provide reduced incidence of rhabdomyolysis, renal toxicity and other side effects by increasing hepatic bioavailability and decreasing systemic availability upon oral administration. The modified release pharmaceutical formulation comprises a therapeutically effective amount of HMG CoA reductase inhibitor or a pharmaceutically acceptable... Agent: Pauly, Devries Smith & Deffner, L.L.C.

20110003836 - Pro-neurogenic compounds: This invention relates generally to stimulating neurogenesis (e.g., post-natal neurogenesis, e.g., post-natal hippocampal neurogenesis) and protection from neuron cell death.... Agent: Fish & Richardson P.C. (bo)

20110003838 - Whitening agent and skin external preparation: i

20110003839 - Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases: A hydantoin compound useful for the prevention or treatment of hyperproliferative diseases or disorders.... Agent: Venable LLP

20110003840 - Pyridoindolobenzox-and thiazepine derivatives and uses thereof: A is —CH(R9)—X—, —XCH(R9)—; —CO—X— or —X—CO—; X is —O—, —S—, —SO—, or —SO2—. Y is a single bond or a double bond. D and E are independently —(CH2)n—; and ‘n’ varies from 0 to 2. R1 to R9 are various electron donating, electron withdrawing, hydrophilic, or lipophilic groups selected... Agent: Raghavan Rajagopalan

20110003841 - Bioactive composition for the treatment of the hiv/aids, method for manufacturing and using the same: The present invention is about a bioactive composition for the treatment of HIV, particularly by the removal of the most prominent HIV antigen glycoproteins. The present invention further relates to the method for making and using such composition.... Agent: Lambert & Associates

20110003842 - Marker for determination of sensitivity to anti-cancer agent: Provided are a marker for determining sensitivity to an anticancer agent capable of distinguishing a therapeutic response of an individual patient and a novel means for a cancer therapy using the marker. The marker for determining sensitivity to an anticancer agent contains a substance in a metabolic pathway in which... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20110003843 - Novel compounds derived from indole and pharmaceutical compositions containing them: wherein X represents N, CR8 or N+R8, wherein R8 represents a hydrogen atom, a hydroxyl or alkyl or methoxy group optionally substituted with a phenyl group; R2, R3 and R4 independently represent a hydrogen atom or a halogen atom or an optionally substituted alkyl, amine, alkene, ester, sulfonamide, ether or... Agent: Foley And Lardner LLP Suite 500

20110003844 - Regulation of cardiac contractility and heart failure propensity: The methods and compositions of the present invention find use in altering expression of PKCα in transgenic animals. The compositions of the invention include isolated transgenic animal cells, transgenic tissue, transgenic animals, and transgenic mice. The transgenic animals of the invention exhibit altered PKCα activity. The methods allow generation of... Agent: Davis Wright Tremaine LLP - San Francisco

20110003845 - Substituted azabicyclic compounds and the use thereof: The present application relates to novel substituted pyrrolopyridine, pyrazolopyridine and isoxazolopyridine derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, preferably for the treatment and/or prevention of cardiovascular disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20110003846 - Polymorph and amorphous form of (s)-(+)-clopidogrel bisulfate: The present invention relates to new polymorphs of S-(+)-Clopidogrel bisulfate and a process for preparing the same.... Agent: Nixon & Vanderhye, PC

20110003847 - Prasugrel salts with improved properties: Acid addition salts of 2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine with sulfuric acid or sulfonic acids, pharmaceutical compositions comprising the same and processes for the production thereof. The acid addition salts have a low toxicity.... Agent: Swanson & Bratschun, L.L.C.

20110003848 - Polymorphic form of a [1,2,4]triazole[4,3-a] pyridine derivative for treating inflammatory diseases: The present invention relates to a polymorphic form B of Λ/[3-tert-butyl-1-(3-chloro-4-hydroxyphenyl)-1H-pyrazol-5-yl]-N-{2-[(3-{2-[(2-hydroxyethyl)sulfanyl]phenyl}[1,2,4]triazolo[4,3-a]pyridin-6-yl)sulfanyl]benzyl}urea (I) as de-fined herein. This polymorph is useful in the treatment of various conditions, particularly in the treatment of inflammatory conditions such as chronic obstructive pulmonary disease.... Agent: Pfizer Inc. Patent Department

20110003849 - Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment: Compounds of the formula: as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating diabetes, inflammation, atherosclerosis, hypertension, pain and the like are disclosed. Pharmaceutical compositions and methods of use are also included.... Agent: Merck

20110003850 - Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators: where X=0 or S; Y is 0 or S; q=1 or 0; and other substituents are defined herein. Such compounds can affect the opening of, or otherwise modulate, voltage-gated potassium channels. Such compounds useful for the treatment and prevention of diseases and disorders which are affected by activation or modulation... Agent: Mcdermott, Will & Emery LLP

20110003851 - Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors: The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.... Agent: Knobbe Martens Olson & Bear LLP

20110003853 - Metalloproteinase inhibitors: Compounds of the formula (I) wherein z is SO2 or SO, useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.... Agent: Fish & Richardson P.C.

20110003852 - N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase: Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly... Agent: High Point Pharmaceuticals, LLC

20110003854 - Breast cancer treatment and treatment prediction: The present invention provides a new method and means for determining whether a mammalian subject having a breast cancer is likely to benefit from an endocrine treatment. The method comprise the steps of: providing a sample earlier obtained from said subject; evaluating the amount of CRABP2 protein present in at... Agent: Ladas & Parry LLP

20110003855 - Antiviral compounds for the treatment of hcv infection: Disclosed are compounds and methods of synthesis of Formula I for the development of antiviral drugs for the treatment of HCV infection.... Agent: Knobbe Martens Olson & Bear LLP

20110003856 - N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase: Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly... Agent: High Point Pharmaceuticals, LLC

20110003857 - Stabilized, antimicrobially effective composition with a content of bispyridinium alkane: An aqueous-based composition which includes a) at least one bispyridinium alkane (for example octenidine) and b) at least one stabilizer selected from antioxidants, complexing agents, reducing agents, UV filters and photoprotective agents, in particular α-tocopherol, and BHT. The composition can also include c) one or more auxiliaries selected from, for... Agent: Young & Thompson

20110003858 - Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors: The invention provides compounds of formula (I) and formula (IV) (M)-(L)-(M) (I) [(M)-(L4)]t-G (VI) wherein M, L, L4, G and t are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and... Agent: Morgan Lewis & Bockius LLP

20110003859 - N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer: Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.... Agent: Viksnins Harris & Padys Pllp

20110003860 - Hydroxyl compounds and compositions for cholesterol management and related uses: The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence,... Agent: Brinks Hofer Gilson & Lione/ann Arbor

20110003861 - 2-aryl and 2-heteroaryl 4h-1-benzopyran-4-one-6-amidino derivatives, new pharmacological agents for the treatment of arthritis, cancer and related pain: e

20110003862 - 3-animopyraolines for treatment of neurodegenerative and psychiatric diseases: Compounds of the formula (I), inhibit D-amino acid oxidase and hence find use in treating degenerative and psychiatric diseases.... Agent: Merck

20110003864 - Crystalline 1-(3-fluorophenyl)-5-methyl-2-(1h)pyridone, the preparation methods, compositions and applications thereof: Crystalline pyridone compound, which is the white needle crystal containing no water and other crystallization solvents. Its unit cell belongs to monoclinic system and has space group of P21/n, wherein a=3.8512(2), b=20.2535(12), c=12.1628(6) Å, β=92.850(5)° and crystal cell volume V=947.53(9) Å3. Pyridone compound crystal of this form has the needed... Agent: Jones Day

20110003863 - Method for synthesizing pirfenidone: A process for synthesizing pirfenidone from bromobenzene having less than about 0.15% by weight dibromobenzene is disclosed. Also disclosed are processes of synthesizing pirfenidone without using ethyl acetate or n-butanol, and pirfenidone having controlled levels of ethyl acetate, n-butanol, di(5-methyl-2-pyridinone)benzenes, and other impurities having specified retention times. Also disclosed are... Agent: Marshall, Gerstein & Borun LLP

20110003865 - Novel 2-diethylamino-3-amido-6-amino-pyridine derivatives useful as potassium channel activators: This invention relates to novel 2-diethylamino-3-amido-6-amino-pyridine derivatives having medical utility, to use of the 2-diethylamino-3-amido-6-amino-pyridine derivatives of the invention for the manufacture of a medicament, to pharmaceutical compositions comprising the 2-diethylamino-3-amido-6-amino-pyridine derivatives of the invention, and to methods of treating a disorder, disease or a condition of a subject, which... Agent: Birch Stewart Kolasch & Birch

20110003866 - Novel 2-dimethylamino-3-amido-6-amino-pyridine derivatives useful as potassium channel activators: This invention relates to novel 2-dimethylamino-3-amido-6-amino-pyridine derivatives having medical utility, to use of the 2-dimethylamino-3-amido-6-amino-pyridine derivatives of the invention for the manufacture of a medicament, to pharmaceutical compositions comprising the 2-dimethylamino-3-amido-6-amino-pyridine derivatives of the invention, and to methods of treating a disorder, disease or a condition of a subject, which... Agent: Birch Stewart Kolasch & Birch

20110003867 - Novel 2-ethyl-methyl-amino-3-amido-6-amino-pyridine derivatives useful as potassium channel activators: This invention relates to novel 2-ethyl-methyl-amino-3-amido-6-amino-pyridine derivatives having medical utility, to use of the 2-ethyl-methyl-amino-3-amido-6-amino-pyridine derivatives of the invention for the manufacture of a medicament, to pharmaceutical compositions comprising the 2-ethyl-methyl-amino-3-amido-6-amino-pyridine derivatives of the invention, and to methods of treating a disorder, disease or a condition of a subject, which... Agent: Birch Stewart Kolasch & Birch

20110003868 - Treatment of a neuropathy with rapid release aminopyridine: A process for treating neuropathy includes administration to a patient suffering from a neuropathy more than 5 and less than 18 mg of aminopyridine in a dose. The aminopyridine is formulated in an immediate release formulation. At least two such doses are provided per day to create spike serum plasma... Agent: Gifford, Krass, Sprinkle, Anderson & Citkowski, P.C.

20110003869 - Use of succinate dehydrogenase inhibitors for controlling sclerotinia ssp.: The invention relates to the use of succinate dehydrogenase inhibitors, especially of fluopyram, for controlling Sclerotinia ssp., to a method for treating plants or plant parts for controlling Sclerotinia ssp. and to a method for treating seed for controlling Sclerotinia ssp. in the seed and in the plants which grow... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20110003870 - Method of treatment of a neurological disorder: A method of treating neurological conditions, such as Parkinson's Disease and Restless Leg Syndrome, in a mammalian subject is disclosed. The method comprises the administration of a once-a-day controlled release formulation of pramipexole, which formulation provides a consistently ascending PK profile during sleeping hours.... Agent: Foley & Lardner LLP

20110003871 - Microbicidal composition: A solid microbicidal composition containing a mixture of 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-4-isothiazolin-3-one, magnesium sulfate, a metal nitrate, magnesium chloride, and water.... Agent: Rohm And Haas Company Patent Department

20110003872 - Material formed from dendritic molecules containing associative groups: The present invention relates to a material comprising dendritic molecules each constituted of fragments that are at least bifunctional and of fragments that are at least trifunctional joined together by ester or thioester bridges, alone or in combination with amide or urea bridges, said bridges being formed from two functions... Agent: Millen, White, Zelano & Branigan, P.C.

20110003873 - Pharmaceutical composition and its use in the preparation of a medicament for the treatment of cerebrovascular diseases: A pharmaceutical composition comprises 3-methyl-1-phenyl-2-pyrazolin-5-one and borneol, and can be used to prepare the medicine for treating cerebrovascular diseases.... Agent: Seed Intellectual Property Law Group PLLC

20110003874 - Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40: The present invention relates to novel 1-benzyl-3-hydroxymethylindazole derivatives according to Formula (I) described in the claims, and to a pharmaceutical composition comprising them, together with a pharmaceutically acceptable vehicle. In addition, the present invention relates to the use of 1-benzyl-3-hydroxymethylindazole derivatives for the preparation of a pharmaceutical composition that is... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20110003875 - Oil-based suspension concentrates: e

20110003876 - Tetrahydroindoles having sphingosine-1-phosphate receptor activity: Compounds are disclosed herein having the formula (I). Therapeutic methods, compositions, and medicaments related thereto are also disclosed.... Agent: Allergan, Inc.

20110003877 - Smac mimetic: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.... Agent: Banner & Witcoff, Ltd.

20110003878 - Novel derivatives of phthalimide as histone deacetylase inhibitors: The invention relates to novel compounds of general formula (I), or one of the salts thereof, particularly one of the pharmaceutically acceptable salts thereof, or one of the corresponding solvates thereof. These compounds are inhibitors of the histone deacetylase enzymes and are suitable as pharmacologically active agents in a medicament... Agent: Cantor Colburn LLP

20110003887 - Treating oncogenic ras driven cancers: Oncogenic Ras-driven cancer is treated with agent by interrupting pathway comprising activation of Akt by oncogenic Ras, activated Akt causing phosphorylation of eNOS at S1177 site of eNOS to provide activated eNOS in cancer cells and activated eNOS causing activation of wildtype Ras by nitrosylation thereof at C118 to provide... Agent: Bacon & Thomas, PLLC

20110003888 - Hops extraction methods and mixtures: Methods and mixtures for extracting prenylflavonoids from prenylflavonoid-containing hops materials are provided.... Agent: Townsend And Townsend And Crew, LLP

20110003889 - Membrane fusion inhibitor: The present invention provides a pharmaceutical composition that has excellent safety and targets a different step in the virus propagation cycle than conventional pharmaceutical compositions, applicable as an antiviral agent. A pharmaceutical composition containing an epigallocatechin gallate derivative represented by the following chemical formula (1), an isomer thereof, or a... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20110003890 - Use of angiogenesis antagonists in conditions of abnormal venous proliferation: The present application describes therapy with angiogenesis antagonists such as anti-VEGF antibodies. In particular, the application describes the use of such angiogenesis antagonists to treat end-stage liver disease and end-stage liver disease complications. The present application also describes the use of such angiogenesis antagonists to treat disorders of altered venous... Agent: Ballard Spahr LLP

20110003891 - Novel use of zinc n-acetyltaurinate: e

20110003892 - All-trans retinoid esters as active pharmaceutical ingredients, oral and topical dosage form compositions thereof, and methods of treating skin conditions thereof: Active pharmaceutical ingredients being retinoic acid ester compounds including all- trans-retinoic acid tent-butyl ester, all-trans-retinoic acid iso-butyl ester, all-trans-retinoic acid iso-propyl ester, all-trans-retinoic acid sec-butyl ester, and, all-trans-retinoic acid 1-adamantyl ester, oral and topical dosage form compositions thereof, and methods of treating various skin conditions thereof.... Agent: Intellectual Property Dept./dewitt Ross & Stevens Wisconsin Alumni Research Foundation

20110003893 - Aqueous loxoprofen-containing patches: An aqueous loxoprofen-containing patch is provided, which has good stability and excellent transdermal absorption of loxoprofen. The aqueous patch includes loxoprofen or a salt thereof and triacetin. Specifically, the aqueous patch includes, based on the weight of the adhesive gel base, 0.1 to 5% by weight of loxoprofen or a... Agent: Crowell & Moring LLP Intellectual Property Group

20110003894 - Dermatological compositions comprising retinoids, dispersed benzoyl peroxide and carrageenans: Dermatological compositions containing, in a physiologically acceptable medium, at least one retinoid, dispersed benzoyl peroxide and at least one gelling agent of the family of the carrageenans, are useful for treating dermatological conditions and afflictions linked to disorders of cell differentiation and/or proliferation and/or keratinization, notably for treating acne vulgaris.... Agent: Buchanan, Ingersoll & Rooney PC

20110003895 - Pharmacology of visual cycle modulators: Described herein are methods for the treatment of an ophthalmic disease or disorder comprising the administration of non-retinoid visual cycle modulators.... Agent: Wilson, Sonsini, Goodrich & Rosati

20110003896 - Dimeric double metal salts of (-)-hydroxycitric acid, methods of making and uses of same: The present invention relates to soluble dimeric double metal salt compositions of (−)-hydroxycitric acid (“HCA”), as well as methods for making and using the same. The invention provides dimeric double metal salts of group IA and IIA of HCA (hereinafter, “DDM-HCAs”). The present invention provides methods to make DDM-HCAs of... Agent: Foley & Lardner LLP

20110003897 - Methods of engineering polar drug particles with surface-trapped hydrofluoroalkane-philes: Disclosed herein are polar drug particles with surface-trapped hydrofluoroalkane-philes and methods of making the same.... Agent: C. Rachal Winger Intellectual Property Docketing Department

20110003898 - Medical glues for surgery comprising bioactive compounds: s

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20141002: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 3.28915 seconds

PATENT INFO